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Abstract
Motor neuron disease, or amyotrophic lateral sclerosis (ALS), is a disorder
characterised by progressive weakness and atrophy of skeletal muscles, caused by
the selective loss ofmotor neurons. It occurs in both familial and sporadic forms.
Although the genetic basis of the disease in a minority of cases has been identified,
the precise molecular mechanism underlying the disease remains to be elucidated.
There is a range ofmouse mutants which model the disease. These mouse models,
both classical and transgenic, have been particularly valuable in providing clues to
the pathogenesis of the disease. One such mutant is wasted, in which the mice
develop a progressive neuromuscular phenotype from 21 days of age. They
deteriorate quickly, and die by 28 days. The genetic defect responsible for wasted is
a 15kb deletion which leads to the abolition of the expression of eukaryotic
elongation factor 1 A-2 (eEFlA-2). This is a tissue-specific isoform, apparently
unique to mammals, of the more widely expressed eEFl A-l. In this PhD thesis I
describe the further characterisation ofwasted as a model for ALS, using
immunohistochemistry to evaluate the similarities between the phenotype ofwasted
mice and that of ALS patients. I have also screened the human gene, EEF1A2, for
mutations in both familial and sporadic patients. Although there were polymorphisms
within the gene which were also present in healthy controls, there were no mutations.
It is thus unlikely that mutations in EEF1A2 are responsible for anything other than
rare cases ofALS. I have designed and generated anti-peptide antibodies against
eEFlA-l and eEFlA-2 which I have shown to be isoform-specific. These were used
to study the expression of the two isoforms in mouse tissues. I have also shown that
the African clawed frog, Xenopus laevis, has a developmentally-regulated, tissue-
specific isoform homologous to eEFl A-2.
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1 Chapter 1 - Introduction
1.1 Introduction
This introduction will outline the current knowledge ofmotor neuron disease, and its
genetics and pathogenesis. There are a number ofmouse mutants which have been
used to model the human disease. These are described, along with any insights into
the pathogenesis of human motor neuron disease that they have provided. This PhD
has focused on the mutant wasted. The genetic defect responsible for wasted has
been identified as a deletion which abolishes the expression of eukaryotic elongation
factor 1A2 (Eefla2). This is a tissue-specific isoform of the more widely expressed
Eeflal. The biology of the proteins encoded by the two genes is discussed, focusing
on the question ofwhy a second isofomi with a restricted expression pattern should
be required.
1.2 Motor Neuron Disease
1.2.1 Introduction
Motor neuron (or neurone) disease is an umbrella term which refers to a group of
neurodegenerative disorders characterised by progressive weakness and atrophy of
skeletal muscles, caused by the selective loss ofmotor neurons. The most common
adult form of the disease, amyotrophic lateral sclerosis or ALS (usually known as
motor neuron disease or MND in the UK) usually affects those in middle age, with
an average age of onset of 56 years of age for sporadic and 45.1 years for familial
cases (Tandan and Bradley, 1985). The symptoms vary from patient to patient, but
typically involve muscle cramping and fasiculations in the initial stages, followed by
a progressive paralysis, shortness of breath and difficulty in breathing and
swallowing. Most patients die between 2 and 5 years after diagnosis, and there is as
yet no cure. The disease been identified in all populations investigated, with an
incidence of between 0.4 and 1.8 per 100,000, depending on the particular population
(Tandan and Bradley, 1985). It has been reported that this incidence is rising
(Kurtzke, 1991; Lilienfield et al., 1989), although this could be due to the continuing
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increase in the life expectancy of the general population, improved disease
ascertainment, or a combination of the two (Annegers et al., 1991). There are also
well-characterised geographical foci of the disease, for example, on the western
Pacific island ofGuam, where it is often associated with parkonsinism-dementia
(Morris et al., 2001).
1.2.2 Pathology
The main histological feature ofALS is the loss ofmotor neurons of the anterior
horn region of the spinal cord, the brain stem and motor cortex (Graham and Lantos,
1997). A diagram of a motor neuron is given in figure 1-1. This is accompanied by
reactive gliosis, in which microglia are activated and astrocytes accumulate and
upregulate the expression of glial fibrillary acidic protein, GFAP (Fujita et al., 1998;
Nagy et al., 1994). Inclusion bodies containing ubiquitin are seen in the surviving
motor neurons of almost all cases (Leigh et al., 1988; Leigh et al., 1991).
Accumulations of phosphorylated neurofilaments are also seen (Manetto et al., 1988;
Munoz et al., 1988; Sobue et al., 1990). In the muscles of affected patients, there are
neurogenic changes involving the atrophy ofmuscle fibres, along with denervation
and renervation (Graham and Lantos, 1997).
Chapter 1 - Introduction 2
Dendrites
jk I %ff W





Initial segment of T ^~^~-Axon hillock
axon Ml

















Figure 1-1 Diagram of motor neuron (from Junqueira et al., 1995).
1.2.3 Genetics
The vast majority of ALS cases occur without any family history - only 10-20% of
cases are familial. In these cases, the pattern of inheritance is usually autosomal
dominant, but there are also rarer recessive forms with a juvenile onset. There is
locus heterogeneity in both forms of the disease. Approximately 10-20% of the
familial cases are linked to chromosome 21q22.1 (Siddique et al., 1991). This locus
is designated ALS1. The mutated gene has been identified as Cu/Zn superoxide
dismutase (SOD1) (Rosen et al., 1993). Over 100 different mutations have now been
identified (Parton et al., 2002). They are uniformly distributed through the protein,
with no obvious clustering. The vast majority ofmutations are dominant, but the
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D90A mutation can be either dominant or recessive, leading to the suggestion that in
the latter case there is a linked protective factor (Al-Chalabi et al., 1998; Parton et
al., 2002). SOD1 mutations have also been reported in a small number of sporadic
cases (Jones et al., 1993). It is still not clear why mutations in superoxide dismutase
cause disease. The findings from SOD1 knockout mice (see below), along with the
autosomal dominant inheritance pattern and the fact that some of the mutant enzymes
have normal dismutase activity (Ratovitski et al., 1999), has led to the hypothesis
that toxicity is caused by the gain of some novel, toxic function. The precise nature
of this toxic function has not been characterised. Although novel protein interactions
have been reported for two ALS-causing mutations, G85R and G93A (Kunst et al.,
1997), it is not clear how this could be extrapolated to other regions of the protein, in
which there are mutations which lead to the same phenotype.
ALS2 is a juvenile-onset recessive form of the disease, shown to be linked to
chromosome 2q33 (Hentati et al., 1994). The genetic basis of the disease at this locus
has recently been identified as a novel gene, alsin (Hadano et al., 2001; Yang et al.,
2001). Three different mutations have been found in three ALS2 families, which all
lead to a frameshift and production of a truncated protein product. Although they
could therefore represent gain-of-function mutations, it is perhaps more likely that
they result in a loss of function, given the recessive mode of inheritance of this form
of the disease. It is currently not clear how mutations in alsin lead to ALS, especially
as, like SOD1, it is expressed in a wide range of tissues. The gene has homology with
guanine exchange factors, and may modulate microtubule assembly, membrane
organisation and cell trafficking (Hadano et al., 2001). Mutations in alsin also cause
a juvenile-onset form ofprimary lateral sclerosis, JPLS (Yang et al., 2001). The
JPLS- causing mutations lie in exon 9, which is only present in one of two differently
sized transcripts of alsin. The shorter transcript remains intact, which may explain
why this mutation causes a milder phenotype. Where the mutations affect both
transcripts, the resulting phenotype is the more clinically severe ALS. Alsin
mutations have also recently been identified in patients with infantile-onset
hereditary spastic paraplegia (HSP) (Eymard-Pierre et al., 2002).
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Other ALS loci for which chromosomal locations have been identified are ALS3 at
18q21 (Hand et al, 2002), ALS4 at 9q34 (Blair et al., 2000), and ALS5 at 15ql5.1-
q21.1 (Hentati et al., 1998). All three are juvenile forms of the disease; ALS3 and
ALS5 are autosomal recessive, whereas ALS4 is dominantly inherited. There is also
an X-linked form of the disease at Xpl l-ql2 (Hong et al., 1998). There are other loci
which remain to be found, as there are families which do not show linkage to any of
the identified loci. Due to this genetic heterogeneity, and the fact that ALS is a late-
onset disease with a short disease duration, it is often difficult to identify loci using
linkage analysis. Association studies and candidate gene approaches have therefore
often been used in an attempt to identify other causative disease genes.
There are several genes in which mutations have been described in a small
proportion of patients. These include the neurofilament heavy chain gene, in which
mutations and deletions have been reported in a small number of patients (Al-
Chalabi et al., 1999; Figlewicz et al., 1994; Tomkins et al., 1998). Mutations have
also been found in apurinic/apyrimidinic endonuclease (APEX nuclease; AP
endonuclease) (Olkowstu, 1998) and in cytochrome c oxidase subunit 1 (Comi et al.,
1998). A mutation has also been reported in the leukaemia inhibitory gene, LIF,
which was present in 4 of 104 ALS patients but was not present in 388 controls
(Giess et al., 2000). The manganese superoxide dismutase gene, SOD2, has been
screened for mutations in ALS patients, although no mutations have been found
(Tomkins et al., 2001).
It is possible that along with causative mutations, there are susceptibility genes which
predispose an individual to the disease in the presence of other genotypes or
environmental triggers. For example, a polymorphism in the APEX nuclease gene
differs in alleleic frequency different between ALS cases and controls (Hayward et
al., 1999). Survival motor neuron 1 (SMN1) is mutated in spinal muscular atrophy
(SMA); both the gene and the disease are discussed in more detail in section 1.2.3.1,
below. Although abnormal copy number of SMN1 has also been identified as a
susceptibility factor for ALS (Corcia et al., 2002), the numbers involved in this study
were not very large, and the findings are probably artefactual (Crawford and
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Scholasky, 2002). The finding that apresenilin-1 polymorphism was associated with
ALS may also be due to the relatively small number of patients involved, especially
as the 95% confidence interval was only 1.06, with a p-value <0.03 (Panas et al.,
2000). The microtubule-associated protein tau (MAPT) has been implicated in a
number of neurodegenerative diseases (reviewed in Lee et al., 2001). A
polymorphism in the MAPT gene has been identified as a susceptibility factor for the
ALS-Parkinsonism Dementia Complex of Guam (Poorkaj et al., 2001).
There may also be genotypes which affect the course of ALS in an individual, for
example, the rate ofprogression of the disease or the age of its onset, rather than the
overall susceptibility to the disorder. For example, the apolipoprotein E (APOE) s4
allele has been associated with decreased survival times in ALS patients (Drory et
al., 2001). Monoamine oxidase B alleles have been found to be associated with the
age of disease onset, but this finding may be artefactual, given the small numbers
involved in the study (Orru et al., 1999).
1.2.3,1 Spinal Muscular Atrophy
Spinal muscular atrophy is the second most common lethal autosomal recessive
disease in Caucasian populations (after cystic fibrosis) (DiDonato et al., 1994), with
an incidence of 1 in 10,000 live births and a carrier frequency of 1 in 50 (Emery,
1991). Classification of the disease (reviewed in Hausmanowa-Petrusewicz, 1991) is
based on age of onset. Where this is during infancy, the disease is classified as
Werdnig-Hoffmann disease, and is invariably fatal by the age of 2 years. Types II
and III are less severe, but still present in childhood. The much rarer Types IV and V
are adult-onset forms of the disease. All three of the childhood forms are usually
recessively inherited, although there are some rare cases of dominant inheritance.
They are linked to chromosome 5ql2.2-ql3.3, and are caused by deletions or
mutations in the survival motor neuron 1 (SMN1) gene (Brahe et al., 1995;
Brussaglia et al., 1995; Burglen et al., 1995; Gambardella et al., 1998; Lefebvre et
al., 1995; Rodrigues et al., 1995). At this locus there is a 500kb inverted repeat.
The resulting (more centromeric) duplicated copy ofSMN1, SMN2, differs from
SMN1 at only 5 nucleotide positions. However, it is only expressed at very low levels
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due to an altered splicing pattern resulting in the loss of exon 7 (Lorson et al., 1999;
Monani et al., 1999). There is also evidence that gene conversion from SMN1 to
SMN2 can occur at this locus, and cause disease (Campbell et al., 1997). A
correlation has been reported between the amount of SMN protein and the severity of
the spinal muscular atrophy phenotype (Lefebvre et al., 1997). There is also some
correlation between the copy number ofSMN2 and the disease, with a higher number
ofSMN2 copies acting as a protective factor (Harada et al., 2002). SMN2 could thus
be acting as a modifying factor in the disease (Frugier et al., 2002). Other candidate
modifying factors include baculoviral IAP repeat-containing protein 1, BIRC1
(previously known as neuronal apoptosis inhibitory protein, NAIP), in which
deletions in SMA patients have been reported (Roy et al., 1995), and SERFA4
(previously known as H4F5) (Scharf et al., 1998), both in the SMN region. The
structure of the gene locus is shown in figure 1-2.
SMN2 y/BIRC1 BIRC1 SMN1
Figure 1-2 Diagram (not to scale) of SMN gene locus on Chromosome 5q.
Arrows indicate the direction of transcription. SMN1 is the survival motor
neuron 1 gene, SMN2 is its duplicated copy, BIRC1 encodes baculoviral IAP
repeat-containing protein 1, and I//BIRC1, the BIRC1 pseudogene.
Unlike the human SMN gene, the mouse gene is not duplicated, and knocking out
Smn results in early embryonic lethality (Schrank et al., 1997). Expressing the human
SMN2 gene in these mice results in a phenotype similar to SMA, with the SMN2
transgene suppressing the phenotype to a degree dependent on the transgene copy
number (Hsieh-Li et al., 2000). Transgenic mice have also been produced in which
an SMN gene containing SMA-associated mutations has been expressed in either
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neuronal (Frugier et al., 2000) or muscle cells (Cifuentes-Diaz et al., 2001). In both
cases, a phenotype similar to SMA was seen in the affected tissues, which suggests
that both muscular and neuronal involvement is required for the disease.
1.2.4 Pathogenesis
Despite the identification of SOD1 mutations almost 10 years ago, the precise cause
ofALS remains unknown at a molecular level. There are several competing theories
of pathogenesis, although it is likely that disease is caused by more than one
mechanism. Theories currently include oxidative stress, neurofilament accumulation,
excitotoxicity and mitochondrial dysfunction. A central question which remains to be
answered is why motor neurons are selectively affected, when both SOD1 and alsin
are ubiquitously expressed. Motor neurons are extremely large cells, with a somatic
diameter of 50-60pM in man and long axonal processes. It is possible that their large
size, with concomitant high energy demands and high metabolic rate, renders them
particularly sensitive (Shaw and Eggett, 2000). Alternatively, the cells may be
particularly susceptible to alterations in the cytoskeleton. Motor neurons are also
uniquely vulnerable to exposure outside the CNS at the neuromuscular junction,
where the axon termini are not protected by the blood-brain barrier. They may be
affected by deleterious factors at this site, and may also require the retrograde
transport of trophic factors and signalling molecules from muscle (Shaw and Eggett,
2000).
1.2.4.1 The Oxidative Stress hypothesis
SOD1 catalyses the reaction:
202 " + 2H+ -a 02 + H202
The role of SOD1 in the metabolism of reactive oxygen led to the theory that
pathogenesis was caused in some way by oxidative stress. Indeed, enhanced oxygen
radical production is seen in transgenic mice carrying mutant human SOD1 genes
(Liu et al., 1998). One hypothesis is that toxicity is caused by the copper-mediated
metabolism of aberrant products. One candidate is peroxynitrite, and increased 3-
nitrotyrosine, a marker for damage mediated by peroxynitrite, has been reported in
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the motor neurons of both sporadic and familial ALS cases (Beal et ah, 1997). The
delivery of copper to SOD1 is mediated through a soluble factor identified as the
copper chaperone for SOD1 (CCS), which interacts directly with SOD1 (Leah et al.,
1998). However, knocking out CCS in mice carrying mutant SOD} genes did not
affect the disease course, suggesting against an involvement for the aberrant copper
mediated activity ofmutant SOD1 in the pathogenesis ofALS (Subramaniam et ah,
2002).
1.2.4.2 Neurofilament Accumulation
Neurofilaments are intermediate filament proteins, and form the major component of
the neuronal cytoskeleton (Julien and Mushynski, 1998). There are three
neurofilament subunits, light, medium and heavy chain (NFL, NFM and NFH;
encoded by the genes NEFL, NEF3 and NEFH in humans and Nefl, Nef3 and Nefh in
mouse). All three contain two coiled-coiled domains, which are involved in the
dimerisation of two neurofilament subunits. They are obligate heteropolymers,
requiring the NFL subunit together with either the NFM or NFH subunit for
polymerisation. NFM and NFH also have tail regions which contain multiple copies
of the Lys-Ser-Pro (KSP) sequence motif. Mutations in these KSP regions have been
found in a small minority ofALS patients (see section 1.2.3, above). These two
subunits are highly phosphorylated, but are more highly phosphorylated in the axon
than in the perikaryon. Neuronal accumulations of phosphorylated neurofilaments
are found in 70% ofALS cases (Manetto et ah, 1988; Munoz et ah, 1988; Sobue et
ah, 1990). This is not, however, due to any alteration in the physiochemical
properties of the protein, but represents the mislocalisation of normally
phosphorylated neurofilaments (Strong et ah, 2001). Paradoxically, NEFL mRNA
levels are decreased in the motor neurons ofALS patients (Bergerton et ah, 1994). It
was assumed that the accumulation of neurofilaments was pathogenic, either due to
the strangulation of axonal transport or the entrapment of cellular organelles (Tu et
ah, 1997). However, more recent work involving transgenic mice, outlined in section
1.2.5.2, below, has suggested that the perikaryal accumulation of neurofilaments may
actually represent a protective mechanism.
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1.2.4.3 Glutamate Excitotoxicity
Glutamate is an excitatory transmitter in the central nervous system, but it is harmful
in excess. Rapid removal of glutamate is therefore required, and is carried out by
excitatory amino acid transporters. In humans, there are five such transporters. The
most abundant is SLC1A2, previously known as EAAT2. The mouse orthologue is
Slcla2 (previously known as GLT1). Mice in which Slcla2 has been knocked out
suffer epilepsy (Tanaka et al., 1997). There have been a number of factors
implicating glutamate transporters in the pathogenesis ofALS, suggesting that a lack
of functional SLC1A2 in ALS leads to the failure of glutamate clearance, resulting in
prolonged neuronal excitation and motor neuron degeneration (Rothstein et al.,
1995).
Reduced levels of glutamate transport have been reported in the brain and spinal cord
ofALS patients (Rothstein et al., 1992). Reduced levels of SLC1A2 in ALS cases
have also been reported in the motor cortex and spinal cord ofALS patients (Fray et
al., 1998; Rothstein et al., 1995). Similarly, in transgenic mice and rats that carry
extra copies of a mutated SOD1 gene, both increased levels of glutamate and reduced
levels ofSlcla2 have been found (Alexander et al., 2000; Howland et al., 2002).
Mutations in SLC1A2 have been found in one sporadic and two familial patients,
although these were from the same family (Aoki et al., 1998). Aberrant SLC1A2
mRNA transcripts, involving either the retention of intron 7 or the skipping of exon
9, have also been found in the motor cortex ofALS patients but not of controls (Lin
et al., 1998). However, not only has a later study failed to replicate these findings
(Flowers et al., 2001), but aberrant transcripts have also been reported in control
individuals (Honig et al., 2000; Meyer et al., 1999; Nagai et al., 1998).
1.2.4.4 Mitochondrial Dysfunction
The skeletal muscles ofALS patients have mitochondrial respiratory chain defects,
with reduced levels ofNADH:cytochrome c oxidoreductase and cytochrome c
oxidase and also reduced levels ofmanganese-superoxide dismutase. They also have
reduced levels ofmtDNA (Borthwick et al., 1999; Vielhaber et al., 2000). As with
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all the pathological findings, it is difficult to separate out primary and resulting
secondary changes - mitochondrial changes may reflect secondary changes,
especially as they are only seen in a proportion of patients.
1.2.4.5 Environmental Agents
A number of environmental agents have been investigated as potential causes of
ALS, reviewed by Mitchell (2000). These include occupational exposure, physical
fitness, smoking, aluminium and heavy metals, with no clear frontrunners. The plant
Cycas circinalis has been implicated in ALS-Parkinsonism-Dementia complex on
Guam. The seeds, from which the islanders produce flour, contain the neurotoxins
beta-N-methylamino-L alanine (BMAA) and methylazomethanol p-D-glucoside
(Spencer et al., 1987). The discovery of enterovirus DNA sequences in the spinal
cord of ALS patients has led to the hypothesis that ALS is caused by latent viral
infection (Berger et al., 2000; Woodall et al., 1994), although a later study failed to
replicate these findings (Walker et al., 2001). ALS can also occur secondary to HIV
infection (Graham and Lantos, 1997).
1.2.5 Animal models of motor neuron disorders
Animal models are becoming increasingly valuable in the study of disease
pathogenesis. Mice are particularly useful due to their short generation times and
ease of breeding. With the advent of transgenic techniques, different mutant mice can
be crossed to test or develop new theories about disease. In the case ofmotor neuron
disease, they are of great value as material such as spinal cord can be accessed which
would not be possible from living patients. They also allow the study ofboth
presymptomatic animals and those at different, defined stages of the disease process,
as the disease course is both known and predetermined. They can also, of course, be
used to assess new treatments - for example, it was found that the administration of
creatine to a transgenic model of ALS significantly increased survival (Klivenyi et
al., 1999). There are two kinds ofmouse models - the "classical" models which have
arisen either spontaneously or through mutagenesis programmes, for which the
underlying genetic lesions are gradually becoming known, and those which have
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been intentionally generated using transgenic or knockout technology. There are also
other animals which have been used as models for ALS, which lie outside the scope
of this thesis and are reviewed elsewhere (Doble and Kennel, 2000). It is interesting,




Wasted is an autosomal recessive mutation which arose spontaneously in the Jackson
laboratory in 1972 (Shultz et al., 1982). Homozygous wst/wst mice are normal until
weaning (approximately 21 days old), but then deteriorate rapidly and die by 28
days. This timecourse is unaffected either by the genetic background of the mice, or
by any environmental influences to which they have been exposed. They develop a
neuromuscular phenotype, which begins with tremoring and gait abnormalities, is
followed by rapid weight loss and culminates in paralysis. The phenotype also has
immunological features, which include atrophy of the spleen and thymus and a
defective response of lymphoid-derived cells to radiation damage (Goldowitz et al.,
1985; Woloschak et al., 1987). This immunological aspect of the phenotype
originally led wasted mice to be considered as a model for ataxia telangiectasia
(Shultz et al., 1982). However, the neurological features of the phenotype, and, in
particular, the specific loss ofmotor neurons of the anterior spinal cord, have led to
the mice being considered as a model for motor neurone disease (Lutsep and
Rodriguez, 1989).
The genetic defect responsible was identified in 1998 as a 15 kb deletion on mouse
chromosome 2 (Chambers et al., 1998). The deleted region includes the promoter
region and first exon of the gene eukaryotic elongation factor la2, Eefla2, which
leads to the abolition of its expression. The protein which it encodes, eEFlA-2, is a
tissue-specific isoform of the more widely expressed eEFlA-1. The two isoforms are
discussed in more detail in section 1.3, below. There is no evidence, either
experimental or in silico, for any other genes within the wasted deletion. The closest
Chapter 1 - Introduction 12
gene is a novel gene, lOkb downstream of the deletion, and is currently being
investigated in our laboratory.
Wobbler, wr
Wobbler (wr) is another autosomal recessive mutation. The mice are normal at birth,
but develop neuromuscular features by their third week. These include tremoring, a
wobbling gait and progressive weakness and wasting of the muscles of the head,
neck and forelimbs. The mice usually die after three or four months, although in
some cases the disease can "plateau" and in these cases the mice can live for over a
year (Duchen et al., 1968). They also have defects in spermatogenesis, caused by the
failure of the acrosome to form properly and attach to the sperm nucleus (Heimann et
al., 1991; Leetsma and Sepsenwol, 1980). Histologically, they show vacuolisation of
the cervical motor neurons, a decrease in the number of a-motor neurons in the
anterior horn region of the cervical spinal cord, demyelination of nerve fibres and
neurofilament accumulation (Baulac et al., 1983; Pernas-Alsono et al., 1996). The
wobbler gene has been mapped to the proximal region of chromosome 11
(Kaupmann et al., 1992), between D1 lMit79 andDllMitl9 (Resch et a/., 1998),
recently narrowed to the region between 147N22rev andMurrl (Fuchs et al., 2002).
The wr locus is in a region of conserved synteny with human Chromosome 2pl4
(Wedemeyer et al., 1996). The genetic defect responsible for the wobbler phenotype
remains unknown, although several genes, including the spectrin isoform Spnb-2,
decarboxylase Ddc (Lengeling et al., 1994) and Rabl have been excluded as
candidates (Wedemeyer et al., 1996). A genetic modifier, which aggravates the
disease, has been identified on Chromosome 14, between D14MIT154 and
D14MIT105 (Ulbrich et al, 2002).
Neuromuscular degeneration, nmd
Neuromuscular degeneration is another spontaneous autosomal recessive mutation.
The mice suffer a loss ofmotor neurons and skeletal muscle atrophy, become
progressively more paralysed and die within four weeks of age. The causative
genetic defect, previously mapped to chromosome 19 (Cook et al., 1995), is in
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immunoglobulin mu binding protein 2 (ighmbp2), a putative transcriptional activator
and DNA helicase (Cox et al., 1998). There are two alleles, the nmd2J allele being
caused by a splice site mutation, and the nmd' allele by a single amino acid
substitution. The authors also identified a modifier locus, Mnm, on chromosome 13.
As with SOD1 and alsin in human ALS, it is unclear why there is a specific neuronal
phenotype as the gene is ubiquitously expressed. Mutations in IGHMBP2, the human
orthologue of the mouse gene, have been identified as the causative mutation in
spinal muscular atrophy with respiratory distress (SMARD) (Grohmann et al., 2001).
Progressive motor neuronopathy, pmn
Progressive motor neuronopathy has been considered as a model for SMA.
Homozygous mice show degeneration of their motor axons, and die from two to six
weeks after birth (Schmalbruch et al., 1991). The genetic defect underlying this
model has recently been identified as an amino acid substitution in the tubulin-
specific chaperone e (TBCE) protein (Martin et al., 2002). Mutations in the human
orthologue have been found to cause hypoparathyroidism-retardation-dysmorphism
and autosomal recessive Kenny-Caffey syndrome (Consortium, 2002). In this case,
there are thus clear differences between the human and mouse phenotypes caused by
mutations in the same gene. This may be due to fundamental differences between
humans and mice, but there may actually be unlooked-for similarities in other
tissues.
Other classical models
Unlike the mutants described above, legs at odd angles (Loo) is an autosomal
dominant mutation. It arose as a result of the ENU mutagenesis programme. The
mice have a progressive loss of function of their hindlimbs and a normal lifespan
(Nicholson et al., 2000; Rogers et al., 2001). The mutation maps to distal
chromosome 12 (Witherden et al., 2002). There are other models in which there is
some motor neuron involvement, but they have been considered as better models for
other diseases. For example, motor neuron degeneration, mnd, has been cloned as
ceroid-lipofuscinosis, neuronal 8 (Cln8) (Ranta et al., 1999). Mutations in the human
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gene cause progressive epilepsy with mental retardation (EPMR) (Ranta et al.,
1999). Gracile axonal dystrophy (,gad) shows sensory ataxia at an early stage,
followed by motor ataxia at a later stage. It is caused by a deletion in Uchll, which
encodes the ubiquitin carboxy-terminal hydrolase isozyme, involved in the de-
ubiquitination pathway (Saigoh et al., 1999). Dysfunction of Uchll in gad mice
disturbs the re-use of free ubiquitin, and causes the accumulation of abnormal
proteins. The chromosomal location ofmotor neuron disease, mneu, is unknown
(Miyata, 1983).
1.2.5.2 Transgenic and knockout models
SOD1
The value of using transgenic mice in motor neuron research was demonstrated by
the finding that SOD 1 knockout mice do not develop clinical features comparable
with ALS, although they do show an increase in cell death after axonal injury
(Raume et al., 1996) and a late-onset neuromuscular pathology (Flood et al., 1999).
This led to the hypothesis that pathogenesis in human ALS is not caused by a loss of
function of SOD1, but is more likely to occur due to a gain of some novel toxic
function. Transgenic mice have been generated which carry several copies of human
SOD1 genes with the ALS mutations G37R (Wong et al., 1995a), G85R (Bruijn et
al., 1997), G93A (Gurney et al., 1994; Tu et al., 1996) and G39R (Friedlander et al.,
1997), along with the mutated mouse gene G86R (Morrison et al., 2000; Ripps et al.,
1995). They recapitulate features of the human disease, including abnormal
neurofilament accumulation, and aggregations ofmutant SOD1 (Johnston et al.,
2000), with an age of onset dependent on the transgene copy number. The G85R
mice show a particularly aggressive disease progression.
These transgenic mice have been an extremely valuable research tool in studies on
the pathogenesis of ALS, not least because they can be crossed with animals which
are knockout or transgenic for other genes. For example, the earlier onset of disease
in G93A mice which are also CNTF deficient suggest the latter is a modifier gene
(Giess et al., 2002). Similar results were reported for SOD2, but this has
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subsequently been found not to be mutated in the disease (Andreassen et al., 2000).
A modifier locus on mouse chromosome 13, between D13MU36 and D13MU76, has
also been identified (Kunst et al., 2000). This region includes SMN, which may
provide a further link between the two diseases.
Transgenic techniques have also been used to restrict the expression of genes to
particular cell types. For example, restricting the expression of the mutant SOD1 to
astrocytes did not result in motor neuron degeneration (Gong et al., 2000). However,
it is difficult to understand why restricting the expression to neurons does not lead to
a phenotype (Pramatarova et al., 2001).
Overexpressing the non-mutated human gene in mice does not lead to clinical
features of disease, although the mice do have subtle motor neuron pathology and
abnormalities in the neuromuscular junctions of their tongues (Avraham et al., 1988;
Canto and Gurney, 1995; Epstein et al., 1987). Aged mice of 2 years also show an
impaired motor performance (Jaarsma et al., 2000). It is interesting to note that the
early studies on the SOD1 overexpressing mice were done in the context of research
on Down syndrome, before SOD1 was identified as being mutated in ALS.
Neurofilaments
Mice in which the neurofilament genes have been knocked out individually either
show no phenotype or a very mild one, despite a reduction in axonal calibre
(diameter), and a loss of large motor axons. Nefl knockout mice have a delayed
axonal regeneration after injury (Zhu et al., 1997), Nef3 knockouts have decreased
NFL levels and increased NFH levels (Elder et al., 1998a), and Nefh is required for
the development of large calibre axons (Elder et al., 1998b; Kriz et al., 2000; Rao et
al., 1998; Zhu et al., 1998). Mice in which both Nef3 and Nefh have been knocked
out show axonal atrophy and hindlimb paralysis at two years of age (Elder et al.,
1999a). These mice also demonstrated that NFL is essential for polymerisation
(Elder et al., 1999b).
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Mice have also been generated which overexpress the neurofilament genes. The
overexpression ofwild-type mouse NefIt at up to 4.5 times the normal level does not
give rise to a clinical phenotype (Marszalek et al., 1996). However, overexpressing
human NEFH does cause an ALS-like phenotype, with neurological defects, muscle
atrophy and neurofilament accumulation (Cote et al., 1993), which can be relieved
by also overexpressing human NEFL (Beaulieu et al., 2000; Meier et al., 1999). This
suggests that human NEFH acts in a dominant negative manner. Increasing mouse
Nef3 did not result in an overt phenotype, although neurofilamentous swellings were
often seen in the perikarya and proximal axons ofmotor neurons (Wong et al.,
1995b), and there were changes in axonal transport (Xu and Tung, 2000).
Overexpressing Nefl results in an ALS-like pathology which resolves on the
cessation of transgene expression (Xu et al., 1993). Mice in which the type III
intermediate filament protein peripherin is overexpressed develop motor dysfunction
and the loss ofmotor neurons at two years of age (Beaulieu et al., 1999). This is
exacerbated by a loss ofNefl (Beaulieu et al., 2000). Mice were also generated which
expressed an NFHLACZ transgene, in which a truncated NFH protein was fused to
P-galactosidase (Eyer and Peterson, 1994; Tu et al., 1997). The fusion protein
accumulated in the perikarya, and the axons which developed had small calibres. The
mice did not develop a phenotype, although they did lose Purkinje cells in old age.
Transgenic mice in which a point mutation in the Nefl gene has been introduced have
massive motor neuron degeneration and neurogenic atrophy of their skeletal muscles
(Lee et al., 1994). However, it is likely that this is due to defective RNA processing
caused by a c-myc tag in the 3'UTR (Canete-Soler et al., 1999), rather than the point
mutation.
Combining neurofilament and SOD1 transgenic mice has given some interesting
insights into the role of neurofilaments in the disease process. Crossing mice
transgenic for SOD1 with those overexpressing human NEFH delayed the onset of
disease by an average of 6 months (Couillard-Despres et al., 1998). The delay was
dependent on the degree ofperikaryal neurofilament accumulation - the greater the
accumulation, the later the disease onset. This effect may be because the
accumulated neurofilaments form a phosphorylation "sink" and are phosphorylated
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in preference to other proteins which would be more detrimental to the cell in a
phosphorylated form (Nguyen et al., 2001). Crossing SOD1 mice with those carrying
extra copies ofmouse Nefl or Nefh also extended lifespan (Kong and Xu, 2000).
Perhaps counterintuitively, the calibre of the axons is not important in the
pathogenesis of the disease. For example, as described above, mice with the Nefh or
Nef2 genes knocked out have a reduced axonal calibre and no phenotype. When mice
hemizygous for all three neurofdament genes were crossed to SOD1 transgenic mice
their axonal caliber was reduced without affecting neurofilament stoichiometry, but
the disease course remained unaltered (Nguyen et al., 2000). Similarly,
overexpressing Nefl led to a 50% increase in neurofilament density without affecting
the disease course (Couillard-Despres et al., 2000).
Vegf
Mice have been generated which lack the hypoxia-response element in the promoter
region of the vascular endothelial growth factor (Vegf) gene (Oosthuyse et al., 2001).
They have a phenotype which is striking in its similarity with human ALS, with
muscle weakness from 5-7 months of age due to the degeneration of lower motor
neurons. Neuronal death may be caused by a reduction in perfusion under conditions
of low oxygen, as the mice have reduced baseline and hypoxic levels of VEGF.
Alternatively, the loss of VEGF may be directly neurotoxic, as VEGF seems to have
a neuroprotective function.
Other transgenic models of motor neuron loss
Mice lacking the ciliary neurotrophic factor (CNTF) gene have a subtle phenotype in
adulthood (Masu et al., 1993). However, mice in which the receptor for CNTF has
been knocked out die perinatally and show severe motor neuron defects (DeChiara et
al., 1995). Transgenic mice which overexpress interleukin 3 develop motor neuron
degeneration from approximately 7 months of age. This is associated with an
autoimmune reaction, and the mice have been proposed as a model for progressive
muscular atrophy, PMA, rather than ALS (Chavany et al., 1998).
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1.3 Eukaryotic elongation factor 1 alpha
1.3.1 eEF1A
The translation ofmature mRNA into protein occurs at the ribosome, and is
composed of three stages: initiation, elongation and termination. The elongation
stage involves the sequential addition of amino acids to the growing polypeptide
chain by the translation elongation complex eEFlH. This complex is comprised of
eEFl A and eEFlB. The role ofeEFl A is to transport aminoacyl tRNAs to the
ribosomal A-site in a GTP-dependent fashion (Hershey, 1996). On correct codon-
anticodon recognition, GTP is hydrolysed to GDP. The continued addition of amino
acids requires the exchange of bound GDP for GTP, which is performed by eEFlB.
The process is illustrated in figure 1-3. eEFlB is comprised of three subunits,
eEFlBa, eEFl Bp and eEFl By. A guide to the current and past nomenclature of the
translation elongation factors eEFlA and eEFlB is given in table 1-1.
Figure 1-3 Diagram showing translation elongation (adapted from Stark et al.)
Gene name, Gene name, Protein Aliases
human mouse
EEF1A1 Eef1a1 eEF1A-1 EF-1oc; EF1otEF1A; EEF1A
EEF1A2 Eef1a2 eEF1A-2 EF-1a2; S1
EEF1B2 Eef1b2 eEFIBa EF-1p; EF1P
EEF1D Eefld eEFIBp EF-15; EF15
EEF1G Eeflg* eEF1By EF-1y; EF1y
Table 1-1 Nomenclature of eEF1A and eEF1B isoforms.
Eeflg is starred because it has not yet been assigned a gene symbol.
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1.3.2 eEF1A-2
eEFl A-2 was initially isolated in the rat by Ann et al. on the basis of its antigenic
similarity to statin, leading to its early designation as SI (Ann et al., 1991). In
humans, eEFlA-1 and eEFlA-2 are 92% identical at the amino acid level (Knudsen
et al., 1993). There is also a high degree of similarity between the isoforms of
different mammalian species, with only one amino acid difference between human
and mouse eEFlA-2 proteins (Lee et al., 1994). In humans, the protein consists of
463 amino acids with a predicted isoelectric point of 9.72 (Knudsen et al., 1993).
The mouse protein also has 463 amino acids. The eEFlA-1 proteins of both species
have 462 amino acids. A line-up of the protein sequences demonstrates the similarity
between the two isoforms, and is shown in figure 1-4. The human gene EEF1A1 is
located on chromosome 6, at 6pl4, and EEF1A2 is on chromosome 20, at 20ql3.3
(Lund et al., 1996). Although EEF1A1 has numerous pseudogenes (Madsen et al.,
1990), EEF1A2 appears to be single copy (Lund et al., 1996).
The fact that there is only 20% homology between Eeflal and Eefla2 in the 5' (and
3') untranslated regions led to initial speculation that the two genes are differentially
regulated (Ann et al., 1991). This was quickly borne out by the finding that the two
isoforms have different expression patterns. Using Northern and RNase protection
analyses, Eefla2 was shown to be expressed in brain, heart and skeletal muscle in
rats (Lee et al., 1992), rabbits (Kahns et al., 1998) and humans (Knudsen et al.,
1993). At the protein level, eEFl A-2 was shown to be expressed in the brain, heart
and skeletal muscle of rats, humans and mice, but not in the smooth muscle of the
gut or bladder (Khalyfa et al., 2001). Within the brain, only differentiated neurons
express eEFl A-2, whereas proliferating neurogenic cells express only eEFlA-1 (Lee
et al., 1995). This, along with the fact that in mouse fibroblasts, Eefla2 is most
abundant in Go phase, but is reduced in Gi and S phase (Ann et al., 1991), suggested
expression is limited to terminally differentiated cells which cannot re-enter the cell
cycle.
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401 ivemvpgkpmcvesfsqypplgrfavrdmrqtvavgviknvekksggagk 450
451 vtksaqkaqkak 462
I I I I II I I I I I
451 vtksaqkaqkagk 463
Figure 1-4 Line-up of mouse eEF1A-1 (top) and eEF1A-2 (bottom), showing
the high degree of similarity between the two proteins. Identity between two
amino acids is indicated by a vertical line, conservative amino acid
substitutions by two dots and semi-conservative substitutions by one dot.
Where there is no agreement between two amino acids, there is no symbol
between them. The amino acids of eEF1A-1 and eEF1A-2 which differ
between the mouse and human proteins are highlighted in red, with the
equivalent human residues at these positions in blue.
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1.3.2.1 Isoform switch
In those tissues in which eEFl A-2 is expressed, there is a switch in expression
between the two iso forms (Lee et al., 1995). In rat brains, Eefla2 mRNA levels
increase steadily during late embryogenesis, and reach a plateau soon after birth.
During this period, there is a slight drop in Eeflal mRNA levels. (Lee et al., 1993a).
In muscle and heart, the increase in Eefla2 mRNA levels occurs after birth, and is
accompanied by a much more precipitous drop in Eeflal levels. A cartoon of the
situation in muscle is shown in figure 1-5, below. This isoform switch explains the
onset ofwasted at 21 days, as it is at this point that Eeflal levels have declined, but
in wasted mice there is no Eefla2 to carry out translation.
Figure 1-5 Cartoon of isoform switching in rat muscle
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At the protein level, levels of eEFlA-2 appear to rise, and of eEFlA-l to drop, from
around postnatal day 1 (PI) in mouse brain and P7 in skeletal muscle. The switch
appears to be much more gradual in mouse heart, with the switch occurring through
late embryogenesis and early postnatal life (Khalyfa et al., 2001). Although it has
been reported that levels of eEFlA-2 in muscle remain stable through adulthood, the
antibody used in this case probably recognises both isoforms (Welle et al., 1997). In
muscle, after injury induced by the toxin Marcaine, there is also a switch back to the
embryonic expression pattern where eEFlA-l levels are high compared to eEFl A-2
(Khalyfa et al., 1999). Regenerating muscle cells could therefore represent a return to
embryonic forms. Increased eEFlA-l mRNA levels have also been reported in
diabetic skeletal muscle (Reynet and Kahn, 2001). However, in this case it is not
clear whether it is actually eEFlA-l which was increased, as the identified clone was
only partially sequenced, and reported as being 99% similar to eEFl A-l. It could,
therefore, represent one of the eEFlA-l pseudogenes which has been expressed.
1.3.2.2 Why are two isoforms needed?
It is not clear why two eEFlA isoforms are required. eEFlA-2 acts as a translation
elongation factor with equal activity to eEFlA-l, although there are differences in
the relative affinities for GTP and GDP between the two isoforms (Kahns et al.,
1998). One possible difference is that eEFlA-2, in contrast to eEFlA-l, has not been
shown to interact with any of the components of the exchange factor eEFlBa
(Mansilla et al., 2002). However, if this is the case, it is difficult to understand how
GDP-GTP exchange can occur, as there do not appear to be tissue-specific isoforms
of eEFlBa (Chambers et al., 2001). Yeast strains with mutations in eEFlBa have a
reduced translation and increased translational fidelity (Carr-Schmid et al., 1999).
Aside from its role in translation, eEFlA-l is also implicated in many other
processes, including actin binding and bundling (Liu et al., 2002; Yang et al., 1990),
the severing ofmicrotubules (Shiina et al., 1994), apoptosis (Chen et al., 2000;
Duttaroy et al., 1998) and tumourigenesis (Tatsuka et al., 1992). eEFlA is
abundantly expressed, forming from 3 - 5% of the total cellular protein content (Lee
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et al., 1993a). It is present at 7-35 times the amount of the other eEFlH components,
which supports the idea that eEFlA-l has important functions beyond its role in
translation (Condeelis, 1995). It is possible that there are key differences between the
two isoforms in one or more of these non-canonical functions.
1.3.2.3 Translation in neurons
One key distinguishing feature of neurons is their large size. It is therefore possible
that eEFlA-2 is required in these cells due to an involvement in cytoskeletal
modelling or transport. Overexpression of eEFlA-l affects the organisation and
function of the cytoskeleton in yeast (Munshi et al., 2001). Alternatively, eEFl A-2
may be required for synaptic translation. In neurons, where the synapse may be some
distance from the cell body, there is evidence that translation occurs locally in the
dendrites (Job and Eberwine, 2001a; Job and Eberwine, 2001b). This spatial
regulation of translation would allow the synthesis of proteins, such as receptors, at
optimal distances from the stimulated membrane for synapse formation during
development and for synaptic plasticity in mature neurons.
It is also possible that specific mRNAs are required to be translated specifically at
the synapse. Although components of the translation machinery, such as ribosomes
(Job and Eberwine, 2001b), and translational activity have been located at the distal
regions of the dendrites, there have been no studies localising eEFlA-2 in neurons.
Although eEFlA has been reported in dendrites, it is not clear whether this is specific
for eEFlA-1 or eEFlA-2 (Job and Eberwine, 2001b). Immunofluoresent analysis of
the subcellular localisation of eEFlA-l has shown that it localises to both the
cytoplasm and the nucleus (Sanders et al., 1996). This is in contrast to the rest of the
eEFlH components, which localise to the endoplasmic reticulum. However, the
subcellular localisation of eEFl A-2 has not been clearly characterised, although this
was investigated by Khalyfa et al. (Khalyfa et al., 2001). A recent study claimed a
cytoplasmic localisation in PC-12 cells, however, in this case an antibody to
eEFlA-l was used (McClatchy et al., 2002).
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There may also be important protein interactions which are specific for eEFlA-2. For
example, the CNS-specific muscarinic acetylcholine receptor subtype M4 has
recently been shown to interact with eEFlA-2 (McClatchy et al., 2002). Muscarinic
activation is known to increase dendritic translation (Feig and Lipton, 1993).
Dysfunction in mAChR signalling has also been implicated in disorders including
Parkinsons and Alzheimers Disease (Flellstrom-Lindahl, 2000). Although eEFlA-1
binds to actin (Eiu et al., 2002; Yang et al., 1990), it is not known whether eEFlA-2
also interacts. Data from yeast mutants has shown that although actin is not required
for translation, it is important in translational fidelity (Kandl et al., 2002).
1.3.2.4 eEF1 A and cancer
There is evidence to implicate both eEFlA isoforms in cancer. eEFlA-1 renders cells
susceptible to transformation (Tatsuka et al., 1992), and is overexpressed in
metastatic rat mammary adenocarcinoma, possibly through alterations in the
cytoskeleton (Edmonds et al., 1996). The PTI-1 oncogene is expressed in human
prostatic carcinomas. It is a fusion between 630 bp of a Mycoplasma ribosomal RNA
gene and 1493 bp of sequence representing a truncated and mutated pseudogene of
EEF1A1 (Shen et al., 1995). EEF1A2 has recently been identified as a putative
oncogene in ovarian cancer (Anand et al., 2002). It was found to be amplified in 25%
ofprimary ovarian tumours and 4 of 12 ovarian tumour cell lines. The expression of
EEF1A2 also rendered NIH3T3 cells tumorigenic, and increased the growth of
ovarian carcinoma cells xenografted into nude mice.
1.3.3 eEF1A and ZPR1 - a link with SMN?
The SMN gene encodes a ubiquitously expressed 294 amino acid protein with a
molecular weight of 38 kD and no obvious sequence identity with any other proteins.
It is currently unknown how mutations in SMN change the function of the protein
and lead to disease. SMN has been implicated in the processing of small nuclear
riboproteins (snRNAs) (Carvalho et al., 1999), pre-mRNA splicing (Pellizzoni et al.,
1998), and transcription (Pellizzoni et al., 2001). Cells in which the SMNAN27
mutant protein is expressed show a reduction in transcription (Pellizzoni et al.,
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2001). The SMN protein is expressed in both the cytoplasm and within nuclear
bodies known as gems (gemini of coiled, or Cajal bodies) (Liu and Dreyfuss, 1996).
The zinc finger protein, ZPR1, has been identified as necessary for the nuclear
translocation of SMN to the nucleus (Gangwani et al., 2001). In the fibroblasts of
patients with the SMNAexon7 deletion, the interactions between SMN and ZPR1 are
disrupted, probably because the missing C-terminus of SMN is required for the
interaction with ZPR1, and neither protein translocates correctly. Mutant SMN
proteins caused by the 472del5 frameshift mutation associated with cases of spinal
muscular atrophy mislocalise to the nucleoplasm and nucleolus (Lefebvre et al.,
2002). Evidence from transgenic mice expressing a mutated SMN in which exon 7
has been deleted suggests that it is this disruption of the nuclear targeting of SMN
which is responsible for the disease (Pellizzoni et al., 2001).
ZPR1 also interacts with eEFlA-1. After stimulation by serum, mitogens, or
epidermal growth factor, ZPR1 and eEFlA-l translocate to the nucleus (Gangwani et
al., 1998). It is thus tempting to speculate that ZPR1, SMN and eEFlA-1 all form
part of the same complex, although there is no direct evidence for this. There is
similarly no indication ofwhether ZPR1 also interacts with eEFl A-2.
1.3.4 eEF1A isoforms through evolution
eEFlA has been conserved through evolution, indeed, it has been used for
phylogenetic analysis (Roger et al., 1999). In mice, rats, rabbits and humans, only the
two previously described eEFlA isoforms, eEFlA-l and eEFlA-2, have been
characterised. The similarities between the same isoforms of different species are
greater than those between the two isoforms of a single species. In chickens, only
one eEFlA gene has been described (Wang et al., 1994). In the African clawed frog
Xenopus laevis there are two adult isoforms which are similar to the mammalian
eEFlA, one oocyte-specific and one somatic (Abdallah et al., 1991a; Dje et al.,
1990). There is a third form which is less similar to the mammalian genes, and is
only expressed in immature oocytes and pre-meiotic germ cells. The A. laevis
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isoforms are described in more detail in Chapter 6, section 6.1.2. In Drosophila
melanogaster, there are two stage-specific genes, F1 and F2 (Hoveman et al., 1988;
Walldorf et al., 1985). Saccharomyces cerevisiae have two genes, TEF1 and TEF2
(Schirmaier and Philippsen, 1984), whereas S. pombe have three genes, with
differential regulation (Mita et al., 1997). In Escherichia coli there are two identical
EF-Tu genes. The presence of two tissue-specific isoforms of eEFl A, in which one is
expressed in the CNS, heart and skeletal muscle of adult animals, thus appears to be
specific to mammals.
1.4 Project Aims
The overall aim of this project was to investigate the potential involvement of
eEFlA-2 in the pathogenesis ofmotor neuron disease. Within this broad theme there
were four main aims. Firstly, to further characterise wasted mice, in order to evaluate
them as a model for motor neuron disease. Secondly, to determine whether there is a
direct involvement ofEEF1A2 in the disease, by mutation screening the gene in
patients. Thirdly, to develop and characterise specific antibodies against eEFlA-2
and eEFlA-l in order to analyse the expression of the two isoforms. Finally, to
investigate the expression of the two isoforms in a non-mammalian species, Xenopus
laevis.
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2 Chapter 2 - Materials and Methods
2.1 General Materials and Solutions
Unless otherwise indicated, general laboratory chemicals were obtained from Sigma.
All PCR primers were obtained from Sigma-Genosys. Cell culture media were
obtained from Invitrogen.
PBS
Phosphate buffered saline was made by dissolving 1 PBS tablet (Sigma) in 200ml
H20, and autoclaving.
2.2 General Equipment
Again, unless otherwise indicated, centrifugation was performed on an eppendorf
5415C microfuge. The vortex used was a Jencons MSI minishaker. Absorbances at
260 and 280 nm were read on a Pharmacia Biotech Ultrospec 3000
spectrophotometer. Mice were weighed on an Avery-Berkel FB411. Their organs
were weighed on a Sartorius BP150.
2.3 Genotyping of wasted mice
2.3.1 Mouse husbandry
Mice were housed at the Biomedical Research Facility at the Western General
Hospital, a semi-barrier facility. They were fed a standard chow diet.
2.3.2 Extraction of genomic DNA from ear notches
For the purposes of identification and genotyping, mice were ear notched. The ear
notches were boiled in 0.6 ml 50 mM NaOH for 10 minutes, vortexed, neutralised
with 50pl TrisHCl pH 8.0 and centrifuged for 6 minutes. The supernatant was
removed and 1 pi was used in the genotyping PCR.
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2.3.3 Genotyping
Two PCRs were used to genotype mice. One amplified the wild type allele, if
present, and one amplified the wasted allele. In heterozygous mice, therefore, both
alleles were amplified. The primers used are given in table 2-1. Primers P2F and
P2R, originally designed by Khalyfa et al. (Khalyfa et al., 2001), were used to
amplify the wild-type allele, and gave a product of 452bp. Primers wstspanF and
wstspanR, designed by Dawn Loh in our laboratory, were used to amplify the wst
allele, and gave a product of 200bp. In each reaction mix were 5mM each primer,
0.05 mM dNTPs, 1 x Sigma Taq Buffer, 0.5U Taq polymerase and, for the wasted
PCR, 1.485M betaine. The total reaction volume was 25pl. PCR conditions were
95°C for 3 minutes, followed by 30 cycles of 94°C for 30 seconds, 54°C for 30
seconds and 72°C for 30 seconds. They were then held at 72°C for 10 minutes. An
MJ Gradient Cycler was used. Products were analysed on a 2% w/v agarose gel.
Primer Sequence
P2F tag tgg etc ctt gga aca g
P2R eta etc tec ctg aat gee tt
wstspanF ata age tec cca atg gta gag aa
wstspanR cgc gee att ctt gta ttg tt
Table 2-1. Primer sequences used in wasted genotyping.
2.4 Immunohistochemistry
2.4.1 Paraffin embedding and sectioning
Dissection and paraffin embedding was carried out in collaboration with Dr. J. Peters
at the MRC Mammalian Genetics Unit, Harwell. After dissection, mouse brain and
spinal cords were embedded in paraffin. The processing schedule is described in
table 2-2. Safeclear (Chemix) is a xylene alternative. Sections were then cut on a
Rachert-Jung 2030 microtome with a thickness of 4 jam.














Table 2-2 Processing schedule for sections
2.4.2 H & E Staining
Sections were hydrated by submersion for 5 minutes in 100% ethanol, followed by 5
minutes in 70% v/v ethanol and then 5 minutes in H20. Nuclei were then stained in
haematoxylin (Surgipath) for 5-10 minutes, washed briefly in H20 and differentiated
in acid alcohol (0.5% w/v HC1 in 70% v/v ethanol). They were again washed in H20
and then stained in saturated aqueous lithium carbonate. They were washed in H20
and then the cytoplasm and connective tissue were stained with eosin (Surgipath) for
5 minutes. The slides were finally washed in H20, dehydrated by submersion in 70%
v/v ethanol, followed by 100% ethanol, and then two changes of xylene. Slides were
mounted in pertex (CellPath).
2.4.3 Immunohistochemistry
The sections were rehydrated through a graded series of ethanols, with 5 minutes in
two changes of 100% ethanol and 5 minutes in two changes of 70% v/v ethanol.
They were then submerged in picric acid for 15 minutes and washed in H20 for 5
minutes. Where antigen retrieval proved necessary (shown in table 2-3), slides were
immersed in 0.01M citric acid (pH 6.0) and microwaved at full power for 15
minutes. They were allowed to cool and then washed in H20 for 5 minutes before
proceeding. All slides were then treated in 3% v/v hydrogen peroxide, to block
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endogenous peroxidases. They were again washed in H20 for 5 minutes, transferred
to a Sequenza (Shandon) and then washed in TBS (25mM TrisEDTA; 137mM NaCl;
27mM KC1; pH 7.4) for 5 minutes. Non-specific binding of the secondary antibody
was then blocked by incubating the slides in 100 pi sera (diluted 1 in 5 in TBS) from
the animal in which the secondary antibody was raised. Sera were obtained from
Diagnostics Scotland. The primary antibody (lOOpl) was then applied, diluted to an
appropriate concentration in TBS, and the slides incubated for 30 minutes. They
were then washed twice in TBS, and then incubated for 30 minutes in lOOpl
biotinylated secondary antibody (Dako), diluted 1 in 200 in TBS. They were then
washed once in TBS and incubated in 3 drops (approximately 135pl) StreptABC
(Dako) for 30 minutes. They were again washed in TBS, removed from the sequenza
and treated in diaminobenzidene (DAB) for approximately 2 minutes. Excess DAB
was removed by washing in H20. The slides were counterstained in haematoxylin
solution (Surgipath), rinsed in H20 and differentiated in saturated lithium carbonate.
They were washed once more in H20, dehydrated through 70% v/v ethanol and then











1:2000 None Swine Swine anti-
rabbit
NF (P) Dako; mouse
monoclonal
1:80 Citric acid Swine Swine anti-
rabbit
NF (de-P) Zymed; mouse
monoclonal








1:500 None Swine Swine anti-
rabbit
EEF1A-2 Goat polyclonal 1:50 Citric acid Rabbit Rabbit anti-
goat
Table 2-3 Experimental details for immunohistochemistry experiments
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2.5 RT-PCR
2.5.1 Extraction of RNA from tissues
2.5.1.1 Extraction from mouse brain
The mouse brains were kept at -70°C on receipt. Approximately half a mouse brain
was homogenised in 1ml RNAzol (Biogenesis) and incubated at 4°C for 5 minutes.
lOOpl chloroform was added, the samples were vortexed for 15 seconds, and
incubated for 5 minutes at 4°C. They were then centrifuged for 15 minutes at 12 000
rpm on a Beckman Coulter Avanti J-201 at 4°C and the upper phase was removed.
An equal volume of isopropanol was added and the samples were mixed by
inversion, incubated further for 15 minutes at 4°C and centrifuged at 12 000 rpm for
15 minutes at 4°C. The supernatant was discarded and the pellet was washed with
75% v/v ethanol (made with DEPC H20), centrifuged for 15 minutes at 12 000 rpm,
and air dried. The RNA was resuspended in 50pl H20 and stored at -70°C.
2.5.1.2 Extraction from X. laevis tissue
The RNeasy® Midi kit (Qiagen) was used to extract RNA from 150mg Xenopus
muscle, as per the manufacturer's instructions. The recommended modifications for
extracting RNA from muscle were observed, namely homogenisation using a
PowerGen 125 (Fisher), followed by Proteinase K incubation. The RNA was eluted
in 300pl RNase-free water.
2.5.2 cDNA synthesis
The extracted RNA was quantified by measuring the absorbance at 260nm. 4pg
RNA was treated with lpl DNasel (Roche) and 1.6pl DNase buffer in a total reaction
volume of 16pl. This was then incubated at room temperature for 15 minutes. The
DNase was inactivated by adding EDTA to a final concentration of 12.5mM and
incubating at 65°C for 10 minutes. Samples were then divided into two aliquots. In
one (RT), the RNA was transcribed, whereas in the other, control sample, no reverse
transcriptase was added. To both aliquots were added 2pl random hexamer primers,
lpl RNase inhibitor, dNTPs at l.OmM, MgCl2 at 5mM, 1 x Reaction Buffer, and
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either 0.8pl AMT Reverse Transcriptase or H20. All reagents were from the First
Strand cDNA Synthesis kit (Roche). Samples were held at room temperature for 10
minutes, 42°C for one hour and 99°C for 5 minutes. The cDNA obtained was either
placed on ice and used immediately for PCR, or stored at -20°C until use.
2.5.3 RT-PCR
Each PCR contained 5mM forward and reverse primers, 0.05mM dNTPs, lxPCR
buffer (Sigma), 1.485M betaine and 1 pi of either the reverse-transcribed or no-RT
control RNA mixes, in a total volume of 50pl. Primer sequences are given in table 2-
4. For the Slcla4 RT-PCR, cycling conditions were 95°C for 3 minutes, 30 cycles of
94°C for 1 minute, 50°C for 1 minute and 72°C for 1 minute, and 72°C for 10
minutes, on a Hybaid Omnigene. Amplification of Gapdh was used as a control
reaction to enable comparison between samples, using the same cycling conditions as
for the RT-PCR. For theA laevis RT-PCR, conditions were 95°C for 3 minutes,
followed by 40 cycles of 94°C for 30 seconds, 55°C for 30 seconds and 72°C for 30
seconds, followed by 10 minutes at 72°C, on an MJ Gradient Cycler.
Primer Sequence
Slc1a4 5F2 atq aaq qac ate gtc atg ct
Slc1a4 6R cac ttc ate ata gac gga agg
Slc1a4 5F aac ccg ttc acg ttc etc ct
Slc1a4 7R tcc aac act gga tgc cgt g
GAPDHF cat cac cat ctt cca gga gc
GAPDHR atg acc ttg ccc aca gcc tt
Xen1A2F2 tga gag gga gcg agg aat c
Xen1A2R1 get tta gaa tgc egg tc
Table 2-4 Primer sequences used in RT-PCR.
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2.6 Mutation screening
2.6.1 Extraction of genomic DNA from mouse brains
Tissues were stored at -70°C after receipt. Approximately half a brain was
homogenised in a sterile Treff homogeniser in 3 ml TNE buffer (lOmM Tris; 400mM
NaCl; 2mM EDTA). Proteins were broken down by the addition of 1OOpg/ml
Proteinase K (Sigma) and incubation overnight at 55°C. To this was added 3ml 2.6
M NaCl, and the cell debris was pelleted by centrifugation at 14 000 rpm. An equal
volume of ethanol was added to the supernatant to precipitate the DNA. It was then
washed twice in 70% v/v ethanol, and resuspended in 200 pi sterile H2O.
2.6.2 PCR
For the amplification ofEEF1A2, each reaction contained forward and reverse
primers at 5mM, dNTPs at 0.05mM each, either glycerol at 10% v/v, betaine at
1.485M, TMAC1 at l.OmM or DMSO at 60mM, 0.5pl Taq, lxPCR Buffer (Sigma)
and lpl DNA in a total reaction volume of 50pl. The PCR conditions used to amplify
the exons ofEEF1A2 are given in table 2-5, and for the amplification of the introns
and exons ofSlcla4 in table 2-6. The primer sequences used to amplify EEF1A2 are
given in table 2-7. Some of the introns ofSlcla4 were amplified using long-range
PCR, described in section 2.6.2.1, below. Where a Hybaid Omnigene was used for
amplification, cycling conditions were 95°C for 3 minutes, 30 cycles of 94°C for 1
minute, the appropriate annealing temperature for 1 minute and 72°C for 1 minute,
and 72°C for 10 minutes. Where an MJ Gradient Cycler was used, the cycling
conditions were 95°C for 3 minutes, followed by 30 cycles of 94°C for 30 seconds,
the annealing temperature for 30 seconds and 72°C for 30 seconds, and then 72°C for
10 minutes.
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Exon Primers Used Annealing Additive PCR machine
temp, °C
2 2F & 2Rnew 54 Betaine MJ
3 3F&2R 60 Glycerol Hybaid
3F1 &2R1 53 Glycerol Hybaid
4 4F & 4R2 58 Glycerol MJ
4F2& 4R4 59.5 Glycerol MJ
5 5F2& 5R2 55 Betaine MJ
6 6F & 6R2 55 Glycerol Hybaid
7 7F1 & 7R 55 Betaine Hybaid
7F & 7R1 55 Betaine MJ
Table 2-5. PCR conditions for amplification of EEF1A2.












Exon 2 2F5& 2R2 49 Glycerol Hybaid
Exon 3 3F3& 3R4 47 TMACI Hybaid
Exon 4 4F2& 4R3 55 Glycerol Hybaid
Exon 5 5F4& 5R3 55 Glycerol Hybaid
Exon 6 6F3& 6R3 55 DMSO Hybaid
Exon 7 7F3& 7R2 50 DMSO Hybaid
Exon 8 8F & 8R3 50 DMSO Hybaid
Intron 2 2F&3R 61 Betaine MJ
Intron 3 3F&4R 60 Long-
range
MJ
Intron 4 4F&5R 58 Long-
range
MJ
Intron 5 5F &6R 55 Betaine MJ
Intron 6 6F & 7R 61 Betaine MJ
Intron 7 7F2& 8R2 62 Long-
range
MJ
Table 2-6 PCR conditions for amplification of Slc1a4.
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Primer Sequence (5' -» 3')
2F Tgt gcc agg aca gtc tct gc
2Rnew Gag atg cca age ctg gcc ac
3F Ctg taa caa gca get cgc ac
2R Ccc tgc tea cct ggg atg
3F1 Aca tea cca tea teg atg cc
2R1 Cag age act gga ttc ate ct
4F Gga gag gcc tgg aag tga g
4R2 Ttc teg ctg tag gcc ggc t
4F2 Cct aca cgc tgg gtg tga ag
4R4 Gga acc tgc att tcc egg g
5F2 Age agt act cct gga age a
5R2 Tct agg gca ggc aga get
6F Gtc cca ggc ttt gtt ggt tt
6R2 Agt cct get get gtc cag cag
7F1 Gca gat tag cgc egg eta c
7R Ctg gat cag cca cag cct g
7F Cct cca gtc age act ccg g
7R1 Cca get tct tgc cag age g
Table 2-7 Primer sequences used to amplify EEF1A2
2.6.2.1 Long-range PCR
Introns 3,4 and 7 ofSlcla4 were amplified using the Expand Long Template PCR
System (Roche), according to the manufacturer's instructions. Briefly, two master
mixes were made up. Mix one contained dNTPs, each at 350pM, forward and
reverse primers at 300nM and 1 pi DNA in a total reaction volume of 25pl per
reaction. Mix two contained 1 x PCR buffer 1 and 0.75pl enzyme mix, also in a total
volume of 25 jllI per reaction. The two were mixed immediately before cycling.
Cycling was carried out on a Hybaid Omnigene. The cycling conditions were 92°C
for 1 minute, 10 cycles of 92°C for 20 seconds, the annealing temperature for 1
minute, 68°C for 8 minutes, 20 cycles of 92°C for 20 seconds, annealing temperature
for 1 minute, 68°C for 8 minute (increasing by 20 seconds per cycle) and finally, 10
minutes at 68°C. The annealing temperatures used were 60°C for intron 3, 58°C for
intron 4 and 62°C for intron 7.
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2.6.3 SSCP
2.6.3.1 Ethanol precipitation of samples
Where the PCR additive betaine had been used, the PCR products were precipitated
to remove it. Two volumes of ethanol and 0.1 volumes of 3M sodium acetate were
added to each sample (usually 20pl) and the samples were kept at -20°C for
approximately 30 minutes. The precipitated DNA was pelleted by centrifugation at
14 000 rpm for 5 minutes, washed with 70% v/v ethanol and air dried. They were
then resuspended in H2O (usually 20pl) before SSCP analysis.
2.6.3.2 SSCP gels
PCR products (lOpl) were mixed with 5pi loading buffer (95%v/v deionised
formamide; 0.1%w/v bromophenol blue and 0.1%w/v xylene cyanol) and heated at
95°C for 5 minutes to ensure they were single-stranded. They were then placed on
ice, and maintained on ice during the loading of samples. All 15jul was then loaded
onto a 10% polyacrylamide gel, containing 1 x TBE (0.1M tris; 0.1M boric acid;
2.5mM EDTA), 0.05% w/v AMPS and 0.06% v/v TEMED. Samples were run at 4°C
overnight at 10 mA per gel on a Hoefer PS 1500 power pack in 1 x TBE buffer.
Silver staining of gels
Gels were carefully removed from the apparatus, ensuring the minimum of handling
to avoid inadvertent staining due to protein contamination. They were shaken in
500ml 10% v/v ethanol in a glass dish for 10 minutes, which was then removed by
vacuum to avoid touching the gels. They were then soaked in 500ml 1% v/v nitric
acid for 2 minutes, and then rinsed in deionised H2O. They were then shaken for 20
minutes in 500ml of a 500pg/l solution of silver nitrate. The silver nitrate was
removed and excess silver was removed by adding approximately 200 ml developing
solution (30g/l sodium carbonate and 0.05% v/v formaldehyde (Analar). This was
removed as it changed colour. The gels were then shaken in 500ml developing
solution, with one change of solution. Once the bands which appeared were of a
sufficient intensity, the developing reaction was stopped by soaking the gels in 10%
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v/v acetic acid for 10 minutes. The acetic acid was removed by soaking the gels
twice in deionised water for 10 minutes. They were dried on a Bio-Rad 583 gel drier.
2.6.4 Sequencing
2.6.4.1 Manual Sequencing
Excess nucleotides and overhanging phosphate groups were removed by the addition
of 10 units exonuclease I (USB) and 2 units shrimp alkaline phosphatase (USB) to
5pi PCR product, lpl of this cleaned PCR product was added to a reaction mix
containing 2.5pmoles primer, 4 units thermosequenase polymerase (USB) and 1 x
reaction buffer in a total reaction volume of lOpl. This mix was divided between four
-3 "3
tubes, each containing 1.25pl termination mix, comprising 0.25pl a P ddNTP and
lpl of each dNTP. Sequencing reactions were carried out on a Hybaid Omn-E, and
comprised 50 cycles of 95°C for 30 seconds, 55°C for 30 seconds and 72°C for one
minute. They were then run on a 6% polyacrylamide gel at a constant temperature of
45°C and 90Watts for 3-5 hours. Gels were dried on a Bio-Rad 583 gel drier.
Autoradiography film was exposed to the gel from 16-48 hours and developed on a
Hyper Processor (Amersham Life Science).
2.6.4.2 ABI Sequencing
PCR Clean up
Nucleotides and primers were removed by adding lpl ExoSapIT (USB) to 5pl PCR
product. They were then incubated at 37°C for 15 minutes, followed by 80°C for 15
minutes to inactivate the enzyme.
Sequencing Reactions
To the cleaned PCR products were added 2pl of either Rhodamine or Big Dye
(ABgene) and 45ng primer in a total volume of 20pl. Cycling was carried out on an
MJ Gradient Cycler, and comprised one cycle of 96°C for 1 minute, followed by 24
cycles of 96°C for 30 seconds, 50°C for 15 seconds and 64°C for 4 minutes.
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Ethanol Precipitation
Samples were precipitated by adding 55pl 95% v/v ethanol, 2pi 3M sodium acetate
(pH5.2) and 0.5pi pellet paint (Novachem). They were then kept at 4°C for 30
minutes, centrifuged at 14 000 rpm for 30 minutes, washed in 70% v/v ethanol and
air dried.
ABI Gels
Gels were run either by Angie Fawkes or Alison Condie an ABI 3100 capillary
sequence analyser. The sequence traces obtained were analysed using the Chromas
programme (Technelysium).
2.6.5 DHPLC
The PCR products were initially heteroduplexed. They were first heated to 95°C for
5 minutes, the temperature was then decreased by 1.5°C and held for one minute.
This was then repeated 40 times. They were then subjected to high performance
liquid chromatography on a WAVE® Nucleic Acid Fragment Analysis System
(Transgenomic). The optimal denaturing temperature for use was determined by
plotting the predicted helical fraction of the sample against the sequence at different
temperatures, using the WAVE® System utility hardware. EEF1A2 exon 2 products
were run at 63°C and 65°C, and exon 5 products at 63°C and 66°C. The flow rate was
0.9 ml/min, and the buffer used was a combination of triethylammonium acetate
(TEAA) and 25% acetonitrile (ACN) in TEAA, as outlined in tables 2-8 and 2-9.
Time, % TEAA, % ACN in 25% % TEAA, % ACN in 25%
mins 63°C TEAA, 63°C 65°C TEAA, 65°C
0.0 49 51 51 49
0.1 44 56 46 54
4.6 35 65 37 63
4.7 0 100 0 100
5.2 0 100 0 100
5.3 49 51 51 49
7.3 49 51 51 49
Table 2-8 Buffer compositions used to analyse EEF1A2 exon 2
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Time, % TEAA, % ACN in 25% % TEAA, % ACN in 25%
mins 63°C TEAA, 63°C 66°C TEAA, 66°C
0.0 51 49 53 47
0.1 46 54 48 52
4.6 37 63 39 41
4.7 0 100 0 100
5.2 0 100 0 100
5.3 51 49 53 47
7.3 51 49 53 47
Table 2-9. Buffer compositions used to analyse EEF1A2 exon 5
2.7 Antibody Generation and Purification
2.7.1 Antibody Generation
Peptides were synthesised by Dr Graham Bloomberg at Bristol University (ordered
through Zinsser Analytic), and conjugated to KLH. Four aliquots of 0.5mg were
injected into a sheep by Diagnostics Scotland at monthly intervals. Serum was
withdrawn one week after the second, third and fourth injections. The serum was
stored at -70°C on receipt.
2.7.2 ELISA
Maxisorp plates (Nunc) were coated overnight at 4°C with different concentrations of
peptide, from 5pg/ml to lng/ml, dissolved in 200pl coating buffer (15mM Na2C03;
35mM NaFfCCh; 3.0mM NaN2; pH 9.6). Blank wells in which coating buffer alone
was added were included. The plates were then washed three times in wash buffer
(0.14M NaCl; 1.5mM KH2P04; 8.0mM Na2HP04; 2.68M KC1; 0.05% v/v Tween 20;
pH 7.4) and blocked in 1% w/v BSA (diluted in wash buffer) for 1 hour at room
temperature. They were again washed three times in wash buffer, and then incubated
for 1 hour at room temperature with 200pl of the appropriate serum diluted in wash
buffer from 1 in 100 to 1 in 50 000. They were then incubated with HRP-conjugated
anti-sheep/goat secondary antibody, diluted 1 in 1 000 in wash buffer, for 1 hour at
room temperature. They were then washed three times and incubated for
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approximately 15 minutes in 200pl o-phenylenediamine dihydrochloride substrate
(OPD). This was prepared by adding lOmg OPD (Sigma) to 25ml OPD buffer
(25mM citric acid; 0.1M Na2HP04; pH 5.0) and adding lOpl 30% v/v H2O2. The
plates were then read at 450nm in an EL312e Microplate Bio-Kinetics plate reader
(Bio-Techniques Instruments).
2.7.3 Antibody Purification
2.7.3.1 Ammonium sulphate precipitation
One volume (usually approximately 50ml) serum was centrifuged at 3 OOOxg for 30
minutes to remove any particulate matter. The supernatant was transferred to a
beaker, and large protein aggregates along with proteins which precipitate at low
concentrations of ammonium sulphate were removed. This was done by gradually
adding 0.5 volumes saturated ammonium sulphate (made by adding 76. lg
ammonium sulphate to 100ml H2O), whilst continuously stirring the mixture. It was
then transferred to 4°C, and stirred either for 6 hours or overnight. The mixture was
then centrifuged at 3 OOOxg for 30 minutes, and the supernatant was removed.
The antibody component of the sera was then precipitated by the addition of another
0.5 volumes ammonium sulphate to the supernatant, bringing the final concentration
of ammonium sulphate to 50% saturation, again whilst stirring continuously. It was
then stirred overnight at 4°C. The suspension was centrifuged at 3 OOOxg for 30
minutes, and the supernatant was discarded. The pellet was drained, and resuspended
in 0.3 volumes (usually 15 ml) PBS. It was then dialysed against PBS at 4°C for 24
hours, with three changes of PBS. The resulting antibody solution was further
purified using immunoaffinity purification.
2.7.3.2 Immunoaffinity purification
The ammonium sulphate-precipitated antibody solution was immunoaffinity purified
using a SulfoLink® Kit. A different kit was used for each antibody raised, with each
peptide coupled to a different column.
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Coupling of peptide to the column
The peptide against which the antibody was raised was coupled to the column
through the terminal cysteine according to the manufacturer's instructions. Briefly,
the column was drained and equilibrated with 12 ml SulfoLink® Coupling Buffer.
Approximately lOmg peptide was dissolved in 2ml SulfoLink® Coupling Buffer and
added to the column, and then incubated for approximately 1 hour at room
temperature. The column was then drained and washed with 6ml Coupling Buffer.
An approximation of the coupling efficiency was obtained by comparing the A280 of
this wash buffer with the A28o of the starting peptide solution in coupling buffer. The
A28o of the peptide solution was much higher than that of the wash solution,
indicating that most of the peptide had been immobilised on the gel and had not been
washed through the column. Nonspecific binding sites on the gel were blocked by
adding 2ml of an 0.05M L-cysteine solution (provided in the kit) and incubated again
for approximately 1 hour. The column was drained and washed four times with 4ml
SulfoLink®Wash Buffer and then three times with 0.05% w/v sodium azide (NaN3).
The column was then either used immediately for affinity purification, or was stored
in 0.05% w/v NaN3 at 4°C.
Affinity purification
The column was equilibrated with 6ml PBS. The antibody was then bound to the
peptide which had been immobilised on the column. This was achieved by passing
the ammonium sulphate-precipitated antibody solution (10-20ml) through the
column. It was collected and recycled through the column approximately 5 times to
maximise the amount of antibody bound. The column was then washed with 16ml
PBS. The bound antibody was eluted by adding 8ml glycine buffer (lOOmM glycine,
pH 2.5-3.0) to the column. Fractions (1ml) were collected and analysed for protein
content by measuring the A28o- The fractions with the highest A2so (usually fractions
2, 3 and 4) were pooled and dialysed against PBS for 24 hours, with three changes of
PBS. The column was regenerated by washing with 16ml PBS, and stored in
degassed 0.05% w/v NaN3.
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2.8 Western Blotting
2.8.1 Protein extraction
Tissues were immediately frozen in liquid nitrogen after dissection and stored at
-70°C, if necessary, before extraction. Approximately 50mg tissue was ground to a
powder using a pestle and mortar in liquid nitrogen. 0.5 ml protein extraction buffer
was added (10 mM Tris.HCl pH 7.5, 2 ml 10 mM EDTA, 1 x Complete Antiprotease
Cocktail, Roche). Samples were boiled for 5 minutes and centrifuged at 14 000 rpm
for 5 minutes. Supernatants were quantified and loaded on an acrylamide gel.
2.8.2 Protein Gel
Protein concentrations were determined using the BioRad DC Protein Assay
detection kit, based on the Bradford Assay, as per the manufacturer's instructions.
Briefly, 5pi sample was mixed with 25pi Reagent A, 200pl Reagent B and then
incubated for 15 minutes. The absorbance at 750 nm was read using an EL312e
Microplate Bio-Kinetics Reader (Bio-Techniques Instruments). A standard curve was
constructed by plotting absorbance values obtained from a range of bovine serum
albumin (BSA) dilutions from 0-1.4 mg/ml, and was used to determine the
concentration of samples.
A 15pg aliquot of protein lysate was mixed with Laemmli protein loading buffer (60
mM Tris.HCl pH 6.8; 2% w/v SDS; 0.1% w/v bromophenol blue; 10% v/v glycerol)
and 1M dithiothreitol (DTT) and loaded onto a 10% SDS-polyacrylamide gel with
4.2% stacking gel. The Kaleidoscope or Broad Range Prestained ladders (BioRad)
were used as markers. Gels were run using a Bio-Rad Protean III at 100-150 V for
approximately 1-2 hours in Laemli running buffer (25mM Tris.EDTA; 192mM
glycine; 0.1% w/v SDS; pH8.3). Proteins were electroeluted onto a polyvinylidene
difluoride (PVDF) Hybond-P membrane (Amersham Pharmacia Biotech) in Bjerrum
and Schafer-Neilsen transfer buffer (48mM Tris.EDTA; 39mM glycine, 20% v/v
methanol, pH 9.2), using a BioRad Trans-Blot SD transfer cell at 15V for one hour.
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2.8.3 Immunoblotting
Membranes were blocked overnight in blocking buffer containing 0.25% v/v Tween
20 and 5% w/v fat free powdered milk in PBS. Membranes were washed four times
in PBS and then incubated in primary antibody at an appropriate dilution in blocking
buffer for 2 hours. As the dilutions varied for different antibodies under different
experimental conditions, they are given in the figure legends for each Western in
chapters 5 and 6. They were again washed four times in PBS, before incubation with
the secondary antibody (HRP-anti goat/sheep antibody for the sheep anti-eEFlA-l
and eEFlA-2 antibodies; HRP anti-rabbit for the rabbit anti-A salina eEFlA-l
antibody; both at 1:500; Diagnostics Scotland). Membranes were again washed in
PBS and detected using either diaminobenzidene (DAB; Sigma) or enhanced
chemiluminesence (ECL; Amersham Biosciences) according to the manufacturer's
instructions. When ECL detection was used, MACO-X-RAY HS90 medical film
(Scientific Laboratory Supplies, SLS) was exposed and developed using a Hyper
Processor (Amersham Life Science).
2.9 Immunofluoresence in cells
2.9.1 Cell Culture
PC-12 cells were a kind gift from Helen Munn. Cells were grown in 85% RPMI
medium, 10% horse serum and 5% fetal calf serum, supplemented with penicillin at
lOOU/ml and streptomycin at lOOpg/ml. Cells were differentiated by adding 50ng/ml
human recombinant Nerve Growth Factor-(3 (Sigma) to the media, and maintained in
this form by feeding them with the NGF-supplemented media every two days. SH-
SY5Y cells were another gift, from Rachel James. They were grown in 44% DMEM,
44% Ham's F12 and 10% fetal calf serum, and supplemented with 1% non-essential
amino acids, penicillin at lOOU/ml and streptomycin at lOOpg/ml. They were fed
every two days and split 1:10 when they reached confluency.
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2.9.2 Immunofluorescence
Cells were washed twice in PBS, then fixed in either 50:50 acetoneimethanol, ice-
cold methanol or paraformaldehyde for 5 minutes. If paraformaldehyde was used,
they were then washed in 0.2% v/v Triton-XlOO. They were then washed twice in
PBS, blocked for 30 minutes in 5% v/v donkey serum diluted in PBS, and washed in
PBS containing 0.2% v/v Tween-20 (PBS-T). They were then incubated in the
primary antibody, diluted in 1% v/v donkey serum and 0.2% v/v Tween-20 in PBS,
for 45 minutes. They were washed three times in PBS-T and incubated for 30
minutes in fluorescently labelled donkey anti-sheep secondary antibody (Alexofluor),
diluted 1:1 000 in 1% v/v donkey serum in PBS-T. They were again washed three
times in PBS-T, then incubated in DAPI for 5 minutes, washed three times in PBS
and mounted in mowiol mount (7.5% w/v mowiol 40-88; 10% v/v glycerol; 1.75%
DABCO; 0.1M Tris.HCl, pH 8.5).
Peptide preabsorption
Different concentrations of the peptide against which each antibody was raised were
added to a 1:10 solution of that antibody in blocking buffer. The concentrations used
were 0.01, 0.1 and 1.0 ng peptide per pi antibody solution. These antibody and
peptide solutions were then mixed overnight on a Labinco LD 79 revolving wheel.
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3 Chapter 3 - Pathological analysis of wasted
3.1 Introduction
The wasted mutation arose spontaneously at the Jackson laboratory in 1972 (Shultz
et al., 1982). Homozygous wasted mice show hypoplasia of the spleen and thymus,
and a decrease in the wet weight of these organs, relative to their declining body
weight (Goldowitz et al., 1985; Kaiserlian et al., 1986; Shultz et al., 1982). They also
have a defective response to radiation damage in their lymphoid-derived cells (Shultz
et al., 1982). On the basis of their immunological defects, wasted mice were initially
considered to be models for ataxia telangiectasia (Shultz et al., 1982) and severe
combined immunodeficiency with adenosine deaminase deficiency (Abbott et al.,
1986). However, the vacuolar degeneration of the anterior horn cell motor neurons of
the spinal cord has led to the mice more recently being considered as a model for
ALS (Lutsep and Rodriguez, 1989).
I have therefore further analysed homozygous wasted mice in order to determine
whether they are indeed a suitable model for the disease. I have analysed their weight
loss in detail, and undertaken further neuropathological observations. I focused on
the neurological, rather than the immunological aspects of the phenotype as these are
more relevant to the study ofmotor neuron dysfunction in humans.
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3.2 Results
3.2.1 Analysis of weight loss in wasted
3.2.1.1 Total body weights
To characterise the weight loss seen in wasted mice, I weighed several litters of
wasted and littermate controls, both heterozygous and homozygous wild-type, during
their development from approximately one week old to the age of death of the
wasted mice. The actual number ofmice varied from 4 to 20 on each day, with the
exception of 27 day-old wasted homozygotes and 20 day-old controls, where only
one animal was weighed, and 20 and 26 day-old wasted homozygotes, where two
animals were weighed. I then constructed a growth curve for wasted and littermate
animals, shown in figure 3-1. The actual weights of the animals at each age is shown
in appendix 2. To determine whether the weight loss seen in wasted was due to the
loss ofmuscle mass, the ratio ofmuscle weight to total body weight was calculated.
This was also done for the spleen, in which there is a known loss ofmass, and for the
brain and heart, to determine whether there is any weight loss in these eEFlA-2
expressing organs. As a control organ, the relative weight of the kidney was also
measured, as it does not express eEFlA-2, and therefore was not expected to
decrease in wasted mice, and because it is easy to excise whole.
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Figure 3-1 Graph showing total body weights of wasted and

















6 4.50 2.5 5.6 1.76 4.84 4.1 5.8 0.80
7 5.38 3.0 6.4 1.02 5.58 4.8 6.6 0.54
8 5.76 3.7 6.6 1.18 6.26 5.5 7.3 0.62
9 6.67 4.8 8.0 0.93 6.67 5.5 8.4 0.85
10 7.08 5.2 8.6 1.03 7.06 6.2 9.0 0.69
11 7.62 5.6 9.2 1.22 7.81 6.6 9.8 0.92
12 8.37 6.4 9.2 0.94 8.79 8.0 9.7 0.61
13 8.10 6.7 8.9 1.21 9.28 8.6 9.9 0.50
14 9.51 7.5 11.0 1.21 9.64 8.4 11.7 1.03
15 9.75 7.6 11.3 1.20 9.82 8.2 12.1 1.14
16 10.26 8.4 11.6 1.08 9.94 8.7 11.9 1.19
17 10.03 7.9 11.5 1.34 10.20 8.7 12.6 1.53
18 10.32 8.3 11.6 1.14 10.48 8.7 13.1 1.54
19 11.35 11.1 11.8 0.31 11.96 9.6 12.7 1.32
20 10.40 10.0 10.8 0.57 12.10 12.1 12.1 ND
21 9.49 7.7 11.0 1.04 11.26 10.4 14.1 1.14
22 9.88 7.4 11.3 1.40 11.65 10.0 13.9 1.21
23 9.82 7.3 11.0 1.13 12.89 11.6 14.8 1.17
24 9.17 7.0 10.3 1.06 12.98 11.2 15.1 1.11
25 8.75 7.8 9.7 0.67 13.17 11.2 16.0 1.22
26 7.30 7.1 7.5 0.28 13.47 12.9 13.9 0.45
27 6.70 6.7 6.7 ND ND ND ND ND
28 ND ND ND ND 16.68 15.3 18.0 1.28
29 ND ND ND ND 17.61 15.4 19.9 1.41
Table 3-1 Mean body weights of mice at different ages.
Maximum and minimum values, and standard deviations (SD), are also
shown. No mice were weighed at the time points marked ND.
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Figure 3-1 demonstrates that the weights ofwasted and littermate controls are
strikingly similar until 19 days, whereupon there is a sharp difference between the
two. It is interesting to note that wild type mice also show a slight drop in average
bodyweight at 20 days. It is probable that this is as a result of weaning, as the
animals recover this weight within two days. The size difference between a wasted
and a heterozygous animal can clearly be seen in figure 3-2, which shows two 24
day-old mice from the same litter, and also demonstrates a typically hunched posture.
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Figure 3-2 wst/wst (left) and +/wst (right) mice, both from the same litter and
24 days old. The smaller size and hunched posture of the wasted
homozygous mouse can clearly be seen.
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3.2.1.2 Weights of different organs
Total organ weights
The spleen, brain, heart, kidney and a quadricep muscle were dissected from three
wasted mice and three heterozygous littermates at 15, 19, 22 and 25 days of age. At
27 days, only one animal of each genotype was analysed, as homozygous wasted
mice often died or were euthanised for welfare reasons before this point. The organs
were then weighed, and the results are shown in figures 3-3 to 3-5 and table 3-2.
Relative organ weights
To calculate the muscle weight relative to the weight of the animal, the excised
quadricep muscle was divided by the total bodyweight of the animal. This approach
was also used to analyse the spleen, brain, heart and kidney. The results are shown in
figures 3-6 to 3-10 and tables 3-3 to 3-7.







Figure 3-3 Graph showing mean total brain weights of homozygous wasted
and heterozygous mice









Figure 3-4 Graph showing mean total organ weights of homozygous wasted



















Figure 3-5 Graph showing mean total organ weights of heterozygous mice.
M, muscle; S, spleen; H, heart; K, kidney.
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Organ
Age, wstlwst wst/wst wst/wst +/wst +/wst +/wsf
days Mean, mg Min, mg Max, mg Mean, mg Min, mg Max, mg
Muscle 15 19 17 20 19 16 23
19 27 22 32 33 29 40
22 23 15 30 58 55 60
25 17 16 20 58 50 70
27 10 10 10 55 55 55
Spleen 15 43 38 47 48 46 50
19 85 81 89 92 82 98
22 17 10 30 83 60 100
25 17 15 20 85 80 94
27 5 5 5 70 70 70
Brain 15 375 354 414 383 361 402
19 392 390 393 390 384 398
22 417 400 440 427 410 450
25 400 390 410 417 380 450
27 350 350 350 390 390 390
Heart 15 50 44 55 55 50 62
19 59 58 59 72 60 90
22 77 70 90 90 80 110
25 73 48 100 81 60 95
27 70 70 70 90 90 90
Kidney 15 49 38 56 56 53 60
19 59 57 61 71 70 71
22 65 60 75 93 90 100
25 71 60 90 93 90 95
27 62 62 62 90 90 90
Table 3-2 Mean, maximum and minimum total organ weights
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Mean ratio, x 103 Min Max
+lwst
Mean ratio, x 103 Min Max
15 2.01 1.96 2.07 1.97 1.51 2.53
19 2.59 2.16 3.02 2.74 2.21 3.39
22 2.66 1.88 3.75 4.75 3.95 5.55
25 2.03 1.76 2.28 4.38 3.73 5.54
27 1.49 1.49 1.49 4.44 4.44 4.44
Table 3-3 Mean, minimum and maximum muscle:bodyweight ratios for
homozygous wasted and heterozygous mice.
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Mean ratio, x 103 Min Max
+lwst
Mean ratio, x 103 Min Max
15 4.56 4.41 4.95 4.87 4.60 5.00
19 8.17 7.94 8.40 7.59 6.95 8.33
22 1.77 1.25 2.80 7.20 5.94 9.00
25 1.88 1.71 2.06 6.41 5.88 7.38
27 0.75 0.75 0.75 5.65 5.65 5.65
Table 3-4 Mean, minimum and maximum spleen:bodyweight ratios for
homozygous wasted and heterozygous mice.























Mean ratio, x 103 Min Max
+lwst
Mean ratio, x 103 Min Max
15 40.7 34.7 43.7 39.2 36.5 48.5
19 37.7 36.8 38.5 32.3 30.4 34.0
22 47.5 41.1 51.3 38.2 30.0 43.6
25 43.5 40.0 46.8 32.0 26.9 41.5
27 52.2 52.2 52.2 31.5 31.5 31.5
Table 3-5 Mean, minimum and maximum brain:bodyweight ratios for
homozygous wasted and heterozygous mice.
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Mean ratio, x 103 Min Max
+lwst
Mean ratio, x 103 Min Max
15 5.41 5.36 5.47 5.61 4.72 6.39
19 5.63 5.57 5.69 5.91 5.08 6.87
22 8.63 8.40 8.75 7.72 7.24 8.00
25 8.00 5.27 11.40 6.22 4.60 8.76
27 10.45 10.45 10.45 7.26 7.26 7.26
Table 3-6 Mean, minimum and maximum heart:bodyweight ratios for
homozygous wasted and heterozygous mice.

















Figure 3-10 Graph showing relative kidney weights of homozygous wasted
and heterozygous mice.
Age, wst/wst Min Max +lwst Min Max
days Mean ratio, x 103 Mean ratio, x 103
15 5.27 4.63 5.89 5.72 5.66 5.82
19 5.68 5.38 5.98 5.95 5.46 6.23
22 7.30 7.00 7.50 8.17 6.60 9.00
25 7.80 6.19 10.30 7.79 5.81 9.28
27 9.25 9.25 9.25 6.22 6.22 6.22
Table 3-7 Mean, minimum and maximum kidney:bodyweight ratios for
homozygous wasted and heterozygous mice.
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It can be seen from the graphs that the greatest drop in the organ:bodyweight ratio of
wasted mice is seen in the spleen. There is a precipitous drop in the ratio from 19
days. There is also a drop in the ratio in muscle. Although this drop is relatively
slight, in comparison, there is a rise in the ratio ofmuscle :bodyweight in
heterozygous animals at this time, so that there is a large difference between the two
sets ofmice. By 27 days, for example, the ratio ofmuscle:bodyweight in
homozygous wasted mice is one-third that of heterozygous controls. The rise in the
muscle:bodyweight ratio for heterozygous animals probably reflects the drop in the
total body weight of the animals at this time, as the increase in the total muscle
weight, as shown in figure 3-5, is more modest. The fact that there is such a marked
difference in the muscle weight:bodyweight ratio between wasted and heterozygous
mice suggests that the dramatic weight loss seen in wasted is due to a loss ofmuscle
mass.
As eEFl A-2 is also expressed in the brain and heart, it was interesting to determine
whether these organs also show a loss ofweight in wasted homozygotes. In contrast
to the situation in muscle, the brain and heart do not show a decrease in the ratio of
organ weight:total bodyweight. Indeed, the ratios actually increase after 19 days,
which probably again reflects the fact that the mice are losing weight. The brain and
heart are probably too essential to sustain life in a reduced size. The kidney was
selected as a control organ which was not expected to vary greatly in size, and was
easily removed intact. It, too, showed an increase in the orgambodyweight ratio
compared to heterozygous controls, but this was not as marked as in heart and brain.
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3.2.2 Neuropathology
Sections were made from the paraffin-embedded spinal cords ofwasted mice and
heterozygous littermates. The spinal cords were originally dissected and embedded in
collaboration with Dr. J. Peters at the MRC Mammalian Genetics Unit, Harwell.
They were taken at the following ages: 19 days (4 wst/wst mice; 1 +/wst mice), 24
days (1 wst/wst, 1 +/wst), 28 days (3 wst/wst; 1 +/wst) and 29 days (1 wst/wst; 1
+/w.sr).
3.2.2.1 H&E Staining
H&E analysis showed vacuolisation of the anterior horn cells of the spinal cord and
brain. An example is shown in figure 3-11. In all 28 day mice examined, vacuolation
of the anterior horn cells of the cervical spinal cord were seen, similar to that
described by Lutsep and Rodruigez (Lutsep and Rodriguez, 1989). Although this was
not quantified, the neuronal loss would appear to be in line with the 4% reported
(Lutsep and Rodriguez, 1989). The 29 day-old mouse was similarly affected. One 28
day-old mouse also appeared to have vacuolation of the thoracic spinal cord neurons.
No vacuolation was seen in the lumbar regions, or in sections from 19 or 24 day-old
mice. It is probable that only late-stage vacuolation is seen at 28 days, and that the
neurons are in fact starting to undergo vacuolation prior to this.
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Control cervical spinal cord:
Whole spinal cord, X 25
Wasted spinal cord:
28 day wasted anterior horn, xioo
Figure 3-11 Sections through cervical spinal cord, after staining with
haematoxylin and eosin. The top pictures are of a control animal, a
heterozygous littermate of the wasted animal sectioned in the bottom picture.
The vacuolated neurons are arrowed.
Anterior horn region, X 100
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3.2.2.2 Glial fibrillary acidic protein
Reactive gliosis is a general response to neurological injury and disease, in which
microglia are activated and astrocytes accumulate and upregulate the expression of
glial fibrillary acidic protein, GFAP (Siegel et al., 1999). GFAP has therefore been
used as a marker for gliosis, and increased immunostaining for this protein has been
reported in the brain and spinal cord ofALS patients (Fujita et al., 1998; Nagy et al.,
1994). I therefore stained sections from homozygous wasted mice and their
heterozygous littermates with an antibody against GFAP. Homozygous wasted mice
showed a characteristic staining pattern, comprising strong foci of staining
throughout the grey matter of the spinal cord. An example is shown in figure 3-12.
These were only very rarely seen in heterozygous littermates. This increased GFAP
staining in wasted homozygotes was then quantified by counting the number of
GFAP-positive foci in the grey matter of the spinal cord. The results are shown in
table 3-8.
Age Region wst/wst +lwst
19 days Cervical 48.0 2.0
Thoracic 27.0 2.5
Lumbar 7.0 3.5
24 days Cervical 43.0 6.5
Thoracic 37.0 1.5
Lumbar 22.0 0.0
28 days Cervical 37.0 0.0
Thoracic 31.0 0.0
Lumbar 4.0 0.0
29 days Cervical 148.0 0.0
Thoracic 52.0 2.5
Lumbar 16.0 0.0
Table 3-8 Mean number of GFAP-positive cells in the grey matter of the
spinal cord.
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There was an increase in the number ofGFAP-positive foci in all wasted animals
examined. Interestingly, the number of foci appears to be higher at the cervical level
of the spinal cord than at the thoracic level, which in turn appears to be higher than at
the lumbar level. There therefore appears to be a gradient in gliosis from the cervical
through to the lumbar region. This would correspond with the results from the H&E
staining, in which there also appeared to be a gradient in vacuolation from the
cervical through to the lumbar region.
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wstlwst cervical spinal cord, x 16
Figure 3-12 Sections stained with an antibody recognising glial fibrillary acidic
protein, GFAP. Both sections are from the cervical spinal cord of 28 day-old
mice. A central portion of the grey matter is shown. The section from the
homozygous wasted mouse, bottom, shows characteristic staining
throughout the grey matter of the spinal cord. An example is arrowed. This
staining is absent in the section from the heterozygous animal.
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3.2.2.3 Neurofilaments
Phosphorylated Neurofilaments
Using an antibody which recognised the light and heavy chain neurofilament proteins
in their phosphorylated form, it was noted that there was increased staining in the
cytoplasm of the neurons ofwasted homozygotes, compared with heterozygous
controls. An example is shown in figure 3-13. This increase in neurofilament staining
was quantified by calculating the percentage of anterior horn neurons which stained





19 days Cervical 64 0
Thoracic 80 13
Lumbar 94 20
24 days Cervical ND 0
Thoracic 75 25
Lumbar 100 ND
28 days Cervical 89 0
Thoracic 75 0
Lumbar 92 14
29 days Cervical ND 0
Thoracic 77 0
Lumbar 75 17
Table 3-9 Percentage of anterior horn motor neurons staining for
phosphorylated neurofilaments. Where ND is given, the section did not have
the correct orientation for a comparison to be made with the other sections.
There is a clear difference between the wasted homozygotes and their heterozygous
littermates in the percentage of neurons staining positively for phosphorylated
neurofilaments. However, there is no obvious correlation between the percentage of
neurons staining positive for phosphorylated neurofilaments and either the age of the
mice or the level of the spinal cord from which the sections were taken. This is in
contrast to the GFAP results, in which there appeared to be a gradient from the
cervical through to the lumbar regions of the spinal cord. However, although there
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was no apparent variation in the percentage of neurons which stained for
neurofilaments, this approach would not have quantified any differences in the
intensity of antibody-staining between different sections.
It is interesting to note that, as with the GFAP results, there are changes in the
homozygous wasted mice from 19 days of age onwards, that is, before the mice are
demonstrating an overt neurological phenotype. This investigation extends previous
work, which only investigated mice at 28 days of age (Lutsep and Rodriguez, 1989).
Although I used an antibody which recognised both the light and heavy chain
phosphorylated neurofilaments, the work of Lutsep and Rodriguez (1989) would also
suggest that it was the 200kD heavy chain which was responsible for the increased
staining. This is also consistent with the NFH overexpression seen in ALS patients
(Munoz et al., 1988; Sobue et al., 1990). It is also the heavy chain subunit in which
neurofilament mutations have been reported in a small proportion of ALS cases (Al-
Chalabi et al., 1999; Figlewicz et al., 1994;Tomkins et al., 1998).
Non-phosphorylated Neurofilaments
No differences were seen between wasted homozygous and heterozygous littermate
control animals, using an antibody which recognised medium and heavy chain non-
phosphorylated neurofilaments. Examples are shown in figure 3-14. The fact that
cytoplasmic accumulation of phosphorylated neurofilaments, rather then the non-
phosphorylated form, is seen in homozygous wasted mice is consistent with the fact
that neurofilaments are more stable in their phosphorylated form. This is in contrast
to other intermediate filament proteins, such as vimentin and laminin, which
depolymerise on phosphorylation (Cooper, 2000).
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28 day wasted cervical spinal cord (x 150)
Figure 3-13 Sections stained with an antibody recognising phosphorylated
neurofilaments. The sections are through the cervical spinal cord showing the
anterior horn region, after staining with an antibody which recognises the light
and heavy chain phosphorylated neurofilaments. The top section is through
the spinal cord of a heterozygous mouse. The bottom section is from a
homozygous wasted mouse, and shows cytoplasmic neuronal staining
(arrowed).
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wstlwst cervical spinal cord, x 16
Figure 3-14 Sections stained with an antibody recognising the medium and
heavy chain non-phosphorylated neurofilaments. Both sections are from the
cervical spinal cord of a 28 day-old mouse, the top section, from a
heterozygous mouse, and the bottom section, a homozygous wasted mouse.
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3.2.2.4 Ubiquitin
Disruption of the ubiquitin-proteasome pathway is a feature ofmany
neurodegenerative diseases (Sherman and Goldberg, 2001), and ubiquitinated
inclusions are seen in the brain and spinal cords ofALS patients (Leigh et al., 1988;
Leigh et al., 1991). I therefore investigated whether these were present in
homozygous wasted mice, using an anti-ubiquitin antibody. No staining was
observed in either wasted or heterozygous animals. A positive control from a human
patient was included, and did show the expected ubiquitinated inclusions.
3.2.2.5 MAP2
Microtubule-associated proteins are involved in the assembly and stabilisation of
microtubules. MAP2 is found specifically in the neuronal cell bodies and dendrites of
the central nervous system, and promotes the polymerisation of tubulin into
microtubules. There are three isoforms of the protein: MAP2A, MAP2B and
MAP2C. Levels ofMAP2 are reduced in the spinal cord of ALS patients (Kikuchi et
al., 1997). I therefore examined, using immunohistochemistry, whether there were
differences in MAP2 expression between homozygous wasted mice and
heterozygous control animals. No differences were seen between wasted and
heterozygous animals in the staining pattern using an antibody which recognises all
three MAP2 isoforms. In both cases, there was intense staining throughout the gray
matter, with limited white matter staining. Typical sections are shown in figure 3-15.
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+/wst cervical spinal cord, x 16
wst/wst cervical spinal cord, x 16
Figure 3-15 Sections stained with an antibody recognising MAP2.
Both sections are from the cervical spinal cords of 28 day-old mice:
top, +/wst; bottom, wst/wst.
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3.3 Discussion
The reduction in total body weights which I have described in this thesis is in broad
agreement with that previously reported, although in the study by Goldowitz et al.
the wasted mice appear to lose weight relative to their heterozygous littermates
slightly earlier, from 17 days of age (Goldowitz et al., 1985). This study does not,
however, record at what age the mice were weaned. In a further, less detailed, study,
the difference between the two sets ofmice appears to occur from 21 days onwards
(Kaiserlian et al., 1986).
I have demonstrated that there is a marked difference in the muscle
weight:bodyweight ratio between homozygous wasted mice and heterozygous
animals. This suggests that the weight loss seen in homozygous wasted mice is due
to a loss ofmuscle mass. The only other organ in which there was such a difference
between the two groups ofmice was in the spleen, which would not affect the total
body weight of the mice. There is actually an increase in the relative weights of the
brain, heart and kidney in both homozygous wasted and heterozygous animals after
19 days, although this was more marked in homozygous wasted animals. This
reflects the fact that both sets of animals lost weight around the period ofweaning, a
process which was continued and exacerbated in the homozygous wasted animals.
I have also extended the previous neuropathological findings in wasted mice,
showing that there is vacuolation of the neurons of the cervical spinal cord from 28
days. I have also demonstrated that there is an increase in antibody staining for
GFAP and phosphorylated neurofilaments in homozygous animals, when compared
with their heterozygous littermates. However, these results were based on a limited
number ofmice, and clearly should be confirmed in a larger number of mice,
particularly at 24 days of age. It would also be of interest to determine from what age
these changes occur.
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There are therefore a number of neuropathological similarities between wasted mice
and ALS. These include the specific loss of anterior horn cell motor neurons, and
accumulations of phosphorylated neurofilaments. One key hallmark ofALS that is
not seen in wasted mice is the presence of ubiquitinated inclusions. It is possible,
however, that this is due to the fact that the time course of the wasted phenotype is
extremely rapid. If it were possible to extend the lifespan of the mice, perhaps by
transgenic approaches, then it is possible that inclusions would be seen. It is usually
only end-stage material which is reported in human ALS, so it is difficult to assess at
what stage the inclusions arise. There were also no differences observed between
homozygous wasted mice and heterozygous animals in MAP2-staining.
Another key difference is that the wasted phenotype begins at around 19 days, which,
in mice, is approximately the time ofweaning. Although there is no definitive
correlation between different mouse and human ages, it is clear that a disease which
afflicts mice from the time ofweaning is affecting mice at a different stage of life
from one which generally occurs in humans in middle or old age. It is therefore
possible that wasted represents a better model of SMA, which usually has a much
earlier age of onset than ALS. The mouse mutant neuromuscular degeneration,
described in Chapter 1, section 1.2.5.1, was initially considered to be a model either
ofALS, or of SMA (Cook et al., 1995). The time course of the phenotype is similar
to that of wasted mice, with impaired movement from 2 weeks of age, and death by
four weeks. Furthermore, mutations in IGHMBP2, the human orthologue of the
mutated mouse gene, have been identified as the causative mutation in spinal
muscular atrophy with respiratory distress (SMARD) (Grohmann et al., 2001).
One further difference between wasted and ALS is that the wasted phenotype has an
immunological component. Although ALS does not have an overt immunological
phenotype, reduced DNA repair has been reported in amyotrophic lateral sclerosis
brain tissue (Kisby et al., 1997). In wasted mice the reduced response to DNA
damage has only been recorded in cells of a lymphoid origin, although it should be
noted that this has not been investigated in the brain.
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4 Chapter 4 - Mutation Analysis of ALS candidate
genes
4.1 Screening of EEF1A2 in ALS patients
4.1.1 Introduction
As both previous reports and the results I have presented in Chapter 3 are consistent
with wasted being a model for motor neuron disease, and that the genetic lesion
responsible for this mutant has been identified as the loss ofEefla2, the human gene
is a potential candidate for involvement in the disease. To test this hypothesis,
EEF1A2 was screened for mutations in DNA samples from patients with both
familial and sporadic amyotrophic lateral sclerosis.
4.1.2 Study subjects
DNA samples were kindly provided by Dr. C. Hayward, previously at the Medical
Genetics Section. The patients were originally recruited through the Scottish MND
register by Shuna Colville and Dr. R. Swingler of the Department ofNeurology at
Ninewells Hospital, Dundee, and were screened for SOD1 mutations. The DNA from
40 familial and 64 sporadic patients was analysed. DNA samples from 60
anonymous healthy Scottish adults were also examined as controls.
4.1.3 Strategy
EEF1A2 was screened on an exon-by exon basis. For most exons, single strand
conformational polymorphism (SSCP) was used. In this method, the exon is first
amplified using PCR, denatured and run on an acrylamide gel. The migration of the
DNA through the gel is dependent on the sequence. Mutations cause a
conformational change in the single stranded DNA which results in a shift in position
of one or more of the bands seen on the gel (a band-shift) (Nataraj et ai, 1999). Exon
5, however, did not produce a reproducible pattern using SSCP analysis, and was
therefore analysed using DHPLC. Exon 2 was also analysed using this method.
DHPLC involves subjecting PCR products to ion-pair reverse-phase liquid
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chromatography through a column (Liu et al., 1998). The products are first denatured
by heating and then cooled down slowly so that duplexes are formed. They are then
run through a column containing alkylated non-porous particles in an acetonitrile
gradient at a temperature which allows the partial denaturation of the samples.
Heteroduplexes, formed by the reannealing of one mutant and one wild type strand,
pass through the DHPLC column more quickly than the homoduplexes formed by
the reannealing of two wild type strands. The elution profile also usually has an
altered shape.
During the course of this project, the EEF1A2 region of chromosome 20 was
sequenced (Bischoff et al., 2000)(accession number AF163763), which allowed the
design of primers for the amplification of all the exons. Exons 3, 4 and 7 were
amplified in two overlapping segments, either to obtain amplicons of a suitable size
for analysis, or because the whole exon would not PCR-amplify. The strategy used
for mutation analysis is described in table 4-1 and figure 4-1. Neither exon 1 (which
does not encode protein) nor exon 8 were analysed as they were unamplifiable using
a range ofPGR conditions. Amplification was attempted using five different forward
and reverse primers (in all possible combinations) at a range of annealing
temperatures, and with a number of different Taq polymerases. The failure of these
regions to amplify is probably due to the extremely GC-rich nature of these parts of
the sequence. This is supported by the fact that when the WAVE® System utility
hardware was used to plot the predicted helical fraction of the sample against the
sequence of these exons, it was not possible to select a suitable annealing
temperature.
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Exons 2,5,6: Exons 3,4,7:
Exon amplified in one Overlapping primers used to
PCR give two PCR products
Figure 4-1 Strategy used to amplify EEF1A2 exons
Exon Primers Product Size, Detection Method
Used bp
2 2F & 2Rnew 369 SSCP & DHPLC
3 3F &2R 268 SSCP
3F1 &2R1 255
4 4F & 4R2 258 SSCP
4F2& 4R4 322
5 5F2& 5R2 297 DHPLC
6 6F & 6R2 409 SSCP & direct
sequencing
7 7F1 & 7R 264 SSCP
7F &7R1 264
Table 4-1 Strategy used to mutation screen EEF1A2
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4.1.4 Results
4.1.4.1 Exon 2
Exon 2 was initially analysed using DHPLC at two different temperatures. No
samples showed changed retention times at 63°C. However, at 65°C the trace
obtained was difficult to interpret. Example traces at the two temperatures are shown
in figure 4-2. The samples were therefore also analysed using SSCP analysis. No
band shifts were seen. A typical gel is shown in figure 4-3.
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Figure 4-2 Typical traces obtained after DHPLC analysis of exon 2.
The top trace shows samples run at 65°C, and the bottom trace at
63°C.
Figure 4-3 Typical exon 2 SSCP gel
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4.1.4.2 Exon 3
Primers 3F and 2R were used to amplify 268 bp comprising most of exon 3. On
SSCP analysis, a specific, reproducible band shift was noted. A typical gel is shown
in figure 4-4. The amplicon producing the SSCP bandshift was manually sequenced,
and revealed that those individuals showing the band shift were heterozygous for a
C —> T transition at nucleotide position 62 of the exon. The sequence is shown in
figure 4-5.
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Figure 4-4 A typical SSCP gel, run after amplification using primers 3F and
2R. The sample in the 11th lane shows a band shift due to the individual
being heterozygous for a C->A transversion.
G A T C
Figure 4-5 Part of exon 3 sequencing gel.
This individual is heterozygous for the nucleotide change at the position
indicated by the arrow. The sequence around this point reads gga gcg tga
gcg c/tgg cat cac cat cga c.
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This change does not result in an amino acid change at the protein level. This would
argue against a functional consequence of the nucleic acid change. However, as this
change was noted in 5 of 64 sporadic ALS patients but in only 1 of 53 healthy
controls, I analysed further patients and controls to determine whether there was a
significant difference between the two groups. This could indicate a role for the
polymorphism in disease susceptibility through being in linkage disequilibrium with
a functionally important polymorphism. The results are shown in table 4-2.
Group CT cc Total (N)
Familial ALS 0 40 40
Sporadic ALS 16 189 205
Healthy Controls 15 225 240
Table 4-2 Genotypes of enlarged study group.
Chi-square analysis gives a p-value < 0.181 (X2 = 3.42; 3x2 table, d.f=2). There are
therefore no significant differences between sample groups. It is interesting that none
of the familial ALS patients carried the polymorphism, whereas the allele frequency
is 0.039 in sporadic patients and 0.031 in healthy controls. This difference is not,
however, significant, with a p-value of 0.068 for familial vs. sporadic patients and
0.104 for familial vs controls.
Primers 3F1 and 2R1 were used to amplify the 3' end of exon 3 and the first part of
intron 3. No SSCP band shifts were seen in the latter part of the exon (data not
shown).
4.1.4.3 Exon 4
Primers 4F and 4R2 were used to amplify the first part of exon 4. SSCP analysis did
not reveal any band shifts. A typical gel is shown in figure 4-6. No band shifts were
noted in the second part of the exon, amplified using primers 4F2 and 4R4, and
shown in figure 4-7.
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Figure 4-6 TypicalSSCP gel after PCR amplification using primers 4F and
4R2.
Figure 4-7 Typical SSCP gel after PCR amplification using primers 4F2 and
4R4.
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4.1.4.4 Exon 5
Exon 5 amplicons did not give clear, reproducible bands on an SSCP gel. They were
therefore analysed using DHPLC at two different annealing temperatures: 63°C and
66°C. At 63°C, three different patterns caused by shifts in the peaks were noted in the
amplicons from a small number of subjects, both ALS patients and controls, and are
shown in figure 4-8.
The first pattern was seen in one sporadic patient and one healthy control. Manual
sequencing showed it to be a C —» A transversion at position 31 of intron 5. It
therefore does not affect the translated protein. The second pattern was only seen in
one familial patient. Sequencing on an ABI 3100 showed it to be a G —> T
transversion at position 39 of intron 5. The third pattern was found in three familial
and four sporadic patients, along with seven controls. Sequencing on an ABI 3100
showed that these individuals carried both polymorphisms, at positions 31 and 39 of
intron 5. The location of the polymorphisms I have found in EEF1A2 and their
frequencies in the control population are summarised in table 4-3 and illustrated in
figure 4-9.
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Figure 4-8 Typical traces obtained after DHPLC analysis of exon 5.
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Position Polymorphism Allele frequency
Exon 3, position 62 C -» T 0.031
Intron 5, position 31 C -> A 0.033
Intron 5, position 39 G -> T 0.058
Table 4-3 Summary of polymorphisms in EEF1A2.
The allele frequencies shown are for the control subjects.
C/T C/A G/T
i w
I I II I I I I
Exon: 1 2 3 4 5 6 7 8
Intron: 1 2 3 4 5 6 7
Figure 4-9 EEF1A2 gene structure (not to scale), showing locations of
polymorphisms (red arrows).
4.1.4.5 Exon 6
A combination of SSCP analysis and direct sequencing was performed by Doreen
Chambers to screen exon 6. No mutations were found.
4.1.4.6 Exon 7
Exon 7 was amplified using two overlapping primer sets, 7F and 7R1, and 7F1 and
7R. SSCP analysis did not show any band shifts in ALS patients or control subjects.
Representative gels are shown in figures 4-10 and 4-11.
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Figure 4-10 Typical SSCP gel after amplification using primers 7F1 and 7R.
Figure 4-11 Typical SSCP gel after amplification using primers 7F and 7R1.
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4.2 Screening of a candidate gene for wobbler
4.2.1 Introduction
As described in Chapter 1, section 1.2.5.1, wobbler is another mouse mutant which
has been described as a model for ALS and SMA. Although the genetic basis has yet
to be identified, it has been mapped to Chromosome 11 (Kaupmann et al., 1992).
The wobbler gene is closely linked to Rabl (Wichman et al., 1992), although the
latter has already been excluded as a candidate for wr (Wedemeyer et al., 1996). In
the region of human Chromosome 2 which shows conserved synteny with the wr
locus on Chromosome 11, RAB1 is close to member 4 of the solute carrier family 1
SLC1A4, at 2pl5-13 (Hofmann et al., 1994). SLC1A4 is ubiquitously expressed, with
the strongest expression in the brain, muscle and pancreas (Arriza et al., 1993;
Shafqat et al., 1993). The expression pattern within the brain is uniform.
SLC1A4 is a neutral amino acid transporter with structural and sequence similarity to
the glutamate transporter family (Arriza et al., 1993; Shafqat et al., 1993). Although
its main substrates are alanine, serine and cysteine (which led to its previous name of
ASCT1, an acronym for alanine, serine and cysteine transporter) (Zerangue and
Kavanaugh, 1996), it will also transport glutamate at pH<7.4 (Makowske and
Christensen, 1982; Tamarappoo et al., 1996). Its most important substrate is cysteine,
which acts as a neurotoxin with a pathology indistinguishable from that produced by
glutamate (Karlsen et al., 1981; Olney and Ho, 1970; Olney et al., 1972; Olney et al.,
1990). The human gene has previously been mutation screened as a candidate gene
for involvement in schizophrenia (Bennet et al., 2000). The mouse gene, Slcla4,
encodes a protein of 532 amino acids with 89% identity with the human gene.
Thus, as well as potentially transporting glutamate under some conditions, the main
substrate ofSlcla4, cysteine, is a neurotoxin. As glutamate excitotoxicity has been
postulated as a mechanism of the pathogenesis of ALS, and Slcla4 maps to the
region of the human genome with conserved synteny with the wr locus, I screened
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the Slcla4 gene for mutations in DNA extracted from the brains of wr/wr and control
littermates.
4.2.2 Strategy
Initially, only exonic sequence from Slcla4 was available. Therefore, designing
primers to amplify and sequence the whole coding sequence necessitated obtaining
intronic sequences which flanked the exons. Exons were identified by aligning the
human and mouse mRNA sequences. As the intron-exon structure of the human gene
had been elucidated, the high degree of nucleotide similarity between the two
orthologues allowed the locations of the exon boundaries to be determined. Primers
were designed from the exonic sequence to amplify each intron, which was then
sequenced. Intron 1 failed to amplify, but during the lifetime of this project, sequence
from this region became available at the NCBI trace archive. This was identified by
blasting the 3' region of exon 1 against the archive. The largest contiguous sequence
available was 7kb. This did not include any of exon 2, which suggests that intron 1 is
at least 7 kb in size. Although a long-range PCR kit was used, it may be that it is just
too large to amplify. The 3' region of intron 1 also became available, which was used
to design the 5' primer used to amplify and sequence exon 2. The sequences used are
all given in tables 4-4 and 4-5.
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Intron Primers Used Sequence, 5' -» 3' Product Size, kb
1 > 7
2 2F & 3R ttg tgg ttg ccg cat tea ct
tgg gtc acc act gtg taa tc
1.4
3 3F&4R ggg aac gtg acc aaa gag aa
cct tcc aca tct gtt aca ac
4.5
4 4F & 5R cac aat ggt get ggt gtc at
ttg ctt ccg ate agg aac at
6 .0
5 5F & 6R aac ccg ttc acg ttc etc ct
cac ttc ate ata gac gga agg
0.4
6 6F & 7R acc tga acg cag gac aga tt
tcc aac act gga tgc cgt g
1.4
7 7F2& 8R2 ttg gag gcc att gga ttg cc
ctt gta get cct get aca ct
2.0
Table 4-4 Primers used to amplify Slc1a4 introns
Exon Primers Used Sequence, 5' -» 3' Product Size, bp
1 1F tga tcc att cat teg aaa cc 676
1F2 atg ctg cgc atg ate ate ct 352
1R2 gtt aag ggc caa cag taa ct
2 2F5 taa cat tgt etc tgc tac ac 247
2R2 tcc etc ttt cct gta ctt ta
3 3F3 acg aat agt age age agt ag 231
3R4 cag taa gta aca ggc aca tg
4 4F2 ttt cag aca ctg cac aga tc 311
4R3 ttg tac cat gac aag eta tg
5 5F4 etc agt acc tcc cag tct ca 367
5R3 etc acc tea etc tgt acc ca
6 6F3 ata ccg atg tgt tct ggt g 286
6R3 tta age cag gcc taa caa tg
7 7F3 atg cat gat gta att ccc tg 254
7R2 tgg age ate aag tac tea ga
8 8F acc age ctg ctt gtg ata g 399
8R3 cag tgt atg agg gcc atg c
Table 4-5 Primers used to amplify Slc1a4 exons
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4.2.3 Results
4.2.3.1 Sequencing of Slc1a4
Genomic DNA was extracted from the brains of homozygous wobbler mice and
littermate control animals, both very kindly provided by Paolo Bigini of the Instituto
di Recerche Farmacologiche Mario Negri, Milan. Introns 3-7 were successfully
amplified and sufficient sequence information was obtained to design primers to
amplify each exon. Each exon was successfully amplified and sequenced from both
wr/wr and control animals. No mutations were found in any of the exons. A typical
sequencing trace is shown in figure 4-12.
4.2.3.2 Expression analysis
RNA was extracted from both wr/wr and control brains. Karen Wilson (a summer
student under my supervision) used RT-PCR to determine whether there were any
differences in the expression levels ofSlcla4 between wr/wr and control brains. Two
sets of primers used: 5F2 & 6R, which gave a PCR product of 215bp, and 5F & 7R,
giving a product of 238bp. A control PCR used to compare the relative levels of
mRNA in samples amplified glyceraldehyde-3-phosphate dehydrogenase, Gapdh.
Levels ofSlcla4 were similar in both cases, as determined by the intensity of the
band on agarose gel electrophoresis and shown in figure 4-13. This was not
quantitative, but as no mutations had been found, it was judged to be sufficient
evidence that SIcla4 was unlikely to be implicated in the wobbler phenotype.
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File: 16crl Run Ended: Jul 17.2001,9:11:45 Signal G:147 A:206 C:I67 T:111 Comment:
Figure 4-12 Typical sequence trace from wr/wr animal, showing exon 1 of
Slc1a4.
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Figure 4-13 Agarose gel (2%), showing results of the RT-PCR analysis of
Slc1a4. The first eight lanes show the products obtained using primers 5F2
and 6R, giving a PCR product of 215bp, and the next eight using primers 5F
and 7R, giving a product of 238bp. The GAPDH primers used gave a PCR
product of 450bp. Lanes marked RT had reverse transcriptase added,and
those marked No RT were control reactions with no reverse transcriptase.
The lanes marked W and C stand for wrand littermate control samples, B for
mouse brains used as an RNA extraction control, and - as a PCR control
with no RNA added.
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4.3 Discussion
No mutations were found in most of the protein-encoding region ofEEF1A2. It is
thus unlikely that mutations in EEF1A2 are responsible for anything other than rare
cases ofmotor neurone disease. There were, however, polymorphisms in the gene
which were also present in healthy controls. These included a silent polymorphism in
exon 3. It is unlikely that this polymorphism has a functional effect as it does not
affect the amino acid sequence. There were also two polymorphisms in intron 5. As
these polymorphisms are all SNPs, they could be useful in the mapping of other
disease genes.
It was not possible, however, to screen the whole coding region, as exon 8, the first
part ofwhich forms part of the translated protein, was unamplifiable using PCR. This
is probably due to the extremely GC-rich nature of this part of the sequence. PCR
was attempted using five different forward and reverse primers (in all possible
combinations) at a range of annealing temperatures, and with a number of different
Taq polymerases. Thus, if mutations in exon 8 do underlie cases ofALS, I would not
have detected them. Exon 1 was similarly refractory to analysis, using a range of
primer sequences and conditions. Although this exon was not protein-encoding, it is
possible that mutations could cause disease through, for example, affecting mRNA
stability. It is also possible that mutations in the promoter region, which was not
analysed, could also be important by, for example, affecting levels of the protein.
Indeed, mutations in the promoter region of Fegfhave been identified as underlying
a mouse model of ALS (Oosthuyse et al., 2001). There are also, for example, known
regulatory sites in the first intron ofEEF1A2 (Bischoff et al., 2000). However, as
with any mutation screening programme, a balance needs to be struck between the
comprehensive analysis of a gene and the resources in terms of both time and cost of
doing so.
The other key question is whether the sensitivities of the techniques used were
sufficient to detect mutations. The method I most often used was SSCP, which is a
technologically straightforward way to analyse a relatively large number of samples.
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Estimates of the sensitivity of this technique vary from 50% to 100%, with the
sensitivity decreasing with increasing size of PCR product (Hayashi and Yandell,
1993). However, the sensitivity can be improved by running the gels under more than
one set of conditions, for example, by running them at room temperature and at 4°C,
and with and without the addition of 5-10% glycerol. Again, there is a balance to be
struck between maximising the chances of detecting a mutation and time
considerations. One potential drawback to the technique is that the precise change in
mobility caused by a particular mutation cannot be predicted, but depends on the
surrounding sequence (Glavac and Dean, 1993; Nataraj et al., 1999). An advantage
of DHPLC is that it is less sequence-dependent, and can also be used for larger
fragments (up to 1.5kb) (Liu et al., 1998). The sensitivity appears to be in excess of
90% (Colosimo et al., 2002; Liu et al., 1998; Matyas et al., 2002; Takashima et al.,
2001). It is also relatively straightforward to screen a large number of samples for
mutations in the same gene. However, conditions do need to be optimised for each
PCR product, so it is probably less suited to analysing a wider range of genes in a
smaller number of samples.
EEF1A2 was also screened in SMA patients heterozygous for SMN1 or SMN2
mutations by Romina Aron-Badin as part of her MRes project (Aron-Badin, 2002).
Subject to the same caveats that apply to the EEF1A2 screening, no mutations were
found. This suggests that EEF1A2 is not implicated in SMA. As outlined in section
1.3.3, it is possible that SMN, eEFIA and ZPR1 are part of the same complex. It may
be worthwhile, therefore, to screen ZPR1 in either SMA cases in which SMA
mutations have not been found, or in ALS cases.
It was hoped to investigate the expression of eEFl A-2 in human ALS spinal cords,
using our specific antibodies, and compare this to healthy controls. Although neither
of the eEFl A-2 antibodies have been tested on human tissue, it is anticipated that
both would work - there are no amino acid differences between the human and
mouse sequences in the regions of the protein where the peptides were selected. Any
differences between these two groups would suggest a role for eEFl A-2 in the
pathogenesis ofALS. If large differences in protein expression levels were noted,
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analysis of, for example, the promoter region may have been justified. Such archival
spinal cord material is available at the Western General Hospital. Unfortunately it
proved impossible to access it within the timescale of this project due to the length of
time needed to obtain ethical permission, in the wake of the Alderhay and other
inquiries.
Slcla4 has also been ruled out as the gene which is mutated in wobbler mice, as there
were no mutations in any of the exons of the gene. If a change had been noted in the
gene in wr/wr animals, the analysis ofmore mice would be necessary, to determine
whether this change was the causative mutation or a polymorphism, as the mice have
a mixed genetic background. RT-PCR analysis performed by Karen Wilson showed
that mRNA levels were similar in wr/wr and littermate controls. This demonstrates
one of the advantages of investigating mouse mutants, as no such material would be
available from human patients.
Since this work was carried out, Slclci4 has been excluded from the wr critical region
(Fuchs et al., 2002). This has been refined to the region betweenMurrl and
147N22rev. All eight genes within the region have been sequenced, but no mutations
have been found in the coding regions or in the parts of the 3' and 5' UTRs that have
been sequenced. The possibility remains that the wobbler phenotype is caused either
by a mutation in an undiscovered gene in the region, or in an as yet unknown
regulatory region. Comparative genomics may be of value to define these potential
regulatory regions, as there is conservation of synteny between mouse proximal
Chromosome 11 and human Chromosome 2p 13-14. It is possible that identification
of the genetic modifier locus on Chromosome 14 will aid in the identification of the
causative gene (Ulbrich et al., 2002).
During the course of this project, sequence information became available as a result
of the mouse sequencing project which allowed the design ofprimers to amplify the
whole of Slcla4 exonl, without having to sequence intron 1. Subsequently, the
whole genomic sequence of the Slcla4 gene has been released on a large contig
(accession number NW_000035, released October 2002). The mouse sequence has
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recently been released (Mouse Gene Sequence Consortium, 2002), so that in future it
will not be necessary for similar projects to sequence introns as all the information
will be available.
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5 Chapter 5 - Expression analysis of eEF1 A-1 and
eEF1 A-2
5.1 Introduction
In order to study the expression of eEFlA-2 and eEFl A-1, and to answer basic
biological questions about the two isoforms, I designed and characterised antibodies
which were specific for eEFl A-2 and eEFl A-1.
5.2 Design, generation and characterisation of antibodies
5.2.1 Antibody design
Due to the high degree of similarity between eEFl A-1 and eEFlA-2, anti-peptide
antibodies were generated to specifically recognise each isofonn. Two peptide
sequences were selected to generate antibodies, one comprising residues 439-452, at
the C-terminus of the protein (hereafter designated eEFlA-2C or eEFl A-1 C), and
one comprising residues 161-176 (hereafter designated eEFlA-2M or eEFlA-lM).
These sequences were selected on the basis ofmaximising differences between the
two isoforms. Their location, and the difficulties in finding sequences with
differences between the two proteins, are illustrated in figure 5-1. Their lengths, of
14 and 16 residues respectively, represented a compromise between maximising both
the number of residues and the proportion of residues which differed between the
two isoforms, and reducing costs. In order to use the antibodies for analysis of both
human and mouse proteins, peptides were selected with no amino acid differences
between the isoforms of the different species. A terminal cysteine was added to each
peptide, to allow for conjugation to keyhole limpet hemocyanin, and also to allow the
(It)
conjugation of the peptide to a SulfoLink column for subsequent immunoaffinity
purification. The cysteine was added to the C-termini of eEFlA-lC and eEFlA-2C,
and to the N-termini of eEFlA-1M and eEFlA-2M.
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1 mgkekthiniwighvdsgkstttghliykcggidkrtiekfekeaaemg 50
I II I I II I I I I I I I I I II I I I I I I I II II II I I I II I I II I I I II I II I I
1 mgkekthiniwighvdsgkstttghliykcggidkrtiekfekeaaemg 50
51 kgsfkyawvldklkaerergitidislwkfetskyyvtiidapghrdfik 100
I II II I I II I I I I I II I I II I II I I II I II I I • I I I : I I II I I I I I II I I
51 kgsfkyawvldklkaerergitidislwkfettkyyitiidapghrdfik 100
101 nmitgtsqadcavlivaagvgefeagiskngqtrehallaytlgvkqliv 150
II I I I II II I I I I II II I I I I I I I I II I I I I I II I I II I I I II I I I II I I
101 nmitgtsqadcavlivaagvgefeagiskngqtrehallaytlgvkqliv 150
151 gvnkmdsteppysqkryeeivkevstyikkigynpdtvafvpisgwngdn 200
II II I II I I I I I : II I : I I I I I II I I I I I I I II II I I I I I I I • II I
151 gvnkmdstepaysekrydeivkevsayikkigynpatvpfvpisgwhgdn 200
201 mlepsanmpwfkgwkvtrkdgnasgttllealdcilpptrptdkplrlpl 250
II I II II I I I I I I I I Ihlllll .111111 I I I I I I I I II I I I II I
201 mlepspnmpwfkgwkverkegnasgvsllealdtilpptrptdkplrlpl 250
251 qdvykiggigtvpvgrvetgvlkpgmvvtfapvnvttevksvemhheals 300
I II II I I I II II II II II II : I : II II I II II I I : I I II I II I II I II II
251 qdvykiggigtvpvgrvetgilrpgmvvtfapvnittevksvemhheals 300
301 ealpgdnvgfnvknvsvkdvrrgnvagdskndppmeaagftaqviilnhp 350
I I I I I I I I I II I I II I I II : I II II I I II - I II III I I • II I I I I I I
301 ealpgdnvgfnvknvsvkdirrgnvcgdskadppqeaaqftsqviilnhp 350
351 gqisagyapvldchtahiackfaelkekidrrsgkkledgpkflksgdaa 400
I I I II II • I I : II I I I II II II I I II I II II I I I I II II II I I I I II I
351 gqisagyspvidchtahiackfaelkekidrrsgkklednpkslksgdaa 400
401 ivdmvpgkpmcvesfsdypplgrfavrdmrqtvavgvikavdkkaagagk 450
I I : I I I I I I II I I I II II I I II I I I II I I I I I I I II I I I : I I • II II
401 ivemvpgkpmcvesfsqypplgrfavrdmrqtvavgviknvekksggagk 450
451 vtksaqkaqkak 461
I I I I I I II I I I
451 vtksaqkaqkagk 461
Figure 5-1 Peptide sequence of eEF1A-1 (top) and eEF1A-2 (bottom).
The regions of the proteins to which antisera were raised are shown in
green for eEF1A-1M and eEF1A-2M and in red for eEF1A-1C and eEF1A-
2C.
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There were other considerations in designing the peptides against which the
antibodies were raised. For example, access of the antigen by the antibody is required
in immunohistochemistry. Although the precise three-dimensional structure ofmouse
or human eEFlA-1 or eEFlA-2 had not been characterised at the time the peptides
were designed, the structure of the bacterial protein EF-Tu had been resolved using
X-ray crystallography (Song et al., 1999). The amino acid sequence of eEFl A-2 was
aligned with the bacterial EF-Tu sequence. Residues 161-176 (forming peptides
eEFlA-lM and eEFlA-2M) correspond with residues 143-159 of the bacterial
protein. Examining the protein structure at the Protein Data Bank (PDB), accessed
through HGMP (www.hgmp.mrc.ac.uk), these residues appear to form an a-helical
loop on the exterior of the protein. This is demonstrated in figure 5-2. Residues 439-
452 (forming peptides eEFlA-lC and eEFlA-2C) are not homologous to any region
of the bacterial protein, which terminates 20 residues short of the C-terminus of the
eEFl A-2 protein. However, as these peptides are very close to the C-terminus of the
protein, it is likely that they are also relatively exposed to the surface.
The antigenicity of the selected peptides was also assessed using the Antigenic
programme of the PIX protein identification suite, also available through the HGMP.
An antigenic peptide is more likely to provoke an immune response in the sheep. The
majority of the residues of eEFl A-1M, and the last 9 amino acids of eEFl A-2M,
were predicted to be antigenic. The first five residues of eEFlA-lC, and the first
three of eEFlA-2C, also showed expected antigenicity.
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Figure 5-2 Structure of E. Coli EF-Tu.
Residues 143-159 are highlighted in cyan. These residues form an exposed
a-helix.
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5.2.2 Antibody Generation and Characterisation
The synthesised peptides were then linked to keyhole limpet hemocyanin, KLH, to
improve the immunogenicity of the peptide and therefore the immune response in the
sheep. The KLH-conjugated peptide was then injected into a sheep as described in
Chapter 2, section 2.7.1, and the sera from three bleeds was obtained for each
peptide. The sera were then characterised and purified for use in experiments.
The serum from each bleed was initially tested to determine whether it recognised
the peptide using an ELISA (enzyme-linked immunosorbent assay). Different
concentrations of sera, from 1:100 tol: 100 000, were tested against different peptide
concentrations, from 5pg/ml to lng/ml. Preimmune serum, obtained from the same
animal into which the peptide was injected prior to immunisation, was used as a
control. The preimmune serum from the animal into which the eEFlA-2M peptide
was injected was not investigated, as the serum from this, and from eEFl A-1M, was
initially tested on a Western blot, as outlined in section 5.2.2.1, below. As the
eEFl A-2M antibody appeared to be specific on a Western blot, it was not considered
necessary to test the pre-immune serum. As the eEFl A-1M antibody did not
recognise a band of the correct size on a Western blot, the recognition of the
antibody for the peptide against it was raised was tested using ELISA, and compared
with that of the preimmune serum. The ELISA results are displayed graphically in
figures 5-3 through 5-6.
In all cases investigated, the response of the serum raised against the peptide was
greater than that of the preimmune serum. Whereas the absorbance at 450nm was
typically at least 1.0, that of the preimmune sera was typically around 0.1-0.2. There
was also a relationship between the concentration of the peptide and the ELISA
response of the antibody-containing sera, with the absorbance at 450 nm increasing
with increasing peptide concentration for each serum concentration. For the
preimmune sera, there was no such relationship, with the graph of absorbance at
450nm versus peptide concentration at different serum concentrations resembling
random noise.




















0 0.5 1 1.5 2 2.5 3 3.5 4
log10 [peptide]
eEF1A-2C Bleed 3
0 0.5 1 1.5 2 2.5 3 3.5 4
log™ [peptide]
1:100 -m-1:1 000 1:10 000 -K-1:50 000
Figure 5-3 ELISA results from eEF1 A-2C sera
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1:100 1:1 000 1: 10 000 1: 50 000
Figure 5-4 ELISA results from eEF1A-2M sera
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eEF1A-1C - Pre Immune
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1:100 1:1 000 1:10 000 -K-1:100 000
Figure 5-5 ELISA results from eEF1A-1C sera.
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eEF1A-1M - Pre Immune
0.5 1.5 2 2.5
log™ [peptide]
3.5
eEF1A-1M - Bleed 1
0 0.5 1 1.5 2 2.5 3 3.5 4
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log™ [peptide]
—•—B2 1:100 —•—1:1 000 1:10 000 -*-1:100 000
Figure 5-6 ELISA results from eEF1A-1M sera.
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5.2.2.1 Antibody specificity
The specificity of the eEFl A-2 antibodies was determined using western blotting.
Protein extracts from mouse brain were used, as it had previously been shown that
the mRNA of both isoforms is expressed in the brain (Lee et al., 1993b). Both anti-
eEFl A-2 antibodies recognised a band of approximately 50kD in the brains ofwild
type mice. No band was recognised in tissue extracts made from the brains ofwasted
animals. In heterozygous mice, which carry one functional eEFlA-2 allele and would
therefore be expected to express half the amount of eEFl A-2 protein, there was a
band of approximately half the intensity of that seen in wild type animals. The fact
that no band was seen in wasted animals demonstrated that the antibody is specific
for eEFlA-2, and does not recognise eEFl A-1, as wasted mice are still expected to
express eEFl A-1 at wild-type levels. An illustrative Western blot is shown in figure
5-7. The specificity of the antibodies was further confirmed by investigating the
expression pattern of eEFl A-2 in a range of tissues. This is discussed further in
section 5.3.1, below.
The specificity of the eEFlA-1 antibodies was also investigated using Western
blotting. Unlike the situation with eEFl A-2, there is no deletion control as there are
no eEFl A-1 knockout mice. However, the known eEFlA-1 tissue specificity allowed
a negative control, as eEFl A-1 is known not to be expressed in muscle after 25 days
at the RNA level (Chambers et al., 1998). The eEFlA-1C antibody recognised a
band of approximately 50kD in all adult tissues examined with the exception of adult
muscle. The results are presented and discussed further in section 5.3.1, below.
Although the eEFl A-1M antisera did recognise the peptide against it was raised, it
did not recognise any bands of the correct size using Western blotting, either before
or after purification. It was therefore not further investigated.




Figure 5-7 Western blot of protein extracts from mouse brains of different
genotypes: w/w, wasted; +/w, heterozygotes; +/+, wild-type animals. 15pg
total protein extract was loaded. The antibody used was the unpurified
eEF1 A-2C antibody at a concentration of 1:50. Similar results (data not
shown) were obtained for the eEF1A-2M antibody. No band is seen in the
extracts from wasted animals, and a much weaker band is seen in the
heterozygous animals than in the wild type animals. This reflects the fact that
they only have half the amount of eEF1 A-2 protein of the wild type animals.
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5.2.3 Antibody Purification
The specificity of the antibodies was improved by purification, as illustrated in figure
5-8. Antibodies were initially purified using ammonium sulphate precipitation, which
separates the immunoglobulin component of the sera from the other components.
This resulted in a decrease in the intensity of non-specific bands on a Western blot.
The precipitated antibodies were further purified using immunoaffinity purification,
in which the antibody is purified against the initial peptide. After such purification,
only antibodies specific for the peptide in question should be present. This resulted in
the removal of all non-specific bands on a Western blot.
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Figure 5-9 Immunoblots ofWesterns after different stages of antibody
purification. The first blot has been immunoblotted with pre-immune sera from
the same sheep into which the eEF1A-2C peptide was subsequently injected,
the second, sera before purification, the third, after ammonium sulphate
precipitation and fourthly, after immunoaffinity purification. Protein extracts
were made from mouse tissues: B, brain; H, heart; L, liver; W, brain from a
wasted mouse. The preimmune and unpurified sera were used at 1:100 in
blocking buffer, and the ammonium sulphate and affinity-purified eEF1A-2
antibodies were used at 1:50 in blocking buffer. The number of bands
recognised progressively decreases until a specific band of 50kD is
recognised. Note that eEF1A-2 is not expressed in liver; the L and W tracks
therefore act as negative controls, demonstrating a lack of cross-reactivity
with eEF1A-1. The numbers next to the blots represent the size, in
kilodaltons, of the bands of the prestained ladder.
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5.3 Expression analysis
5.3.1 Analysis in mouse tissues
The eEFlA-2C and eEFlA-1C antibodies were used in Western blotting in a range
of adult mouse tissues. The resulting blots are shown in figures 5-9 and 5-10. These
confirm previous findings at the RNA level that eEFlA-2 expression in the adult
mouse is confined to the brain, spinal cord, heart and skeletal muscle. No signal was
detected in any of the other tissues examined, namely the kidney, spleen, thymus,
liver or lung. The eEFl A-1 antibody recognised a band in all tissues studied, with the
exception of adult muscle. These results also confirm the specificity of the two
antibodies for their respective eEFl A isoforms.
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Figure 5-9 Western blot showing eEF1 A-2 expression in protein extracts from
a range of adult mouse tissues. M, muscle; K, kidney; S, spleen; T, thymus,
Li, liver; Lu, lung; H, heart; B, brain; W, wasted brain; C, cervical spinal cord;
T, thoracic spinal cord. The antibody used was the affinity-purified eEF1A-2C
at a concentration of 1:50. The numbers to the left of this blot, and the blot
below, represent the sizes, in kilodaltons, of the prestained ladders.
200
128




Figure 5-10 Western blot of a range of mouse tissues (as figure 5-9, with the
exception that SC represents spinal cord and O, an overspill lane), blotted
with the eEF1A-1C antibody at a concentration of 1:50.
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Although at the start of this project the timing of the isoform switch in the central
nervous system in mouse was unknown, work by Khalyfa et al. has subsequently
shown that eEFl A-2 is present at post natal day 1 (PI) in the brain (2001). I therefore
decided to investigate whether eEFlA-2 was present in the developing embryo.
Western analysis on tissue extracts from 13.5 and 14.5 dpc heads showed that
eEFl A-2 was indeed present in mouse embryos at those ages. The blots are shown in
figure 5-11. Although it was not possible within the timescale of this project, it will
therefore be of great interest to investigate the expression pattern in the embryo using
in situ immunohistochemistry.
As the expression pattern of the two isoforms in the eye had not been investigated, I
examined their expression in protein extracts made from adult eyes. This
demonstrated that, at the level ofwhole tissue extracts, eEFl A-2, and not eEFlA-1,
is expressed in mouse eyes. This is shown in figure 5-12. It is clearly possible,
however, that a subset of cells within the eye are expressing eEFl A-l.
As outlined in Chapter 3, there appeared to be a gradient in the severity of the
pathology seen in the spinal cord, from the cervical through the thoracic to the
lumbar region. The timing of the wasted phenotype is presumably coincident with
the loss of eEFlA-l. It is possible that the gradient in the pathology seen within the
spinal cord is caused by a gradient in the loss of expression of eEFlA-l. It was
hoped to determine the switch between eEFl A-l and eEFlA-2 at different levels of
the spinal cord. However, it was not possible to do this using Western blotting, as
there are cell types other than motor neurons within the spinal cord which express
eEFlA-l, so that at best a decrease in eEFl A-l levels would be seen. A more
appropriate method would therefore have been to use immunohistochemistry on
spinal cord sections on mice from a number of ages. However, this was not possible
as neither eEFlA-l antibody worked in immunohistochemical experiments under a
range of conditions, on either paraffin-embedded or frozen cryostat sections.
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Figure 5-11 Western blot of mouse embryo tissue extracts.
The antibody used was eEF1A-2M at a concentration of 1:200.The ages of
the embryos were E13.5 and E14.5 dpc. The extract from an adult brain, A










Figure 5-12 Western blots of mouse eye extracts.
The blot on the left has been probed with the eEF1A-1C antibody, at a
concentration of 1:50. That on the right has been probed with the eEF1A-2C
antibody, at a concentration of 1:200. E, adult eye; B, brain eEF1A-1 positive
control; W, wasted brain eEF1A-2 negative control. The numbers to the left of
the blots in figures 5-11 and 5-12 are the sizes, in kilodaltons, of the
prestained ladders.
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To try to determine the subcellular localisation of eEFl A-2,1 analysed its expression
in wild type mouse spinal cords using immunohistochemistry. This is shown in
figure 5-13. Expression was observed in the neuronal cytoplasm. However, it was not
possible to determine whether eEFlA-2 was also expressed in the dendrites. In order
to do this, it was deemed necessary to perform immunofluorescent expression
analysis in cultured cells.
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Figure 5-13 Immunohistochemistry on sections through spinal cord of 28-day
+/wst mouse, using the eEF1A-2C antibody at a concentration of 1:10,
showing cytoplasmic neuronal staining. The top slide shows the whole spinal
cord, at a magnification of 1:10, and the bottom slide a close-up of the
anterior horn region, at a magnification at 1:100.
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5.3.2 Analysis in cells
5.3.2.1 Establishing a cell culture system
It still not known why two elongation factor isoforms are required in neurons. It may
be that one (or more) of the non-canonical functions of eEFl A-2 is (or are)
important. For example, eEFl A-2 may be necessary for an as yet unidentified
cytoskeletal function which is particularly important for neurons, with their large
cytoplasmic volumes and long axons. An alternative hypothesis is that neurons have
both forms because they function slightly differently in translation. Neurons have an
unusual property in that translation occurs both at the cell body and at the synapse
(Job and Eberwine, 2001a; Job and Eberwine, 2001b). It is therefore conceivable that
eEFlA-2 is required for synaptic translation, particularly as the peak expression of
eEFl A-2 coincides with the completion of synaptogenesis. A key experiment is
therefore to determine the relative subcellular localisation of the two isoforms in
neurons, which, as outlined in Chapter 1, section 1.3.2.3, has not been definitively
characterised.
To this end I investigated a cell system for study. The PC-12 cell line was originally
derived from a rat pheochromocytoma (Greene and Tischler, 1976). On exposure to
nerve growth factor-P (NGF-P), they differentiate, growing processes so that they
resemble neurons. I investigated the expression of the two eEFlA isoforms in PC-12
cells. Using Western blotting, I showed that that they were expressing both eEFlA-1
and eEFlA-2, both before and after differentiation (figure 5-14). Petroulakis et al.
subsequently confirmed this result (Petroulakis and Wang, 2002). I also investigated
the expression of eEFlA-1 and eEFlA-2 in the human cell line SH-SY5Y, originally
derived from a neuroblastoma (Biedler et al., 1978). This cell line was also found to
express both isoforms. Westerns are also shown in figure 5-14.
















Figure 5-14 Expression of eEF1 A isoforms in cell lines.
(a) shows the expression of eEF1 A-1 in the neuroblastoma cell line SU-SY5Y,
(b); eEF1A-2 in SU-SY5Y cells, (c); eEF1A-1 in PC-12 cells , (d); eEF1A-2 in
PC-12 cells. Abbreviations are as follows: NSu, SU-SY5Y cell extracts; M, wild
type muscle; W, wasted brain; B, wild type brain; Pd, differentiated PC-12
cells; Pu, undifferentiated PC-12 cells. Muscle is an eEF1A-1 negative control;
Wasted brain, an eEF1A-2 negative control, and wild-type brain a positive
control for both isoforms. The eEF1A-1 antibody was used at a concentration
of 1:50, and the eEF1A-2 antibody at a concentration of 1:200. 15pg total
protein extract was loaded on the gel. The numbers next to the
autoradiograms represent the sizes, in kilodaltons, of the prestained ladders.
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5.3.2.2 Subcellular localisation experiments
Unfortunately, it was not possible to obtain a specific signal using
immunofluorescent detection on either cell line, using either of the eEFlA-2
antibodies. Different fixation methods, namely 50:50 acetone:methanol, ice-cold
methanol and paraformaldehyde were used. Primary antibody concentrations from
1:10 to 1:1 000 were also tried. However, in all cases the signal obtained resembled
that obtained with the preimmune serum, as shown in figure 5-15. This signal was
not decreased on preabsorption of the primary antibody with different concentrations
from 0.01 to 1.0 ng/pl antibody solution, of the peptide against which the antibody
was raised, confirming that the signal obtained was not specific.
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eEF1A-2C, x 16
Preimmune serum, x100
Figure 5-15 Immunofluorescence analysis in PC-12 cells.
The top figure is of cells stained with eEF1A-2C at a concentration of 1:100,
and the bottom figure, with pre-immune serum from the same animal, also at
a concentration of 1:100. Although the signal obtained with the eEF1A-2C
antibody appears to show cytoplasmic staining, a similar signal is obtained
using the pre-immune serum.
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5.4 Discussion
5.4.1 Specificity of antibodies
During this PhD I have produced antibodies which are completely specific for the
two eEFlA isoforms, that is, two antibodies which recognise eEFlA-2 and not
eEFlA-1, and one antibody which labels eEFlA-1 and not eEFl A-2. Although an
early eEFlA-2 antibody, raised against the whole protein, has been described, no
evidence of its specificity was provided (Liu et al., 1993). Moreover, the more
recently reported eEFl A-1 antibody described by Khalyfa et al. recognises a band in
muscle, in which there is no evidence of eEFlA-l expression (Khalyfa et al., 2001).
Their antibodies to both isoforms also recognise a number of non-specific bands.
Other studies have inferred the localisation of eEFl A-2 using an antibody which
actually recognises eEFlA-l (McClatchy et al., 2002). My antibodies will therefore
be useful for the further expression analysis of eEFlA-l and eEFl A-2, both on
tissues and in cells.
5.4.2 Expression in tissues
The results hereby confirm the expression results obtained at the RNA level. It also
confirms the limited findings ofKhalyfa et al. (Khalyfa et al., 2001), who
demonstrated that the eEFl A-2 protein is expressed in the brain, heart and skeletal
muscle. However, in order to do so, they immunoprecipitated both isoforms from the
respective tissues, using an antibody which recognised both eEFlA-l and eEFlA-2,
and then blotted them with the isoform-specific antibodies. In contrast, I have
investigated the expression of both isoforms directly on a Western blot from tissue
extracts.
I have demonstrated that eEFlA-2 is expressed at least as early as E13.5 in
embryonic development. As expression at this embryonic stage is quite strong, it is
probably expressed at an even earlier stage. It would therefore be interesting to track
the expression of eEFlA-2 during embryonic development. Given that it is expressed
in the eyes of adult mice, it would also be interesting to track its expression during
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the embryonic development of the eye. It would also be worthwhile to investigate the
expression in the eyes of adult mice using immunohistochemistry, to identify the cell
types which express eEFlA-2. Cell types which might be expected to express
eEFlA-2 include photoreceptor cells, which have an elongated cytoplasm
reminiscent of neurons and might therefore share their requirement for eEFlA-2,
muscle cells and neuronal cells such as bipolar cells.
5.4.3 Expression in cells
It was hoped to analyse the subcellular localisation of eEFlA-2. Although this has
been described in mouse brains, the resolution in this case was not sufficient to be
able to tell, for example, whether eEFl A-2 is expressed at the synapse (Khalyfa et
al., 2001). It is interesting to speculate that the second eEFIA isoform is required for
synaptic translation. Unfortunately, it was not possible to obtain a specific signal for
eEFlA-2 in PC-12 or neuroblastoma cells. Although a signal was obtained using
DAB staining on paraffin-embedded sections, this method did not give sufficient
resolution. It is possible, therefore, that it would be necessary to transfect a tagged
Eefla2 cDNA into the cells and analyse the expression pattern obtained. However,
this approach does risk obtaining an expression pattern which does not accurately
reflect the in vivo situation.
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6 Chapter 6 - eEF1A isoforms in Xenopus Laevis
6.1 Introduction
6.1.1 Xenopus laevis
There are seven recognised species ofXenopus, ofwhich the aquatic X. laevis, the
African Clawed Frog, is the most common. They are members of the family Pipidae.
At spawning, between 300 and 1000 eggs are released. Within 3 days, the larvae
hatch, and reach metamorphosis in around two months in conditions ofplentiful
food. They can breed from about 18 months of age onwards. Females can live for up
to 15 years in captivity, and grow continuously. Males, however, stop growing at
between two and four years of age (Deuchar, 1975).
X. laevis have been used in science for many years - an early use was in pregnancy
testing. However, they are better known as a model system in developmental
biology, due to the large size, transparency and external development of their
embryos. These are also robust, as each egg carries its own power source in the form
of its yolk, so that they can be transplanted. Genetic techniques have been developed
which have given great insights into genes involved in embryogenesis. However, a
major drawback to the use o(X. laevis as a model system is that they are
allotetraploid, that is, they have double the usual number of chromosomes. Although
in this case it is relatively straightforward to add genes, it becomes much harder to
subtract them, as four copies of a gene may need to be inactivated. In addition, many
genes are represented by extra copies which may or may not be functional. The
animals also take a long time to reach sexual maturity, resulting in a long generation
time which is not amenable to multi-generation experiments. Because of these
factors, attention has become focused on Xenopus tropicalis (see Amaya et al. and
related links). Indeed, the genome ofA. tropicalis is currently being sequenced. A
summary of some of the important differences between the two species is given in
table 6-1.
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Species X. laevis X. tropicalis
Ploidy Allotetraploid Diploid
Chromosomes 36 20
Genome Size 3.1 x 109 1.7 x 109
Optimal Temp. 16-22°C 25-30uC
Adult Size 10 cm 4-5 cm
Egg Size 1.0-1.3 mm 0.7-0.8 mm
Eggs/Spawn 300-1000 1000-3000
Generation time 1-2 years < 5 months
Table 6-1. Comparison of X. laevis and X. tropicalis (from Amaya et a/.).
6.1.2 eEF1A isoforms in X. Laevis
Two main isoforms of eEFIA have been described inX. laevis. Although the early
literature describes these as EF-laO and EF-laS, I will subsequently refer to these
as eEFlA-O and eEFlA-S respectively, to maintain consistency of nomenclature.
eEFlA-0 is expressed in mature oocytes, spermatogonia and primary spermatocytes
and, transiently, in early embryos (Abdallah et al., 1991a; Dje et al., 1990). The
somatically expressed eEFl A-S is expressed in adult liver (Dje et al., 1990) and in a
small region of the oocyte cytoplasm known as the mitochondrial mass or Balbiani
body (Viel et al., 1990). It is also expressed in the germ cells of the gonad prior to
metamorphosis (Abdallah et al., 1996). At metamorphosis there is a switch from the
somatic to the oocyte-specific form in the germ cells. At the amino acid level, the
eEFlA-0 and eEFlA-S proteins are 91% identical.
eEFlA-S is a major transcript from the midblastula transition (MBT) onwards in
early embryogenesis, representing up to 40% of the total polyadenylated transcripts
(Krieg et al., 1989). It is at the midblastula transition that embryonic sequences begin
to be transcribed into mRNA. Up until this point, only maternal sequences from the
oocyte are transcribed. The high levels of eEFl A-S may be required by the early
embryo in order to accumulate large amounts of translational machinery, or may
reflect the requirement for some other, uncharacterised, function. In gastrula-stage
embryos, two alternative cDNAs have been identified which differ from each other at
3.5% of nucleotide positions, but have no resulting amino acid differences in the
encoded proteins (Potting et al., 1990). One of these differs from the eEFl A-S
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sequence obtained by Krieg et al. (Krieg et al., 1989) at only three nucleotide
positions, but all three changes lead to amino acid substitutions, one of them non-
conservative. These alternative cDNAs probably represent expressed
retropseudogenes, as several have been identified (Abdallah et al., 1991a), including
one with similarity to one of the cDNAs identified by Potting et al. (Potting et al.,
1990). They may, however, represent functional genes which have been duplicated
as a result of the allotetraploidy of the A. laevis genome.
There is a third eEFlA isoform, described as 42Sp50, 42Sp48 or thesaurin a, which
is expressed in immature oocytes and pre-meiotic germ cells (oogonia) (Abdallah et
al., 1991b; Dje et al., 1990; Viel et al., 1987). It appears to be encoded by two
different genes (Coppard et al., 1991). With 69% identity at the amino acid level
with eEFlA-0 and eEFlA-S, this isoform is much more diverged, especially at the
C- and N-termini (Dje et al., 1990). However, although it is structurally similar to
both eEFlA-l and the bacterial EF-Tu (Viel et al., 1991), it appears to be used
mainly in the storage of tRNAs (Morales et al., 1993).
X. laevis eEFlA-S is 96% identical to human eEFlA-l (Potting et al., 1990). There
are no reports in the literature of an equivalent of the mammalian eEFlA-2, that is,
an isoform of eEFlA which is expressed only in the CNS, heart and skeletal muscle.
This is perhaps surprising, given that amphibians also have a central nervous system.
It is difficult to reconcile a need for an isoform switch to eEFl A-2 in neurons with
the lack of an eEFlA-2 orthologue in A. laevis. On searching the A. laevis EST
database at NCBI with the mouse Eefla2 sequence, Dr. C. Abbott noted ESTs
generated from brain, eye and heart libraries which, once translated, were more like
eEFl A-2 than any of the knownA laevis EEFlA isoforms. It is therefore possible
that there is an eEFlA-2 orthologue inA laevis. I investigated this possibility using
expression analysis and sequencing.
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6.2 Results
6.2.1 Expression analysis of eEF1 A isoforms in X. laevis
In order to test the hypothesis that an orthologue of eEFlA-2 exists in A. laevis, and,
as in mammals, is expressed in a tissue-specific and developmentally-regulated
manner, I used anti-eEFlA-l and anti-eEFl A-2 antibodies on a range of tissue
extracts from an adult female frog and also on a late gastrula-stage embryo. I used
both our sheep anti-eEFlA-2 antibodies and an antibody raised in rabbit against the
eEFl A protein from the brine shrimp, Artemia salina (Sanders et al., 1996). As
described in Chapter 5 (section 5.2.1), the eEFl A-2M antibody was raised against a
peptide in the centre of the mouse protein, whereas eEFlA-2C recognises a peptide
near its C-terminus.
6.2.1.1 eEF1 A expression is tissue-specific
The eEFl A-2M antibody recognised a single band of approximately 50kD (and the
same size as the band in a positive control mouse brain sample) on a Western blot of
a range of adult tissues fromA laevis. This is shown in figure 6-1. A band was
present in the extracts from brain, spinal cord, optic ganglion and muscle. A weaker
band was also seen in heart. No signal was observed in liver, gall bladder, lung,
kidney, spleen or oocyte. Neither of the sheep anti-eEFlA-l antibodies which I
generated recognised a specific band in tissue extracts from X. laevis (data not
shown). However, the antibody raised against the A. salina eEFlA protein
recognised a protein of approximately 50kD present in spleen, kidney, lung, liver,
gall bladder, heart, spinal cord and brain (figure 6-1). No signal was observed in
muscle, optic ganglion or oocyte.
These data are compatible with the idea that there is an additional, tissue-specific
eEFl A isoform. This X. laevis orthologue of eEFl A-2 is expressed in the same
tissues as those of the previously studied mammalian species (rat, mouse and
human); namely the central nervous system, skeletal muscle and heart. For clarity,
this novel isoform will subsequently be described as XeEFlA-2. The other isoform is
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expressed in the same tissues as the mammalian eEFlA-1. It is probable that this
isoform is the previously described eEFlA-S. The two isoforms are distinct from the
oocyte-specific eEFlA-O, as neither of the antibodies used recognised a band in
oocyte tissue extracts.
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eEF1A-1:
OG BSC M H O Li GB Lu K S C
eEF1A-2:
Figure 6-1 Western blots of a range of adult X. laevis tissues.
The top filter was blotted using the anti-A. salina eEF1A antibody at a
concentration of 1:50, and the bottom filter using our eEF1A-2M
antibody at 1:20. The tissues used were as follows: OG, optic
ganglion; B, brain; SC, spinal cord; M, muscle; H, heart; O, oocyte; Li;
liver; GB, gall bladder; Lu, lung; K, kidney; S, spleen; C, control. The
positive control sample in the last lane was a protein extract from a
human neuroblastoma cell line which expresses both eEF1A-1 and
eEF1A-2. The 50kD band corresponding to eEF1A-1 and eEF1A-2 is
arrowed.
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The eEFlA-2C antibody recognised bands of approximately 50kD in all adult
tissues, with the exception of oocyte. A Western blot is shown in figure 6-2.
However, the band in muscle and heart was slightly larger than in liver, lung and
spleen. This suggests that the eEFlA-2C antibody recognises both eEFlA-S and
XeEFlA-2, and that eEFl A-2 is slightly larger than eEFlA-S isoform. This is
consistent with the situation in the rat, in which eEFl A-2 has been described as
0.5kD larger than eEFl A-1 (Petroulakis and Wang, 2002). As the two proteins differ
in size by only one amino acid (of 462 or 463 residues), it is possible that that this
difference is as a result of posttranslational modifications. However, although a
number ofmodifications have been described for eEFlA-1, including
phosphorylation (Keilbassa et al., 1995; Venema et al., 1991), the methylation of
lysine residues (Dever et al., 1989) and the addition of ethanolamine-
phosphoglycerides (Rosenberry et al., 1989; Whiteheart et al., 1989) no such
modifications have been described for eEFlA-2 in any species.
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Figure 6-2 Western blot of a range of adult X. laevis tissues, using the
eEF1A-2C antibody at a concentration of 1:20. Tissues used are: M, muscle,
H, heart, Lu, lung, S, spleen. B represents a mouse brain extract used as a
control.
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6.2.1.2 XeEF1A-2 expression is developmentally regulated
As there appeared to be an orthologue of eEFlA-2 inA laevis, I decided to
determine whether this protein is developmentally regulated in these frogs, as it is in
mammals.
The anti-A salina eEFl A and eEFlA-2M antibodies were used in an immunoblot of
protein extracts from a late gastrula stage embryo. Immunoblotting with the
anti-A salina eEFl A antibody resulted in a very strong 50kD band (figure 6-3). No
band was observed using the eEFlA-2M antibody. Thus, whilst A. laevis adult
tissues have two isoforms, antigenically similar to eEFl A-1 and eEFl A-2, early
embryos have only one form, antigenically similar to eEFlA-1. InA laevis,
XeEFlA-2 is thus developmentally regulated. Further work, is, however, required to
determine from which stage in A. laevis development this novel isoform is expressed.
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eEF1A-1 eEF1A-2
Figure 6-3 Western blots of gastrula-stage embryos.
The left-hand filter was blotted with the anti-A salina eEF1A antibody at 1:50,
and the right-hand filter with the eEF1A-2M antibody at 1:20. The samples
used were: O, adult oocyte; G, gastrula and C, control, a cell extract from a
human neuroblastoma cell line which expresses both eEF1A-1 and eEF1A-2.
The band representing eEF1A-1 oreEF1A-2 is arrowed. Note that there are
also some non-specific bands, particularly at just smaller than 50kD in
gastrula, using eEF1A-2. The numbers to the right of the autoradiograms
represent the sizes, in kilodaltons, of the prestained ladders.
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6.2.2 Completing sequence of XeEF1A-2
In the available EST sequence of the XeEFl A-2, there was a gap which resulted in a
break in the deduced amino acid sequence of 77 residues. This is demonstrated in
figure 6-4. In order to generate full-length cDNA sequence and to confirm the
identity of this as an eEFl A-2 orthologue, the mRNA was sequenced. RNA was
extracted from muscle and reverse transcribed into cDNA. RT-PCR primers were
designed from the EST sequence information to specifically amplify mRNA from
XeEFl A-2. The location of the primers within the RNA is shown in figure 6-4. A
product of 625bp, the expected size based on alignment with the mouse eEFl A-2
sequence, was successfully amplified from the cDNA generated from adult muscle.
This was then sequenced in duplicate in both directions. An agarose gel showing the
RT-PCR product obtained is shown in figure 6-5, and a typical sequence trace
obtained is shown in figure 6-6. The completed nucleotide sequence obtained is
shown in figure 6-7. It was translated into amino acids, and the protein sequence thus
obtained is shown in figure 6-7. This was then aligned with the other known mouse
eEFl A and A. laevis eEFl A protein sequences, using the multiple alignment general
interface (MAGI). The alignment is shown in figure 6-8.













































Figure 6-4 Figure legend and continuation of sequences on following page.



























Pr I KNVE KKI GGAGKVTKSAQK
Mla2 AGAAGGCGCAGAAAGCGGGCAAGTGAACCGGCGCCCGGCGAGGCCCTGCGCGCCCCCAGC
Xen2 AGAAAGCCCAGAAGGCTGCAAAATGAATTGCCG GTTCCCTTCGC
Pr A Q K A A K
Mla2 CCCGCCCCCGGCACTGGCCCCTGCCCCGCCCCAGCGCGGCCCCTCTGCCCCGACCCCCTG







Figure 6-4 Line-up of mouse Eef1a2 mRNA sequence (Mla2) with X. laevis
EST sequences: Xeni, from BG814373, available through NCBI
(http://www.ncbi.nlm.nih.gov); Xen2, from TC28037, available through TIGR
(http://www.tigr.org/tdb/xgi) and Pr, deduced amino acid sequence of X.
laevis ESTs. The sequences used for the RT-PCR primers are underlined.
Xeni and Xen2 represent either end of the predicted eEF1A-2 orthologue.
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Figure 6-5 Agarose gel (2%) showing RT-PCR product obtained from
X. laevis adult muscle. Lanes are: L, Gibco 1kb ladder; no sample;
+RT, reverse transcriptase in cDNA synthesis reaction; -RT, no
reverse transcriptase; C, PCR control with no DNA. The sizes of the
bands in the 1 kb ladder are given to the left of the gel picture. The
expected size of the RT-PCR product, based on alignment with the
mouse mRNA sequence, is 625bp.
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Figure 6-6 Typical sequence trace of X. laevis RT-PCR product.























































Figure 6-7 Completed nucleotide sequence and deduced amino acid
sequence of X. laevis eEF1A-2 orthologue.









































Figure 6-8 Line-up of deduced X. laevis eEF1A-2 orthologue (xia-2) and
eEF1A isoforms from mouse (mia-2 and mia-i) and X. laevis (xia-s and xia-
o). The peptide sequences used in generating the antibodies are highlighted
in green foreEF1A-2M and red foreEF1A-2C, as in Chapter 5, section
5.2.1. Differences between mouse eEF1A-2 and itsX. laevis othologue are
highlighted in blue.
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6.3 Discussion
6.3.1 eEF1A isoforms in X. laevis
The available data from the literature suggested that the presence of a second, tissue-
specific eEFl A isoform is mammalian specific. I have shown that there is an isoform
of eEFlA in an amphibian species, Xenopus laevis, which is consistent with the
situation in mammals in that it is expressed in the heart, skeletal muscle and cells of
the central nervous system. This experimental finding is consistent with the in silico
data, as the ESTs were isolated from the brain, eye and heart. An eEFlA isoform,
presumably the previously described eEFlA-S, is expressed in all tissues examined,
except muscle, oocyte and optic ganglion. XeEFlA-2 is also developmentally
regulated, as this isoform is not present in a gastrula stage embryo. It would therefore
be of great interest to determine at what stage in X. laevis the potential switch in
expression between the two isoforms occurs. The very strong band observed using
the eEFlA-1 antibody against gastrula tissue extracts is consistent with previous
findings which found that eEFlA-S is a major transcript in developing embryos
(Krieg et al., 1989).
The RT-PCR result confirms the existence of XeEFlA-2 in muscle at the RNA
level. The primers I designed could also be used to confirm the presence of the
mRNA for this isoform in the heart and brain. Other tissues, for example the eye,
could also be examined. Primers at the same position in the eEFlA-S transcript could
be used to investigate its expression at the RNA level, and could also be used to
sequence the isoform in, for example, liver, to confirm that the protein recognised by
the anti-A salina eEFIA antibody is, in fact, eEFlA-S.
The striking feature ofXeEFl A-2 is the similarity of its amino acid sequence with
the mouse eEFlA-2 protein. Like mouse eEFlA-2, it is 463 amino acids long, and
there are only three differences between them. There is less similarity with the
knownA laevis isoforms. The percentage identity between XeEFlA-2 and the
known isoforms in mouse and A. laevis are shown in table 6-2. At the nucleotide
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level, the coding regions of the mouse eEFl A-2 mRNA and its X. laevis orthologue
are the most similar. As with eEFlA-1 and eEFlA-2 in mammals, there is much
more divergence between the isoforms in the 3' and 5' UTRs than in the coding
regions, which were not included in the analysis.
mouse eEF1 A-2 mouse eEF1 A-1 eEF1A-S eEF1A-0
Nucleotide 83.2% 77.4% 79.0% 78.2%
Amino acid 99.4% 93.3% 90.5% 88.6%
Table 6-2 Percentage identities between the coding regions of XeEF1A-2
and the known mouse and X. laevis isoforms. The identities between the
nucleotide sequences are calculated from the coding regions of the genes
6.3.2 Antibody Specificity
Both eEFlA-2 antibodies (eEFlA-2C and eEFlA-2M) recognised XeEFlA-2. This
is despite the presence of one amino acid difference between each peptide and
XeEFlA-2. Within the 16 amino acids of the peptide against which eEFlA-2M was
raised, there are three which differ between eEFl A-S and the peptide. This was
sufficient for the antibody to be specific for XeEFlA-2, and not recognise eEFlA-S.
However, the eEFlA-2C antibody appeared to recognise both XeEFl A-2 and
eEFlA-S, even though there were 4 (of 14) amino acid differences between
XeEFlA-2 and eEFl A-S. It is therefore possible that there are differences in the
secondary structure between the two peptides. It may be important that one of the
differences between the peptide and eEFl A is at the C-terminus of the peptide, and
may therefore be more exposed. It is also possible that eEFlA-2C is recognising
anotherA laevis eEFlA isoform. However, there is no evidence for another isoform
in the EST databases. Given that 4 amino acid differences were sufficient for
antibody specificity of both eEFlA-2 antibodies in mice, it is difficult to draw any
general conclusions which would aid in the design of future anti-peptide antibodies.
It is also intriguing that the antibody raised against the A. salina eEFl A protein was
apparently specific for eEFlA-S, unlike the two anti-eEFlA-1 antibodies which I
raised. This antibody was raised against the whole protein, rather than a peptide.
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There are 80 amino acid differences between the A. salina eEFIA andA laevis
eEFl A-S proteins (82.7% identity), whereas there are 85 differences between the
A. salina protein and A. laevis eEFlA-2 orthologue (81.6% identity). It is difficult to
account for why such a small difference in the overall percentage identity could
affect antibody specificity so dramatically. It is possible that there are more
differences between the A salina eEFIA andA laevis eEFlA-2 orthologue in the
more exposed residues of the proteins, or that there are differences in
posttranslational modification between them. Alternatively, this antibody may also
recognise another, as yet uncharacterised, isoform of eEFIA, although again, there is
no evidence for this from the EST databases.
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7 Chapter 7 - General Discussion
7.1 Discussion
7.1.1 Project Aims
The genetic mutant wasted is caused by a deletion which results in the loss of
eEFlA-2, a tissue-specific isoform of the more widely-expressed eEFlA-1. The
main theme of this project has been the potential relationship between eEFl A-2 and
the motor neuron diseases. Within this area of research there were four main aims.
Firstly, to further characterise wasted mice, and evaluate whether they are a suitable
model for ALS. Secondly, to determine whether there is a direct involvement of
EEF1A2 in ALS, by mutation screening the gene in patients. Thirdly, to develop and
characterise specific antibodies which recognise the two isoforms of eEFl A, eEFl A-
1 and eEFlA-2. Finally, to investigate whether eEFl A-2 is really confined to
mammals, or whether there is evidence for its existence in other vertebrates.
7.1.2 Pathological analysis of wasted
In this thesis I have extended the previous pathological observations ofwasted mice.
I have shown that the weight loss seen in homozygous wasted mice is due to muscle
atrophy. Vacuolation of their motor neurons is seen from 28 days, and not at 24 days,
and therefore represents a later feature of the phenotype. Both astrogliosis and the
accumulation of phosphorylated neurofilaments are present from at least as early as
19 days, which preceeds the onset of overt neuromuscular symptoms. There also
appears to be a gradient in the severity of vacuolation and of gliosis from the cervical
to the lumbar region. The features of the wasted phenotype are summarised and
compared with those ofALS in table 7-1.
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Feature Wasted ALS
Age of onset 19 days 55 years (mean for
sporadic disease)
Muscle Muscle atrophy Muscle atrophy
H&E Loss of anterior horn motor Loss of anterior horn motor
neurons neurons







Ubiquitin No increased staining Ubiquitinated inclusions
MAP2 No decreased staining Decreased staining
Table 7-1 Summary of neuropathological findings, and comparison with ALS.
There are thus several features in common between the phenotype ofwasted mice
and human ALS. Both are progressive neurodegenerative conditions in which there
is increasing paralysis and a loss ofmuscle mass. On a microscopic level, both show
the specific loss of anterior hom cell motor neurons, gliosis and the neuronal
cytoplasmic accumulation of phosphorylated neurofilaments (Graham and Lantos,
1997; Manetto et al., 1988; Munoz et al., 1988; Sobue et al., 1990). One difference
between them is that wasted mice do not have ubiquitinated inclusions, which are a
common feature ofALS. However, the time course of the wasted phenotype is
extremely rapid. If it were possible to extend the lifespan ofwasted homozygous
mice, perhaps using transgenic approaches, then it is conceivable that ubiquitinated
inclusions would then be seen. The presence of ubiquitinated inclusions may
represent an end-point of the human disease, as it is usually only autopsy material
which is available from ALS patients.
Another obvious difference between the phenotypes ofwasted mice and the
symptoms of human ALS sufferers is one of timing. The wasted phenotype has an
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onset at 19 days, around the time ofweaning, whereas ALS usually occurs in middle
or old age in humans. Wasted mice may actually therefore provide a better model of
SMA, or of one of the rarer forms ofALS with a juvenile onset, than of the more
common, adult-onset form ofALS. There may indeed be some degree of overlap
between ALS and SMA, as, for example, there are reports of families in which the
two diseases coexist (reviewed in Orrell et al., 1997). However, reports of an
association between SMN gene copy number and ALS probably represent artefactual
findings (Crawford and Scholasky, 2002).
One further key difference between the wasted phenotype and human ALS is that
there is no overt immunological phenotype in ALS, whereas wasted mice show
atrophy of the spleen and thymus, and a defective response to radiation-induced
damage in lymphoid-derived cells. It is not known what potential long-term effects
these defects would produce, but it is possible that they would include lymphoma. It
has been suggested that ALS sufferers are more likely to also have
lymphoproliferative disease than the general population (Gordon, 1997). However,
there does not seem to have been a systematic evaluation of this, which would in any
case be difficult given the relative rarity of the two diseases. The available data
appears to be confined to case reports.
7.1.3 Mutation analysis of ALS candidate genes
Both my pathological observations, summarised above, and previous reports (Lutsep
and Rodriguez, 1989; Woloschak et al., 1987) are consistent with wasted being at
least a partial model of human motor neuron disease. As the genetic lesion
responsible for wasted abolishes the expression of the gene encoding eEFlA-2
(Chambers et al., 1998), I screened the human EEF1A2 gene for mutations in
patients with both familial and sporadic ALS. No mutations were found, which
argues against the gene having a major involvement in the disease. Although I found
polymorphisms in exons 3 and 5 of the gene, these were not associated with disease
susceptibility.
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As eEFl A-2 is expressed during embryonic development from at least as early
as 13.5 dpc, and that the wasted phenotype has an early onset in homozygous mice, it
is possible that EEF1A2 is actually a better candidate for involvement in spinal
muscular atrophy (SMA). The age of onset is during childhood for the more common
types of SMA (Hausmanowa-Petrusewicz, 1991), whereas it is on average 45.1 years
for familial ALS and 56 years for sporadic ALS (Tandan and Bradley, 1985).
Romina Aron-Baden therefore screened a small cohort of SMA patients as part of her
MSc project, but did not find any mutations (Aron-Badin, 2002).
Wobbler is another mouse mutant which has been described as a model for human
motor neuron disorders (Duchen et al., 1968; Mitsomoto and Bradley, 1982). On the
basis of its location, apparently close to the wr interval, and function as an amino
acid transporter, I investigated the mouse solute carrier family 1, member 4 gene,
SlclA4, for mutations in a wr/wr homozygous mouse and a littermate control. As no
mutations were found, and the gene had similar expression levels in a wobbler and a
littermate control mouse, I excluded Slcla4 as a candidate for wr. Slcla4 has
subsequently been excluded from the wr critical interval (Fuchs et al., 2002).
During the course of this project, several genes were identified which are mutated
either in ALS or in the mouse models of the disease. These include Alsin, mutated in
human ALS2 (Hadano et al., 2001; Yang et al., 1990), Tbce, mutated in the mouse
mutant progressive motor neuropathy (pmr) (Martin et al., 2002) and Vegf
(Oosthuyse et al., 2001), which has subsequently become a novel mouse model of
the disease. As the genetic causes of other mouse models and of human forms of
ALS are revealed they may resolve long-standing questions about the pathogenesis
of the disease. However, the tenth anniversary of the discovery ofmutations in SOD1
in familial ALS is approaching, with no clear mechanism linking these mutations
with the disease revealed.
One key question in ALS research is why motor neurons are selectively vulnerable to
mutations in ubiquitous proteins such as SOD1. It is possible that SOD1 has one or
more as yet unidentified alternative functions which are responsible for the
Chapter 7 - Discussion 144
neuromuscular phenotype. It is also unclear why the different SOD1 mutations
responsible for ALS cause the same phenotype, with no apparent genotype-
phenotype correlation, when the mutated residues are scattered throughout the
protein.
eEFlA-2 appears to be unusual amongst the genes mutated in human and animal
motor neuron disorders in that it has a restricted expression pattern. It is interesting to
note that mutations in another translation factor, the initiation factor eIF2B, have
recently been identified as responsible for the rare neurological disorder
leukoencephalopathy with vanishing white matter (VWM) (Leegwater et al., 2001).
However, in contrast to eEFl A-2, eIF2B is ubiquitously expressed.
There is a clear need to identify the other genes involved in the approximately 90%
of familial ALS cases for which the genetic defect has not been identified. Moreover,
most ALS cases are apparently sporadic, although it is possible they represent novel
mutations in unknown genes. There may also be environmental triggers, although no
obvious candidates have emerged (Mitchell, 2000). A recent study has intriguingly
implicated physical fitness, although the criteria for identifying subjects as "varsity
athletes" or "slim" were hardly rigorous (Scarmeas et al., 2002).
The precise relationships between ALS and the other forms ofmotor neuron disease,
particularly SMA, have yet to be determined. The fact that there are families in
which the two diseases coexist suggests that the two may in fact be part of the same
clinical spectrum (Orrell et al., 1997). There have been many attempts at a rigorous
classification of the motor neuron diseases (see, for example, Orrell et al., 1997).
However, ultimately the diseases will be classified according to the genetic lesions
responsible, as these become known.
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7.1.4 Expression analysis of eEF1A isoforms
eEFl A-2 is a tissue-specific isoform of the more ubiquitously expressed eEFl A-l. In
those cells in which it is expressed, namely the brain, heart and skeletal muscle, there
is a switch in isoform expression from eEFlA-1 to eEFl A-2. Understanding the
functions of these two isoforms may help to elucidate why two isoforms are required
in neurons, which may in turn give us fundamental information about the biology of
motor neurons. A key experimental tool for the functional investigation of eEFlA-l
and eEFlA-2 are antibodies which specifically recognise the two isoforms. However,
at the start of this project, such antibodies were unavailable. In this thesis I have
described the design and characterisation of antibodies which are completely specific
for the two isoforms of eEFl A. These were used to show that expression of the
eEFl A-2 protein is confined to the brain, spinal cord and muscle of adult mice. This
confirms the previously described results at the RNA level, and the results of
Khalyfa et al. (2001). I have also shown that eEFlA-2 is expressed from at least as
early as 13.5dpc.
It is still unclear, however, why there is a requirement for a second isoform in certain
cells from a particular developmental stage. As eEFlA-l has a known role in
cytoskeletal remodelling, it is possible that eEFlA-2 has a subtly different role which
means that it is required in neurons and other cells. This may form a link between
eEFlA-2 and motor neuron dysfunction, as many of the genes which have been
identified in motor neuron disease have links with the cytoskeleton. For example,
alsin, mutations in which underlie ALS2, contains domains which are homologous to
RhoGEF, which may be involved in the organisation of the cytoskeleton. In addition,
the perturbation of neurofilament metabolism is a feature of both human ALS and
animal models of the disease, and overexpression of human NEFH in mice
recapitulates the disease (Cote et al., 1993). Moreover, neurofilament gene mutations
have been found in a small proportion of patients (Al-Chalabi et al., 1999; Figlewicz
et al., 1994; Tomkins et al., 1998).
Alternatively, there may be novel energy requirements in certain cells, which
necessitate a second eEFl A isoform. One obvious feature of neurons is their large
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size, with large cytoplasmic volumes and long axonal processes. It is conceivable
that these have requirements for an enhanced energy supply or for novel metabolites.
A second isoform may also be required in neurons for the translation of proteins at
sites other than the endoplasmic reticulum. For example, there is evidence that, in
neurons, translation occurs locally in the dendrites (Job and Eberwine, 2001a; Job
and Eberwine, 2001b). This spatial regulation of translation may be important to
allow the synthesis of proteins, such as receptors, at optimal distances from the
stimulated membrane for synapse formation during development, and for synaptic
plasticity in mature neurons.
Determining and comparing the subcellular localisation of eEFlA-l and eEFlA-2
may therefore help to explain why two isoforms are required. If the two isoforms
localise differently within the cell, this suggests that they function differently in
translation. For example, if eEFlA-l localises to the cell body alone, whereas
eEFlA-2 also localises to the dendrites ofneuronal cells, this would suggest that
eEFl A-2 is required for translation at these sites. It may also explain why neurons
require this second isoform.
There have not been any definitive studies which have investigated the relative
localisation of the two isoforms. Immunofluoresent analysis of the subcellular
localisation of eEFlA-l in fibroblasts has shown that it localises to both the
cytoplasm and the nucleus (Sanders et al., 1996). This is in contrast to the rest of the
eEFlH components, which localise to the endoplasmic reticulum. Flowever, the
subcellular localisation of eEFlA-2 has not been clearly characterised, although this
has been investigated by Khalyfa et al. (Khalyfa et al., 2001). One study has claimed
that eEFl A-2 localises to the cytoplasm ofPC-12 cells, but in this case an antibody
to eEFlA-1 was used (McClatchy et al., 2002). And although eEFlA has been
reported in dendrites, it is not clear whether this is specific for eEFlA-l or eEFlA-2
(Job and Eberwine, 2001b). There is thus a need for a comparative analysis of the
subcellular localisation of the two isoforms to be made, using clearly specific
antibodies. Unfortunately, I was unable to obtain a specific signal for either isoform,
using immunofluorescent detection on differentiated PC-12 cells or glioblastoma SU-
Chapter 7 - Discussion 147
SY5Y cells. The specific antibodies which I have raised will, however, be useful in
continuing studies investigating the subcellular localisation of the two isoforms. This
should, in turn, help to answer questions about their biological functions.
7.1.5 eEF1A isoforms in X. laevis
Given that eEFl A-2 is essential for neuronal survival, demonstrated by the fact that a
loss of eEFl A-2 leads to the loss ofmotor neurons and the death of homozygous
wasted mice, it seemed surprising that the data from the literature suggested that
eEFlA-2 was restricted to mammals. I have shown that there is in fact an orthologue
of eEFlA-2 in the frogA laevis, which is expressed only in the brain, optic ganglia,
muscle and heart of adult animals. This is consistent with the mammalian expression
pattern. Like the mammalian eEFlA-2, this novel eEFlA-2 orthologue is also
developmentally regulated. Moreover, its amino acid sequence is strikingly similar to
the mouse amino acid sequence. This implies that the amino acid differences
between eEFl A-1 and eEFl A-2 are functionally important, as they are conserved
between mouse and X. laevis. It is not clear what functional effect the amino acid
substitutions between eEFlA-1 and eEFlA-2 have. There are only two substitutions,
one conservative and one semi-conservative, in the first 160 amino acids, and the
remaining 33 substitutions appear to cluster slightly. Perhaps unsurprisingly, given
the essential role ofGTP hydrolysis in translation elongation, the three GTP binding
sites are unaffected.
This thesis also demonstrates the value of using peptides to generate antibodies
where it is necessary to distinguish between two very similar proteins. Both the short
peptides selected had four differences between the two isoforms, out of 16 residues
for eEFlA-2M and 14 for eEFlA-2C. However, the results from the X. laevis work
have shown that it is difficult to deduce any firm rules about antibody specificity in
designing peptides. The eEFlA-2M antibody was specific for the novel X. laevis
eEFlA-2 isoform (XeEFl A-2), and did not recognise eEFlA-S, even though there
were only 3 amino acid differences between XeEFl A-2 and eEFlA-S within the
peptide. In contrast, the eEFl A-2C antibody appeared to recognise both, despite
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there being four amino acid differences between XeEFl A-2 and eEFlA-S within this
peptide. This reflects the fact that there is some inherent uncertainty in designing
anti-peptide antibodies, as it is rarely possible to predict the exact in vivo
conformation of the peptide. The protein in question may also have posttranslational
modifications which would render the peptide antigenically different from the native
protein.
7.2 Future work
7.2.1 The wasted phenotype
There are further experiments which would expand on the neuropathological findings
presented in this thesis. Mice at a younger age could be analysed to determine from
what age gliosis and neurofilament accumulation occurs in wasted mice. More mice
could also be investigated, both for GFAP and for neurofilament staining, at the time
points studied, particularly at 24 days, where only one homozygous wasted and one
heterozygous animal were compared. The antibody I used to show the accumulation
of phosphorylated neurofilaments in homozygous wasted mice was a pan-specific
antibody which recognised both the light and heavy chain neurofilament proteins.
This was selected to maximise any differences seen between wasted and control
animals. Antibodies specifically raised against the light and heavy chains could be
used to determine which of the two proteins was responsible for the increased
antibody staining. Lutsep et al. showed that the increased staining they observed was
due to the heavy chain neurofilament (Lutsep and Rodriguez, 1989). It is therefore
likely that the increased neurofilament accumulation I observed was also due to the
heavy chain protein, although as Lutsep et al. only investigated mice at 28 days, the
possibility cannot be ruled out that there are differences in the other neurofilament
proteins at 24 and 28 days.
It would also be interesting to determine whether the muscle atrophy seen in wasted
mice is as a result of denervation atrophy or a primary myopathy. Experiments are
currently being carried out in our laboratory to determine which process is
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responsible. Conditional knockouts, in which the expression ofEefla2 is specifically
eliminated from neurons and from muscle, could be a way to investigate this
question. One further potential transgenic approach would be to produce mice with
Eefla2 controlled by a muscle-specific promoter, and to cross these with wasted
mice. This would confine the phenotype to its neurological (and immunological)
components. It may also be possible to generate transgenic mice in which the
immunological features of the phenotype are removed, which may then provide a
better model of ALS.
The wasted mutation is recessive, and heterozygous animals are apparently normal.
They do not show any weight loss or obvious neurological or immunological defects,
and breed normally. As eEFlA-l is known to be expressed at high levels, forming
between 3 and 5% of the total cellular protein (Lee et al., 1993a), it is expected that
eEFlA-2 is also expressed at high levels. Eleterozygotes express half the amount of
eEFlA-2, which is presumably sufficient for normal cellular function. However, it is
possible that heterozygous mice do show subtle defects, perhaps in old age, or in
response to particular environmental stresses. It may therefore be worthwhile to
examine aged wasted heterozygotes, by, for example, behavioural testing using the
SHIRPA protocol (Rogers et al., 2001). It would also be interesting to perform
neuropathological analysis on old heterozygotes, to see if any of the features seen in
wasted homozygotes are recapitulated. For example, spinal cord sections could be
stained with H&E, to determine whether there is any neuronal vacuolation, and with
the GFAP and neurofilament antibodies, to investigate whether there is any increase
in their expression. This would help to determine whether wasted represents a true
recessive phenotype.
Wasted and ALS/SMA
The timing of the eEFlA-l/eEFlA-2 switch in humans is still unknown, and clearly
has a direct bearing on the relevance for an involvement of eEFlA-2 in human ALS.
It would therefore be of interest to determine the relative levels of eEFlA-l and
eEFlA-2 in human brain and muscle at different ages. If the isoform switch occurs
early in postnatal life, as in mice, then EEF1A2 becomes a much less promising
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candidate for involvement in the common, adult-onset form ofALS, and is more
likely to be involved in either the rarer juvenile-onset forms, or in SMA. However, it
is becoming increasingly difficult to obtain ethical permission to access human
material.
7.2.2 Functions of eEF1A isoforms
It remains to be determined why two eEFlA isoforms are required. Do they have
equivalent functions? As outlined above, determining whether the two proteins have
the same subcellular localisation would help to answer this question. For example,
eEFl A-2 may be required for synaptic translation.
Although I was not able to determine the subcellular localisation in cells using the
native protein, it may be possible to achieve this by transfecting a tagged protein into
cells. This was not possible within the timescale of this project. This approach has
been undertaken with GFP-fusion proteins, in the human epithelial kidney cell line
HEK293, and both isoforms localised to the cytoplasm (Danielewicz, 2002).
However, as eEFlA-2 is not normally expressed in the kidney, this may not represent
its normal localisation. Moreover, kidney cells do not possess dendrites. As there
have been problems noted with the use of (3-gal fusion proteins (Berns, 2000), this
approach may also not accurately reflect the localisation of the native protein.
Nevertheless, if differences between eEFlA-1 and eEFlA-2 were noted in their
localisation, this is highly suggestive that the two isoforms do indeed have different
functions.
Another cellular approach used in the understanding of gene function is the use of
RNA interference, or RNAi. In this technique, (reviewed in McManus and Sharp,
2002), double-stranded RNA is introduced into a mammalian cell. It binds to the
mRNA of the target gene, which is then degraded by the RNA-induced silencing
complex (RISC), abolishing the expression of that gene. RNAi could be used in
human and mouse cell lines to knockdown the expression of eEFlA-1 and eEFl A-2,
and possibly illuminate their relative functions. For example, it would be interesting
Chapter 7 - Discussion 151
to study the phenotype of neuronal cells such as SU-SY5Y, which I have shown to
express both isoforms, after the abolition of eEFlA-l or eEFl A-2 expression. This
would demonstrate whether both isoforms are required for cell viability, and it would
also be interesting to determine whether there were any cytoskeletal differences
between the two knockdowns.
Many useful mutant mice have been generated by the ENU mutagenesis programme
(Hrabe de Angelis et al., 2000; Nolan et al., 2000). In this programme, male mice are
exposed to ethylnitrosourea, which leads to point mutations in the DNA of the
premeiotic spermatogonial stem cells, with a specific locus mutation rate of 0.00108
(Coghill et al., 2002). After a briefperiod of sterility, the mice are mated, and the F1
offspring examined for phenotypic abnormalities. The DNA of the F1 males has been
stored, and can be screened for the presence ofmutations in a particular gene of
interest. The sperm of these mice is also stored, so that lines ofmice which express
the mutation can be generated. Screening the DNA of the F1 mice for mutations in
Eeflal and Eefla2 may uncover novel mutations in either or both of these genes.
This would be particularly instructive for Eeflal, in which there are no known
mutations. Any such mutations would be expected to have a subtle effect on the
protein, as Eeflal null mutants would be expected to be early embryonic lethal, as
the gene product has such a crucial role, and is almost ubiquitously expressed. If
more than one allele was generated, it may be possible to construct an alleleic series,
with different mutations having different severities of phenotype. It is possible that
the mice generated could also be crossed to generate further alleles, with more subtle
differences between them.
Gene trapping is based on the random integration of a reporter gene cassette into the
genome of an embryonic stem (ES) cell. The reporter cassette comprises a reporter
gene such as lacZ with a selection gene such as neomycin, and serves to both mutate
and identify the locus into which it integrates. These ES cells are used in the
generation of chimaeras, which are then used to produce mice which are usually
effectively null for the integrated locus. Several reference libraries of such cell lines,
with sequence information on the trapped genes, are now available, (for example, see
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Wiles et al., 2000). Gene traps could thus be a further way to generate mice carrying
mutated alleles ofEeflal and Eefla2, and a further way to investigate the functions
of eEFl A-l and eEFl A-2. The fact that the trapped gene contains a lacZ reporter
gene, under the control of the endogenous promoter, could be a further tool to
investigate the expression of the two isoforms. There is the caveat that the signal
obtained may not reflect that of the native protein, as problems have been noted with
the use of a lacZ reporter gene (Berns, 2000). Elowever, in this case the lacZ gene
was located in the 3'UTR of the Eeflal gene. It is possible that the location of the
gene trap lacZ gene will not lead to such effects.
Transgenic approaches could also be used to investigate whether the two isoforms
are functionally equivalent. One way to determine this would be to substitute
eEFlA-l for eEFlA-2. If eEFlA-l were to be placed under the control of the
eEFl A-2 promoter in transgenic mice, then eEFlA-l would be expressed when and
where eEFlA-2 is ordinarily expressed. If, when crossed to wasted mice, these
transgenic mice correct the wasted phenotype, then the implication is that the two
isoforms have identical functions.
The two isoforms may also have different interactions. eEFlA-l is known to interact
with components of the cytoskeleton, for example actin and microtubules (Liu et al.,
2002; Shiina et al., 1994; Yang et al., 1990). There may be differences between
eEFlA-l and eEFlA-2 in, for example, the affinity for these cytoskeletal
components, leading to differences in cytoskeletal modelling capabilities between the
two isoforms. The antibodies I have generated could be used to investigate such
interactions using, for example, immunoprecipitation. This could also be used to
investigate the ZPR1/SMN complex. Although eEFlA-l is known to interact with
ZPR1, it is not known whether eEFlA-2 also interacts. A direct interaction has not
been demonstrated between either of the eEFlA isoforms and SMN. Intriguingly, an
unidentified 50kD protein has been pulled-down in immunoprecipitation experiments
using an anti-SMN antibody (Charroux et al., 2000). It is therefore tempting to
speculate that eEFlA-l, SMN and ZPR1 all form part of the same complex, and that
eEFlA-2 also interacts.
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As part of her MRes Project, Romina Aron-Badin investigated whether there was a
difference in the expression of ZPR1 and SMN between homozygous wasted mice
and their wild type littermates (Aron-Badin, 2002). There were no differences
between the two groups of animals in ZPR1 mRNA levels, assessed using RT-PCR.
However, using Western analysis, it was noted that the expression of SMN was
reduced in the heart and muscle of homozygous wasted mice when compared with
those of control animals. This was not, however, due to a general loss of translational
capacity in homozygous wasted mice, as the levels of other proteins were unaffected.
It would be interesting to detemiine whether this reduction in SMN is at the level of
transcription or translation. RT-PCR analysis could therefore be used to compare
SMN mRNA levels between homozygous wasted mice and controls. It is possible
that the differences seen at the protein level were caused by the mislocalisation of
SMN to the nucleus. Although Romina Aron-Badin performed immunohistochemical
analysis on cryostat sections ofmuscle, brain and spinal cord, the morphology was
not of a sufficient quality to resolve this question (Aron-Badin, 2002). It may
therefore be useful to investigate SMN localisation in paraffin-embedded sections
from homozygous wasted mice and controls.
7.2.3 eEF1A-2 expression in mice
Given that eEFlA-2 is strongly expressed in 13.5 and 14.5 dpc embryos, it would be
very interesting to perform in situ hybridisation to determine the precise expression
pattern ofEefla2 during embryonic development. If novel sites of expression were
uncovered, it could hint at new potential functions of eEFl A-2. Given the finding
that eEFl A-2 is also expressed in the eye, it would also be of interest to determine
where within the eye it is expressed, and also to determine whether there is also an
isoform switch in this organ. There are several cell types which might be expected to
express eEFlA-2 on the basis of either their shape or function. These include
neuronal cells such as bipolar cells, and muscle cells. The shape of photoreceptor
cells, with their elongated cytoplasm, is somewhat similar to neurons, and may
indicate that these cells also have a requirement for eEFlA-2. However, there are
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many cells which would not be expected to express eEFl A-2, so the fact that there
was no eEFl A-1 signal at the level of a Western blot was somewhat surprising. It
would therefore be interesting to study the expression ofboth isoforms in the adult
eye using immunohistochemistry.
Immunohistochemistry could also be used to study the expression of eEFlA-1 in the
spinal cord. There appeared to be a gradient in the severity of the vacuolation and
gliosis from the cervical through the thoracic to the lumbar spinal cord. It is
conceivable that this phenotypic gradient is due to a gradient in the loss of eEFlA-1
expression. However, it was not possible to test this hypothesis using Western
blotting, as there are also cells within the spinal cord which permanently express
eEFlA-1, and do not switch to eEFl A-2 expression. This means that the decrease in
eEFl A-1 levels is modest at the whole tissue level. Immunohistochemistry would
therefore probably be the best method to investigate this question, as it would enable
the reduction in eEFl A-1 levels to be visualised in different cells. However, I was
unable to obtain a positive signal using either of our eEFl A-1 antibodies, so it is
possible that this would necessitate the designing of another eEFlA-1 anti-peptide
antibody.
7.2.4 eEF1A expression in non-mammalian species
I have shown that there is an eEFlA-2 orthologue in X. laevis, which has a restricted
expression pattern in adults and is not expressed in gastrula-stage embryos. It would
therefore be of interest to investigate the precise developmental stage at which this
gene is first expressed. This could be done using both Western analysis and in situ
hybridisation on developing embryos. The sites of expression determined using in
situ analysis could be compared with those obtained in mouse embryos.
I have also confirmed the presence ofXeEFlA-2 in muscle at the RNA level, using
RT-PCR. Other tissues could also be tested, to confirm the Western results. As the
primers were specific for XeEFl A-2, demonstrated by the unambiguous sequence
obtained, primers at the equivalent locations in the gene encoding eEFlA-S could be
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used to confirm the expression pattern of eEFlA-S at the RNA level. If the tissues in
which eEFlA-S mRNA is expressed is consistent with those in which the protein is
expressed, and the sequence is that of eEFlA-S, this would confirm the protein
recognised by the anti-A salina eEFlA antibody and eEFlA-2C as eEFlA-S.
It would also be interesting to determine whether there is an orthologue of eEFlA-2
in other non-mammalian vertebrates, for example, the zebrafish, another model
organism. Establishing this timing may be useful in the construction of a
developmental "clock" between different organisms. It is currently difficult to
directly compare different developmental stages between different organisms. It may
also be worthwhile to examine whether there is an eEFlA-2 orthologue in X.
tropicalis, especially as this organism is both more amenable to genetic analysis, and,
more practically, will have its genome sequenced.
The eEFlA isoforms therefore represent a very interesting system for study on
several levels. As vertebrate-specific, evolutionarily conserved proteins, they can be
used to study the relationships between organisms. Understanding why there is an
isoform switch in, for example, neurons could improve the knowledge of their basic
cell biology. There is even a link with human disease in the form of the wasted
mouse, a spontaneously-occurring eEFl A-2 knockout.
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Appendix 1
Genetic background of wasted mice
The wasted mutation arose spontaneously in the inbred HRS/J colony at the Mouse
Mutant Stocks Center of the Jackson Laboratory. The mutation was then crossed to a
segregating C3HeB/FeJ x C57BL/6J background.
For the immunohistochemistry experiments described in Chapter 3, section 3.2.2,
mice heterozygous for the wasted mutation were also heterozygous for the closely
linked mutation ragged, Ra (Abbot et al., 1994). This allowed the presymptomatic
identification of homozygous wst/wst and +/wst animals, as +/Ra heterozygotes
show visible coat defects. Ra/Ra homozygotes, which did not carry any wasted
alleles, died soon after birth. The animals used in the weighing experiments,
described in section 3.2.1, did not carry the ragged mutation, and were genotyped
according to the method described in Chapter 2, section 2.3.3.
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6 3 2.5; 5.5 5.6
7 9 3.0; 5.1 5.1; 5.2; 5.5; 5.8; 6.0; 6.3; 6.4
8 5 3.7; 5.9 6.2; 6.4; 6.6
9 10 4.8; 6.0 6.2; 6.3; 6.6; 6.8; 6.9; 7.4; 7.7; 8.0
10 9 5.2; 6.5 6.6; 6.8; 6.9; 7.3; 7.4; 8.4; 8.6
11 9 5.6; 5.8 7.2; 7.7; 8.0; 8.3; 8.3; 8.5; 9.2
12 7 6.4; 8.2 8.4; 8.6; 8.7; 9.1; 9.2
13 3 6.7; 8.7 8.9
14 10 7.5; 8.1 8.4; 9.1; 9.4; 9.9; 10.4; 10.6; 10.7; 11.0
15 16 7.6; 8.0
11.3
8.3; 8.5; 8.8; 9.5; 9.6; 9.7; 10.2; 10.2; 10.7; 10.7; 10.8; 11.0; 11.1;
16 8 8.4; 9.0; 10.1; 10.4; 10.6; 11.0; 11.0; 11.6
17 10 7.9; 8.3; 8.5; 9.6; 10.6; 10.8; 10.8; 11.0; 11.3; 11.5
18 12 8.3; 8.6; 9.2; 9.5; 10.2; 10.6; 11.1; 11.1; 11.2; 11.2; 11.2; 11.6
19 4 11.1; 11.2; 11.3; 11.8
20 2 10.0; 10.8
21 7 7.7; 8.9; 9.1; 9.8; 9.9; 10.0; 11.0
22 12 7.4; 8.0; 8.0; 9.4; 9.5; 10.3; 10.6; 10.9; 10.9; 10.9; 11.3; 11.3
23 9 7.3; 9.0; 9.6; 9.9; 10.0; 10.3; 10.4; 10.9; 11.0
24 9 7.0; 8.4; 8.6; 8.8; 9.6; 9.9; 9.9; 10.0; 10.3
25 6 7.8; 8.3; 8.6; 9.0; 9.1; 9.7









6 5 4.1; 4.2; 4.5; 5.6; 5.8
7 17 4.8; 4.9; 5.0; 5.2; 5.2; 5.3; 5.4; 5.4; 5.5; 5.5; 5.5; 5.5; 6.0; 6.2; 6.4; 6.4;
6.6
8 8 5.5; 5.5; 6.0; 6.2; 6.2; 6.7; 6.7; 7.3
9 16 5.5; 5.7; 5.8; 6.0; 6.2; 6.3; 6.3; 6.4; 6.5; 6.6; 6.7; 6.9; 7.3; 7.8; 8.2; 8.4
10 19 6.2; 6.4; 6.4; 6.5; 6.7; 6.7; 6.8; 6.9; 6.9; 7.0; 7.0; 7.0; 7.1; 7.2; 7.2; 7.3;
7.3; 8.6; 9.0
11 13 6.6; 6.8; 6.9; 7.0; 7.5; 7.7; 7.8; 7.9; 8.0; 8.0; 8.5; 9.1; 9.8
12 9 8.0; 8.2; 8.3; 8.3; 8.8; 9.1; 9.3; 9.4; 9.7
13 6 8.6; 8.9; 9.1; 9.5; 9.7; 9.9
14 20 8.4; 8.4; 8.4; 8.5; 8.6; 8.7; 8.9; 9.1; 9.4; 9.6; 9.8; 9.9; 10.0; 10.2; 10.2;
10.3; 10.4; 10.6; 11.7; 11.7
15 28 8.2; 8.5; 8.6; 8.6; 8.7; 8.7; 8.7; 8.7; 8.8; 8.9; 8.9; 9.1; 9.5; 9.7; 10.0; 10.1;
10.2; 10.4; 10.5; 10.6; 10.6; 10.7; 10.8; 10.9; 11.0; 11.5; 12.0; 12.1
16 11 8.7; 8.8; 9.0; 9.0; 9.1; 9.2; 9.3; 10.7; 11.2; 11.3; 11.9
17 15 8.7; 8.8; 8.8; 8.9; 8.9; 8.9; 8.9; 9.1; 11.0; 11.1; 11.2; 11.5; 12.3; 12.3;
12.6
18 20 8.7; 8.9; 9.0; 9.1; 9.1; 9.3; 9.3; 9.3; 9.4; 9.5; 9.5; 11.2; 11.4; 11.7; 11.8;
11.8; 12.0; 12.5; 13.0; 13.1
19 5 9.6; 12.4; 12.5; 12.6; 12.7
20 1 12.1





10.2; 10.3; 10.6; 10.8





11.3; 11.3; 11.4; 11.7;
13.9





11.9; 12.2; 12.2; 12.2











12.1; 12.8; 12.8; 12.9
16.0
13.0 13.0 13.0; 13.4; 13.4; 13.8;
26 6 12.9 13.0 13.3; 13.8; 13.9; 13.9
27 0
28 5 15.3; 15.4; 16.9; 17.8; 18.0
29 8 15.4; 16.6; 16.8; 17.2; 17.8; 18.5; 18.7; 19.9
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fmice,men and motor neurons
len J.Newbery and Catherine M.Abbott
jse ofmouse models has been of particular importance in studying the
ogenesis of amyotrophic lateral sclerosis. Here, we describe both
sgenicand classical mutants for which the genetic lesion is known. We
i attention, wherever possible,to pathological factors common to
iple models.
The term 'motor neuron disease' encompasses a
group of clinically distinct neurodegenerative
conditions. The most common adult-onset form is
known as either amyotrophic lateral sclerosis (ALS),
Lou Gehrig's disease, or simply, motor neuron
disease (MND). At any one time, ~30 000 individuals
in the USA and -5000 in the UK are affected byALS.
The specific loss ofmotor neurons in the spinal cord,
brain stem and motor cortex leads to progressive
paralysis and, usually, death within five years of
diagnosis. This neuronal loss is also associated with
astrocytosis and the presence ofubiquitinated
inclusions. Approximately 10% of cases are familial.
Of these, around 20% are caused by dominant
mutations in the Cu/Zn superoxide dismutase gene,










form is 46 years, about 10 years earlier than for
sporadic ALS. There are also rare recessively
inherited forms ofALS, which tend to have juvenile
onset [1]. Spinalmuscular atrophy, anothermotor
neuron disease that predominantly affects young
children, has an incidence of 1 in 6000 live births and
is almost invariably caused by mutations in the
survivalmotor neuron gene (SMN1; see OMIM
reference #253300).
One of the central mysteries in MND research is
why ubiquitously expressed genes such as SOD1
should cause such devastation to motor neurons in
the absence of pathology in other tissues. Another
key question is why such different underlying
causes (e.g. mutations in a metabolic enzyme, a
translation elongation factor or a transcriptional
activator) all lead to motor neuron degeneration. It
is only by studying as many underlying causes as
possible that we will gain some insight into the final
cascade(s) of events inALS, and how these might be
prevented. For example, a number of common
downstream events (such as neurofilament
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i 1. Mouse models of amyotrophic lateral sclerosis'




























aryotic elongation 15.8 kb
ctor 1A-2 Eefla2 deletion
Tremors and progressive paralysis,
with age of onset from 3-14 months,
depending on transgene copy number.
Loss of spinal motor neurons; presence
of phosphorylated NF inclusions and
reactive astrogliosis.
tNF-H Delayed age of d isease onset in those
(mouse) mice in which there is perikaryal NF
accumulation. Delay is proportional to
degree of accumulation. Overexpressing
murine NF-H also extends lifespan of
G93A mice.
Tnf-l Extension of lifespan of sod1 transgenic
(mouse) mice
NF-L 4/- Mice heterozygous for all three neurofilament
NF-M 4/- genes have a reduced axonal caliber, butthis
NF-H 4/- does not affectthe lifespan of G37R mice.
Tnf-l Increasing nf density does not affect
(human) disease course.
nf-l -/- Extension of lifespan, despite an increase
in axonal loss.
Correlation between severity of symptoms
(tremors, weakness) and NF-H levels.
Overexpression of NF-L rescues phenotype.
Growth retardation and muscle atrophy.
Recovery of mice that survive the third week,
which could be attributed to decreased
expression of transgene.
NF-L -/- Decreased grasping time from six months,
and motor dysfunction from eight months.
Mice overexpressing peripherin alone show
late-onsetmotor dysfunction at age two years.
60% die at birth. From four months,
survivors show muscle weakness and limb
paresis, owing to neurogenic atrophy of
muscle. Lower motor neuron degeneration.
Spontaneous recessive mutant — wasted
(wst). Tremors, ataxia and muscle wasting,
from 21 days
Spontaneous recessive mutant —
neuromuscular regeneration (nmd).
Impaired movementattwo weeks
Perikaryal NF inclusions, [4] (and
axonal spheroids references
therein)
Perikaryal NF inclusions [16,17,28]





























[25]nunoglobulin mu Two alleles
iding protein 2
imbp2
ne symbols for the mouse genes are given. T represents transgenic overexpression of a gene. Abbreviations: NF, neurofilaments (NF-H, heavy form; NF-M, medium form;
., light form); n.r., not reported; TH, triple heterozygote.
accumulation) can be identified, in spite of the great
diversity of the gene products that are mutated in
mouse and humanALS. Here, we will highlight
similarities and potential links between apparently
differentmodels.
That mouse models are valuable in the study of
human disease pathogenesis can be in no doubt, but
there are specific disorders in which they are
especially useful because ofparticular constraints on
the study of human subjects. ALS provides a good
example of this: pre-symptomatic stages of the
disease can be studied in mice, and it is possible to
access material, for example from the spinal cord,
that cannot be obtained from living patients. Here, we
will discuss some of themanymouse mutants
(classical, knockout and transgenic) that undergo
motor neuron degeneration, but wewill confine the
scope to those in which the underlying genetic lesion
has been identified. Our main emphasiswill be on
mouse models ofALS, concentrating in particular on
interactions between genotypes. The keymutants are
described in Table 1. More comprehensive reviews
that also describe mutants for which the genetic
cause is unknown can be found elsewhere [2].
Transgenic models: SOD 1
The identification of dominantly inherited point
mutations in the SOD1 gene in familial ALS in 1993
was rapidly followed by the generation of the first
specific mouse models. A crucial early result was the
finding that SOD 1 nullmice are essentially normal [3],
which gave strong support to the idea that the
http://tmm.trends.com
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SODl mutations underlyingALS have caused the
protein to acquire a new toxic function. Transgenic
mice carrying several copies of human SODl genes
withALS-causing mutations (SODlG37R, S0D1G85R,
SODlG93A, SODlG93R) develop a pathology
resemblingALS, including abnormal neurofilament
accumulation, with an age of onset dependent on
transgene copy number [4]. These mice have been
used extensively in ALS research and have led to a
number of new insights into disease pathogenesis.
Intercrosses with other transgenic mice have been
particularly informative (Table 1). One of the most
dramatic findings has come from crosses of
S0D1G37R transgenic mice to mice overexpressing
the human neurofilament heavy chain: the lifespan
of these mice is a full six months longer than that of
those carrying only the SODl transgene. These
intercrosses are discussed in more detail later in
this review. Simpler, but invaluable results have
also been obtained using SODl transgenic mice.
Oral administration of creatine, for example, was
found to improve motor performance and extend
survival in these mice, a result with obvious
application to the human disease [5]. An interesting
but baffling recent result is that mice overexpressing
mutant S0D1G37R solely in neurons do not have
any apparent motor deficits [6]. If the reverse is
true, and expressing the same transgene in such a
way that it is depleted specifically in neurons does
give rise toMND, study in this field will be opened
up enormously.
Neurofilaments and the role of the cytoskeleton
Neurofilament proteins represent the main
intermediate filament component of the cytoskeleton
ofneurons. There are three forms of neurofilament:
heavy (NF-H); medium (NF-M); and light (NF-L).
There is considerable evidence to implicate the
perturbation ofneurofilament biology in the
pathogenesis ofALS. Accumulations of
phosphorylated neurofilaments are a feature of the
disease [7], Mutations in the KSP (Lys-Ser-Pro
repeat) region have also been found in a small
proportion of sporadic patients [1]. Fundamental
insights into the role of neurofilaments and the
cytoskeleton inALS have been obtained by the study
of transgenic mice.
Neurofilament knockouts
Mice in which any of the three neurofilament genes
have been targeted are outwardly phenotypically
normal, although they have a reduction of axonal
caliber and show a loss of large motor neurons [8-12].
Neurofilament overexpression
Mice have been engineered to overexpress human [13]
or mouse [14] NF-H. There is a surprising discrepancy
in the results of these studies. Twofold overexpression
ofhuman NF-H (compared with endogenous NF-H)
gives rise to mice with neurological defects, muscle
atrophy and abnormal accumulation of
neurofilaments, a phenotype strikingly similar toALS.
By contrast, overexpression ofmouse NF-H at
4.5-times the normal level gives rise to no clinical
phenotype and no notable neuronal loss even in the
presence of abnormal perikaryal NF accumulation
(the perikaryon is the cytoplasm of the cell body of
the neuron). These results suggest that human
NF-H acts as an aberrant subunit in a dominant
negative manner.
Neurofilament-SOD 1 interactions
Perikaryal accumulation of phosphorylated
neurofilaments is a hallmark ofALS. This has been
suggested as one of the possible causes of the disease,
either through the strangulation of axonal transport
or the entrapment ofcellular organelles [15]. It was
therefore expected that crossingmutant
SODl -bearing mice to NF-H overexpressing
transgenic mice might exacerbate disease
progression. Surprisingly, however, it was found that
mice overexpressing both SODlG37R and human
NF-H had a delayed age ofonset of disease, by up to
six months [16]. This delay appeared to be dependent
on the degree ofperikaryal neurofilament
accumulation - the greater the accumulation, the
later the disease onset. It was postulated that this
accumulation protects neurons by forming a
'phosphorylation sink': these neurofilaments are
phosphorylated in preference to other neuronal
proteins that would be detrimental to the cell in a
phosphorylated form [17]. In view of the very different
phenotypes ofmice overexpressing mouse and human
NF-H, it would be interesting to establish the effect of
'humanizing' all NF genes in mouse simultaneously,
and to examine interactions ofmutant SODl
transgenes with this genotype.
Efficient intracellular transport is clearly crucial for
cells such as motor neurons, which in humans can be
over a meter long. However, the caliber, or thickness,
of the axons is not a factor in disease pathogenesis
(as noted above, mice null for either NF-H or NF-M
have a reduced axonal caliber and no phenotype). In
an elegant experiment by Nguyen et al. [18], mice
were produced that were hemizygous for all three NF
genes, which resulted in a reduction of axonal caliber
without affecting neurofilament stoichiometry.
Crossing these to S0D1G37R transgenics did not affect
either the age of disease onset or the lifespan of the
mice. The disease course was also unaltered when
mice overexpressing NF-L, which have a 50%
increase in neurofilament density, were crossed to
SODl transgenics.
Vascular endothelial growth factor
Recently, mice carrying a targeted deletion of the
hypoxia response element (HRE) within the vascular
endothelial growth factor (VEGF) promoter were
described [19]. These mice have a phenotype that is
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strikingly similar to that of SOD1 mutantmice and
humanALS. From 5-7 months of age, they show
muscle weakness owing to the degeneration of lower
motor neurons, and again display abnormal
accumulation of neurofilaments. Their neurons have
reduced baseline and hypoxic levels ofVEGF, which
could cause motor neuron death by reducing
perfusion under low oxygen conditions. Alternatively,
the lack ofVEGFmight be actively neurotoxic - there
is evidence to suggest that, at least in vitro, VEGF has
a direct neuroprotective effect. Of course, motor
neuron death could result from a combination of these
(and indeed other) mechanisms.
Classical models
Although there are many 'classical' (non-targeted)
models ofALS, only two have so far been characterized
at a molecular level - wst and nmd. As many other
mutants are the subject of intensive positional cloning
efforts, it is probable that significant progress will be
made in this areawithin the next few years.
Wasted
The spontaneous mutation wst is a 15.8 kb deletion
that removes the promoter region and first exon of
the gene encoding translation elongation factor 1A-2
(eEFlA-2), abolishing its expression [20]. Homo¬
zygous wst/wst mice die at about four weeks. They
suffer from immunological abnormalities, possibly
caused by the effect of the deletion on a neighboring
gene, and muscle atrophy. The only defect within the
central nervous system (CNS) of these mice is loss of
motor neurons within the spinal cord; although they
were reported in early studies to have cerebellar
defects this is not in fact the case (Ref. [21] and our
own unpublished results). This clearly makes them a
better model for ALS than previously thought. As in
ALS patients and SOD1 transgenics, wst/wst mice
have abnormal accumulations ofphosphorylated
NF-H in the perikarya ofmotor neurons [21]. Unlike
eEFlA-1, with which it shares 92% identity, eEFlA-2
is only expressed in terminally differentiated cells of
the CNS, heart and skeletal muscle. eEFIA-1 has a
number of functions in addition to its role in protein
synthesis. Interestingly, it has been shown to
interact with the transcription factor ZPR1 [22],
which also interacts with SMN1 [23]. In both cases,
binding to ZPR1 is required for translocation of the
proteins from cytoplasm to nucleus. It is therefore
possible that all three proteins are part of a complex.
SMN is deleted or mutated in >95% of cases in spinal
muscular atrophy (SMA). If eEFIA-2 also interacts
with this complex, this would provide a molecular
link between wst mice and SMA. In addition,
eEFIA-1 is a known cytoskeletal interacting protein:
it can bind and bundle actin and severmicrotubules
[24]. IfeEFlA-2 also has this activity then there
could be a link with the cytoskeletal component of
ALS and a possible explanation for NF-H
accumulation in wst mice. Alternatively, motor
neurons could simply be particularly susceptible to
mutations affecting de novo protein synthesis
because of their high metabolic requirement.
Neuromuscular degeneration
nmd is a spontaneous autosomal recessive mutation
inwhich mice develop a progressive paralysis leading
to death within four weeks of age. NF accumulation
appears not to have been investigated in these mice.
The nmd mutation is in the gene encoding immuno¬
globulin mu binding protein 2 (Ighmbp2), a putative
general transcriptional activator andDNAhelicase [25].
As the gene is ubiquitously expressed and has
numerous downstream targets, it is not clear why
mutations in this gene should cause a specific
neuronal pathology. An interesting aspect of these
studies was the identification ofamodifier locus on
chromosome 13, which enables some nmd mice to
survive beyond seven months. Intriguingly, it has
recently been shown that mutations in the human
orthologue of the nmd gene, IGHMBP2, are
responsible for spinal muscular atrophy with
respiratory distress (SMARD) [26], This suggests that
there is a need to be open-minded about classification
ofmouse models ofmotor neuron degeneration in
terms ofALS and SMA.
Therapeutic implications
Insights from mouse models can clearly lead to
therapeutic advances. The identification of new
genetic mutations in the mouse that cause motor
neuron degeneration can provide new targets for
intervention. However, many factors identified in
the study of transgenic mice affect the age of onset of
the disease rather than its progression. For a
disease in which over 80% of cases are sporadic, and
in which the genetic lesion is unknown even in most
of the familial cases, itwill be crucial in the future to
identify therapeutic interventions that affect
disease progression.
Future directions
Mouse models have providedmany valuable insights
into both the pathogenesis ofALS and the
fundamental biology ofmotor neurons and
neurofilaments. They have also posed many
questions.What is the precise role of neurofilaments
in the pathogenesis of the disease? It was initially
thought that theywere pathogenic, but recent
evidence supported a protective role, at least for
perikaryal accumulations. A number of transgenic
animals, including the neurofilament knockout mice,
display amarked loss ofmotor neurons and/ormotor
axons with either a mild or no clinical phenotype.
Does this imply that there is a threshold proportion of
motor neuron loss that can be tolerated before clinical
features are seen?
The identification of further modifier genes in
mice has an obvious relevance to human disease,
and could go some way to explain the differences in
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age of onset and disease duration, even between
members of the same family. A modifier of
SOD1 -transgene-induced pathology has been shown
to exist on mouse chromosome 13 (in a region
distinct from the nmdmodifier locus) [27].
Interestingly, the region identified includes the
spinal muscular atrophy locus, which could provide
another link between the two diseases.
Why do ubiquitously expressed proteins such as
SOD 1 and IGHMBP2 when mutated affect only
motor neurons? It is possible that their sheer size is a
factor - the cell volume ofa motor neuron is typically
5000 times that of a normal animal cell, placing
particular demands on transportmechanisms and
metabolic requirements. Motor neuronsmight be
particularly sensitive to insult ofany description.
However, the fact that expression ofmutant SOD1
specifically in neurons does not cause disease casts
doubt on these interpretations. Why do mutations in
genes with such diverse roles in metabolism, protein
synthesis and cell growth all have a similar
pathological outcome? Almost invariably, abnormal
perikaryal accumulation of neurofilaments is seen. Is
this the default reaction of damagedmotor neurons,
or does it suggest the convergence ofdifferent
biochemical pathways? In the last few months, a new
familialALS gene with a recessive mode of
inheritance has been identified. Mutations in a
putative GTPase regulator were found to underly
ALS2 [34,35]. This gene contains domains that have
homology to RhoGEF. This provides yet another
possible link between misregulation of cytoskeletal
structure andmotor neuron disease. Knockout mice
for this genewill undoubtedly provide another
valuable tool. As more genes involved inmotor neuron
degeneration are identified, the key challenge is to
identify possible interactions, and common endpoints
in the pathogenesis ofmotor neuron disease.
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